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AraC family proteins are transcriptional regulators that are defined by the presence of a 
conserved DNA binding domain (DBD). My research focused on three AraC family activators: 
Rns (activator of virulence genes in diarrhea-causing ETEC), VirF (activator of virulence genes 
in diarrhea-causing Shigella) and RhaR (activator of L-rhamnose catabolic operons in 
Escherichia coli). With the ultimate goal of discovery of novel antibacterial agents that inhibit 
the AraC family proteins, here I have investigated the molecular mechanism of transcription 
activation by Rns and RhaR. Site-directed mutagenesis of residues in the ETEC Rns N-terminal 
domain (NTD) identified three residues (N15, N16 and I17) that are required for the transcription 
activation function of Rns. Site-directed mutagenesis of residues in the Rns DBD (predicted to 
be contacted by the NTD residues) identified three residues (K216, Y251 and G252) that are 
required for transcription activation, and one residue (H250) that is required for both DNA 
binding and transcription activation. We propose that transcription activation by Rns involves 
contacts between RS2 and AS2 region residues and these contacts may impart the structure or 
dynamics required by Rns to activate transcription.  
In RhaR, I investigated the role of the RhaR Arm in transmission of the signal that 
effector (L-rhamnose) is bound from the NTD to the DBD, converting RhaR to its activating 
state. Site-directed mutagenesis results suggested that the RhaR Arm is involved in maintaining 
RhaR in its non-activating state.  Our results suggest that residue L35 in the Arm makes inter-
domain interactions with the RhaR DBD to reduce transcription activation by RhaR in the 
absence of L-rhamnose.  
  To identify novel agents that target AraC family proteins, I tested the small molecule SE-
1, which our lab identified as an effective inhibitor of the AraC family proteins RhaS and RhaR. 
Despite limited sequence identity, SE-1 was also shown to inhibit VirF and Rns activity in cell-
based assays in E. coli.  I showed that SE-1 blocked in vitro DNA binding by VirF and Rns, and 
expression of VirF-dependent virulence genes in Shigella. A collaborator showed that SE-1 
inhibited invasion of Shigella into eukaryotic host cells. SE-1 did not detectably inhibit the 
growth or metabolism of the bacterial or eukaryotic host cells, respectively, indicating that the 
inhibition of invasion was not due to general toxicity. Overall, SE-1 appears to exhibit selectivity 
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Significance. Approval of the first antibiotic Penicillin in 1940s and subsequent release of 
several classes of antibiotics in 1950s and 1960s have dramatically reduced bacterial infections 
worldwide (1, 2). However, indiscriminate use of antibiotics led to rapid development of 
resistance by many pathogenic bacteria (3). This unfortunate situation has been exacerbated by 
the decrease in antibiotic research, which was evident from the fact that no new class of 
antibiotic was released between 1962 and 2000. In recent years, the development of new 
antibiotics has generally been limited to modifications of existing antibiotics to improve their 
efficacy (2, 4-6). A recent report showed that only six antibiotics have been approved for public 
use in USA since 2003 (7) 
Until recently, the targets for antibiotics are essential bacterial proteins that have roles in 
important cellular processes like cell wall synthesis, DNA replication and protein synthesis (8-
15). Targeting of these essential cellular processes by antibiotics can either kill or inhibit the 
bacterial growth, and thus put pressure on the bacteria to select for resistant population (9). In 
order to successfully combat the antimicrobial resistance we need new strategies to develop 
antibiotics. One such approach has been suggested recently and involves targeting of bacterial 
virulence factors that are required to cause successful bacterial infection (9, 10). Given that 
targeting virulence proteins does not kill the bacteria directly this strategy might decrease the rate 
at which bacteria develop resistance. In addition, inhibition of virulence factors could allow the 
immune system to act on bacterium to clear the infection (9, 16-18). As an alternative to 
targeting of virulence proteins, strategies that target the AraC family virulence activators were 
thought to have potential to develop into antibacterial agents (19-23).  In many pathogenic 
bacteria it has been shown that these AraC family proteins are required for the bacteria to cause 
infection (24-28). Further, several recent studies that targeted AraC family proteins showed a 
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reduction in the bacterial virulence and thus suggesting that AraC family proteins can be 
developed as antibacterial targets (19-23). In addition, AraC family virulence activators in many 
pathogenic bacteria show sequence similarities, and therefore compounds that target AraC family 
proteins could be used as broad-spectrum antibiotics to treat multiple infections (29-34). 
General characteristics of AraC family proteins. AraC family proteins constitute one of the 
largest family of bacterial regulatory proteins with more than 1900 proteins identified to be in 
this family so far (35). Proteins in the AraC family are present in ~70% of the sequenced 
bacterial genomes and mainly regulate transcription (35). Protein members of this family are 
defined by a sequence similarity within 99 amino acids that constitutes the DNA binding domain 
(36). Multiple AraC family proteins are present in each bacterium, with E. coli K12 having 27 
AraC family proteins identified so far (37). Although majority of the proteins in this family are 
still uncharacterized, proteins characterized so far are found to have roles in control of 
expression of genes involved in various biological processes including carbon metabolism, stress 
responses, and most importantly virulence (37). Majority of the well-studied AraC family 
proteins are transcriptional activators, with the exception of CelD (transcriptional repressor) (38), 
AraC, YbtA and Rns (both activators and repressors depending on the promoter regions where 
they bind) (39-44). 
Depending on the biological processes AraC family proteins regulate, these proteins can 
be categorized into three different classes. AraC family proteins that are found to be involved in 
regulation of virulence genes include Rns/CfaD (pili forming genes in Enterotoxigenic E. coli) 
(41), VirF (genes involved in invasion and cell-to-cell spread of Shigella spp. in human intestine) 
(45-49), PerA (bundle-forming pili genes in Enteropathogenic E. coli) (50), RegA (attachment 
and effacement of Citrobacter rodentium to mice intestinal epithelium) (51), MxiE [expression 
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of Type3 secretion system (T3SS) effectors after invasion of Shigella spp. into host intestinal 
epithelial cells] (52), ToxT (Cholera toxin and toxin-coregulated pilus in Vibrio cholerae) (53), 
ExsA (exoenzyme S in Pseudomonas aeruginosa) (54), UreR (Urease in various bacterial spp.) 
(55), InvF (T3SS genes in Salmonella typhimurium) (56). Some of these regulatory proteins 
respond to specific effector molecules (RegA - bicarbonate ions; ToxT - fatty acids and 
bicarbonate ions; UreR – urea) (57-60) while some of these respond to physical stimuli like 
temperature, pH, osmolarity of the medium and Ca
2+
 concentration (36).  
AraC family proteins that are involved in carbon catabolism include RhaS and RhaR 
(sugar L-rhamnose in E. coli K12) (61), AraC (L-arabinose in E. coli K12) (62), MmsR (amino 
acid valine in Pseudomonas aeruginosa) (63), XylS (degradation of toluene in Pseudomonas 
putida) (64), MelR (melobiose in E. coli K12) (65) and many more . Members of this group are 
found to activate transcription in response to binding of effector molecules. AraC family proteins 
that regulate stress response genes include Rob (antibiotic resistance and heavy metal resistance 
in E. coli K12) (66), SoxS (superoxide response regulon in E. coli K12) (67), MarA (antibiotic 
resistance in E. coli K12) (68), Ada (alkylating agents in E. coli and Salmonella typhimurium and 
Mycobacterium tuberculosis) (69, 70) and many more. 
Structural domains and biochemical functions of AraC family proteins. Members of the 
AraC family proteins are generally comprised of two structural domains: a less conserved N-
terminal domain (NTD) and a conserved DNA binding domain (DBD). However, given the large 
size of the family there are few members (~5%) that do not fit into this classification and found 
to have a single domain (36, 71). The two domains in the AraC family proteins can be connected 
by a flexible linker (72). In AraC, recently it was found that substitutions in linker affect the 
affinity of AraC to bind to its half-sites on DNA. Further, their results suggest that AraC linker is 
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more likely involved in interactions between NTD and DBD of AraC (73). In RhaS and RhaR, 
single alanine substitution in the linker region have at most smaller effects on L-rhamnose 
response, suggesting that linker may not play a crucial role in RhaS and RhaR activation (74).   
N-terminal domain (NTD). NTD is a less conserved domain among AraC family proteins, 
although NTDs of some subgroups with in the family are conserved (36, 71, 75). For examples, 
NTDs of some protein such as AraC, RhaS and RhaR share sequence similarity to each other 
over their entire length. Unlike the DBD, N-terminal domain of the AraC family proteins is not 
studied extensively. Studies on AraC, ToxT, RhaS and RhaR showed that NTD is involved in 
dimerization and binding of effector molecules (76-78). Conclusive evidence for the 
dimerization and effector binding by AraC is obtained from the crystal structure of this protein 
solved in the presence of its effector L-arabinose. Evidence for the dimerization of Vibrio 
cholerae virulence activator ToxT came from dominant inhibition, LexA fusion, and two-hybrid 
analysis (20, 78) while evidence for effector binding was found from the crystal structure of 
protein solved in the presence of fatty acid effector (79). Evidence for the dimerization of RhaS 
and RhaR came from dominant negative experiments done by former graduate student Ana 
Kolin from my lab (76) (Ana Kolin, G.K. Hanjun and Susan Egan unpublished result). In 
dominant negative experiments, first she overexpressed RhaS-NTD and RhaR-NTD in strains 
that encode wild-type RhaS and RhaR leading to a dominant negative phenotype (a phenotype of 
decreased RhaS and RhaR activity because of formation of heterodimer between NTD and full-
length protein). Then she overexpressed different RhaS-NTD and RhaR-NTD variants that have 
mutations in the predicted dimerization residues and tested for the loss-of- dominant negative 
phenotype. This screen resulted in identifications of residues in the NTDs of RhaS and RhaR that 
might have role in dimerization. 
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Conserved DNA binding domain (DBD). As mentioned before AraC family proteins are 
characterized by the presence of DBD which is ~99 amino acids long and share sequence 
similarity within the family. The DBD is generally present at the C-terminus of the protein 
(although Rob and CfaR from E. coli have DBD at the N-terminus of the protein). DBD was 
found to have a role in DNA binding and transcription activation through contacts with RNA 
polymerase (RNAP) (35, 36, 71, 76, 77, 80-88). For members that have only the DBD (MarA 
and SoxS), it was shown that this domain is sufficient for transcription activation (89, 90). 
Secondary structure predictions and availability of full-length structures of MarA, Rob, (both 
were solved as co-crystals with DNA), ToxT (solved in effector bound state) and DBD of AraC 
have shown that DBD has two independent helix-turn-helix motifs (HTH1 and HTH2) connected 
by an α-helix. Sequence comparison of both the HTH motifs indicated that HTH2 is more 
conserved, with certain residues showing more than 90% identity (36). Genetic and biochemical 
analysis showed that many members of this family (MarA, AraC, Rns, PerA, RhaS, XylS and 
VirF) use both the HTH motifs to make base specific contacts with DNA (91-97). Structure of 
MarA specifically showed that a recognition helix from each helix-turn-helix motif is placed in 
the major groove of DNA (91). Genetic and biochemical analysis have revealed that DBDs have 
a role in interacting with σ
70
 of RNA polymerase (RNAP) to activate transcription, especially the 
transcription activators that bind at site on DNA overlapping -35 hexamer (80-83).  
Mechanism of transcription activation by AraC and ToxT 
AraC. AraC is the founding member of the AraC family proteins and is by far one of the very 
well characterized protein in the family. AraC is a dimer and each monomer of AraC binds to a 
single molecule of sugar L-arabinose (77, 98). AraC activates the transcription of genes in the L-
arabinose operon in E. coli in the presence of its effector L-arabinose (99). In AraC, an Arm 
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region (comprising of residues 7-14) was found to be required to keep AraC in a non-activation 
state in the absence of L-arabinose (100). Genetic and biochemical data showed that the Arm in 
the AraC-NTD makes differential contacts with DBD and arabinose in the absence and presence 
of arabinose, respectively (100, 101). The role of these structural changes in the Arm was 
explained by the proposed “light switch” signaling mechanism of transcription activation by 
AraC (79, 101-106) (Fig. 1). According to this mechanism, contacts between the N-terminal Arm 
and the DBD in the absence of L-arabinose constrain the DBD, such that the DBD of one 
monomer binds at a distantly spaced half-site (araO2) from the DBD of another AraC monomer 
(bound at half-site at araI1), and thus repress transcription of the araBAD operon (101, 103, 106-
111) (Fig. 1). When arabinose is bound to the AraC-NTD, N-terminal Arm moves to contact 
arabinose and thus releases the constraint on the AraC-DBD (105, 106, 108). In this arabinose 
bound state, the two domains of the AraC are flexibly connected and adopt a conformation in 
which both the DBDs of both the AraC monomers bind to closely spaced half sites (araI1 and 
araI2) on the araBAD promoter and thus activate transcription (Fig. 1). However, very recently it 
was found that NTD makes inter-domain contacts with the DBD even in the presence of 
arabinose, and these contacts are different from the contacts made in the absence of arabinose 
(112). 
ToxT. ToxT is an AraC family virulence activator of cholera toxin and toxin coregulated pilus 








Fig. 1. AraC light-switch mechanism. In the (-) arabinose state, AraC N-terminal Arm in the 
NTD interacts with the DBD. In this conformation, the DBD binds at two distantly spaced half-
sites (araO2 and araI1). In the (+) arabinose state, the N-terminal Arm bends over the arabinose 
and thus releases the DBD. DBDs of both the AraC monomers bind at adjascent half-sites (araI1 
and araI2), which activates transcription from the arabinose operon promoter region PBAD. Figure 
is from the reference (113).
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 the promoter region where it binds. The crystal structure of the ToxT is available and is the only 
available structure among the virulence activators of the AraC family and serves as a model for 
the other AraC family virulence activators (Fig. 2). The crystal structure of ToxT was solved 
with fatty acid effector bound in an effector binding pocket in the NTD (79). ToxT crystal 
structure showed a very large (~2000 Å
2
) polar inter-domain interface, with many polar and few 
hydrophobic interactions between NTD and DBD (79). ToxT responds to the bile salts and 
unsaturated fatty acid effectors such as arachidonic, linoleic, oleic, and plamitoleic acid (59, 79, 
114). When bound by these effector molecules ToxT does not interact with DNA and therefore 
does not activate transcription (59, 79, 114).  
To explain the mechanism of transcription activation by ToxT, a model has been 
proposed based on the structural and genetic analysis (79, 114). According to this model, ToxT is 
in “closed” conformation in the presence of effector and in “open” conformation in the absence 
of effector. In the presence of effector, NTD residues that surround the entrance to the ToxT 
effector-binding pocket, as well as the fatty acid effector itself, contact the DBD and keep the 
ToxT-DBD in an orientation that is not favorable to DNA binding (closed conformation) (79). 
These effector dependent inter-domain interactions between the ToxT NTD and DBD are a 
likely mechanism for transmission of the effector-binding status in ToxT. The model propose 
that in the absence of effector, the inter-domain interactions would be lost between NTD and 
DBD leading to destabilization of the closed complex into an open conformation that is capable 
of binding DNA and activating transcription. Alternatively, given the large ToxT inter-domain 
interface (79) and the presence of inter-domain contacts in AraC in both (+) and (-) arabinose 
state (112) we hypothesize that the ToxT inter-domain contacts may be altered/rearranged, but 
not eliminated, in its activation state.   
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AraC family virulence regulator Rns in Enterotoxigenic E. coli.  
Enterotoxigenic Escherichia coli (ETEC) is a common cause of infantile and traveler’s diarrhea 
(115, 116), and is most commonly acquired through contaminated food and water. It is estimated 
that ETEC causes nearly a billion cases of diarrheal disease and 300,000 – 500,000 deaths 
worldwide each year, mostly in children under the age of five (117). In the United States, ETEC 
infections are most often acquired during travel to endemic areas or in sporadic food-borne 
outbreaks (118-122). Worldwide, there are an estimated 40 million cases of traveler’s diarrhea, 
of which approximately one-third are caused by ETEC (118).  
Pathogenicity of ETEC strains is dependent on production of either one or both 
enterotoxins called heat-stable (ST) and heat-labile (ST) toxins (123, 124). These enterotoxins 
enter the host intestinal epithelial cells through receptor mediated endocytosis and causes 








) and thus 
causing profuse watery diarrheal symptoms (125-130). Effective release of the enterotoxins into 
the host intestinal epithelial cells occurs upon successful intestinal colonization by the bacteria 
and requires adherence of bacteria to the intestinal epithelial cells (131). Adherence of bacteria to 
the target epithelial cells is mediated through proteinaceous surface structures called pili/fimbrial 
colonization factors (CFs) (132, 133) and the expression of many of these CFs are activated by 
transcriptional activator Rns or its closest homolog CfaD (40-42).  
At least 25 different fimbrial CFs have been identified in different ETEC strains, 
although most strains express only two or three CFs (134-138). The most commonly expressed 
CFs are CFA/I, CS1, CS2, CS3, CS4, CS5 and CS6 (133, 139-143), out of which regulation of 
CFA/I, CS1 and CS2 are well studied so far. ETEC strains lacking fimbriae are unable to 
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colonize intestine and cause disease (132), indicating the central role fimbriae has in the overall 
ETEC pathogenesis. In well-studied infectious ETEC strains, Rns is found to activate the 
expression of fimbrial types and thereby considered as a major virulence regulator (41, 42). The 
fimbrial types Rns activates include CS1, CS2, CS3, CS4, CS14, CS17 and CS19 (41, 42). An 
Rns homologous protein CfaD/CfaR is required for the expression of CFA/I fimbriae (40). 
CfaD/CfaR is ~95% identical (251 out of 265 residues) and is functionally interchangeable with 
Rns, and recognizes the same binding sites as Rns (40). Limited information is available 
regarding the regulation of expression of other fimbrial types and it is possible that Rns/CfaD 
may enhance the transcription of these fimbrial types as well. 
In addition to the activation of fimbrial genes, Rns positively regulates the expression of 
its own gene (144) directly by binding at three sites in the promoter region of rns. The regions 
where Rns binds are centered at -227, +43 and +82 relative to transcription start site (TSS) (144). 
Rns activates the expression of several other putative virulence factor genes like cexE (encodes 
an uncharacterized extra-cytoplasmic protein) (145) and yisS (unknown function) (146). Rns 
represses the expression of a periplasmic protein NlpA by binding (at +5 to +40 relative to TSS) 
and preventing the formation of an open complex by RNAP at the nlpA promoter region (39). 
DNaseI footprinting has revealed Rns binding site immediately upstream of -35 region 
relative to TSS at promoters of CfaA, CS1 (Pcoo promoter), CS17, CS19 and PCFO71(42, 147), 
suggesting that Rns may activate transcription by directly contacting RNAP. In addition to 
binding site near -35 region, a second binding site was identified at all the promoter regions of 
these fimbrial types ( CfaA at region covering -88; CS1 at -144; for CS17 and PCFO71 at -109.5; 
CS19 at -108.5) (42, 147). It was found that each site has an additive effect on Rns dependent 
transcription and therefore is required for full activation of Rns. A highly unconventional 
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arrangement of binding sites is found to be involved in Rns autoactivation from its own 
promoter. The binding sites at rns promoter regions are centered at -227, +43 and +82 relative to 
TSS. Presence of downstream binding sites is commonly associated with transcription 
repressors. However, it was found that activation of rns requires the presence of upstream 
binding site (-227) and at least one of the two downstream binding sites (144). 
Rns homologs have been identified in several ETEC strains and other enteric bacterial 
pathogens. Proteins with strong homology to Rns are CsvR and FapR from ETEC (33, 34), 
AggR of enteroaggregative E. coli (32), PerA of enteropathogenic E. coli (31), VirF of Shigella 
(30) and ToxT of Vibrio cholerae (29). Among these, CsvR, AggR, PerA and ToxT regulate the 
expression of fimbrial genes (29, 31-34). VirF of Shigella activates the expression of icsA and 
virB genes, that have roles in invasion and cell-to-cell spread of bacteria in host epithelial cells 
(45-49, 148). Activation by Rns and the above mentioned homologs are sensitive to temperature 
and activate the expression from promoters that are repressed by nucleoid associated global 
transcriptional regulator H-NS at low temperatures (149-153)     
Mechanism of transcription activation by Rns. Rns activates the transcription of many genes 
encoding the fimbrial colonization factors (CFs) required for ETEC infection. However, the 
molecular mechanism of transcription activation by Rns is not clearly understood. Like AraC 
family proteins, the DBD of Rns has two predicted HTH motifs through which it binds to DNA. 
Uracil interference studies by Munson et al showed that Rns contacts the two major grooves of 
the DNA (147, 154) to activate transcription. Pentapeptide insertional mutagenesis experiments 
revealed that Rns uses both HTH motifs for making DNA contacts and thereby activating CS1 
fimbrial gene expression (93). Like many DBDs of AraC family proteins, DBD of Rns is thought 
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to be involved in making RNAP contacts, although the region involved in making RNAP 
contacts has not been identified.  
Unlike the DBD, the role of the NTD in Rns function is largely unknown. It was not fully 
known whether Rns acts primarily as a monomer or dimer as the previous reports were quite 
contradictory to each other (155, 156) Additionally, there is no evidence that Rns responds to 
exogenous effector molecules (156) (although structural prediction program I-TASSER (157) 
predicted the presence of a large effector binding pocket similar to effector binding pocket of 
ToxT structure). Nonetheless, both in vivo and in vitro experiments with N-terminal deletions of 
Rns indicate that the NTD is required for transcription activation (156). An Rns deletion 
construct with first 61 amino acids deleted has shown a complete loss of DNA binding and 
transcription activation or repression at their respective promoter regions (156). A region of 
residues I12-M18 in Rns-NTD are highly conserved among the closest homologs of Rns and 
shares a sequence identity of ~74% compared to the overall NTD identity of 26% among these 
proteins. This high percentage identity suggests an important role of this region in overall 
function of Rns. In further support of this hypothesis, Munson et al have isolated two random 
mutations at the N-terminus of the protein (I14T and N16D) whose activities were decreased 
dramatically at rns promoter indicating the importance of I14 and N16 residues in the 
transcription activation (156). They found that these mutations have disparate effects at other 
Rns regulated promoters and suggested that these residues may interact with DBD in a manner to 














Fig. 2. ToxT structure (79). Ribbon diagram of the ToxT with the effector palmitoleic acid 
(shown in stick form) bound in the NTD. The models are colored with rainbow effect with the 
blue at the N-terminus and red at the C-terminus. Rectangular black box represents the interface 
of the potential inter-domain interactions. The structure of ToxT serves as model structure for 












AraC family virulence regulator VirF in Shigella spp 
Shigella is a major cause of bacillary dysentery (shigellosis) in humans, a disease that is 
characterized by a short period of watery diarrhea with intestinal cramps, followed by bloody 
mucoid stools.  Various pathogenic species of Shigella, such as S. flexneri,  S. dysenteriae, S. 
sonnei and S. boydii cause shigellosis and are responsible for 165 million illnesses and over 1.1 
million deaths worldwide each year, with 70% of the deaths occurring in children under the age 
of five (158, 159). Among Shigella species, S. flexneri causes more mortality than any other 
species, with as few as 100 cells being sufficient to cause disease (160).  All these species carry a 
large 220 kb virulence plasmid that contains majority of the virulence genes required for the 
successful infection of the bacteria into colonic and rectal epithelial cells. These include genes 
required for the formation of the type 3 secretion system (T3SS) machinery, invasion of Shigella 
into host epithelial cells, and cell-to-cell spread (45-49).  
Expression of majority of the plasmid encoded virulence genes are regulated at the 
transcriptional level by an AraC family transcriptional activator VirF. Expression of VirF has 





C (148, 161).  At 37
o
C, VirF (96) and activates the expression of a regulatory cascade of 
genes involving icsA and virB genes, which encode IcsA and VirB virulence proteins, 
respectively (Fig. 3). VirB in turn activates the expression of many virulence-associated genes 
(located in mxi, spa and ipa operons) (148) responsible for the formation of the T3SS machinery, 
invasion and cell-to-cell spread (45-49).  
Transcription of VirF and its direct targets IcsA and VirB are under the negative control 













Fig. 3. VirF regulatory cascade. VirF activates transcription of the virB and icsA operons (148). 
VirB in turn activates expression of genes in mxi, spa and ipa operons that are required for the 
formation of T3SS machinery, invasion and cell-cell spread of Shigella into host epithelial cells 











C, low osmolarity, and low pH by binding at these promoter regions 
within intrinsically curved regions (162-164). H-NS binds at two regions at virF promoter region 
(centered at -250 and -1 relative to TSS), three regions at icsA promoter region (centered at +25, 
+115 and +330 relative to TSS), and one region at virB promoter region (-20 to +20 TSS) (149, 
162, 163, 165). H-NS binding sites at these promoter regions overlap binding site for RNA 
polymerase and therefore probably inhibit transcription initiation by preventing DNA binding by 
RNA polymerase (149). At 37
o
C, a change in DNA structure results in the release of H-NS from 
DNA and thereby facilitates expression from these promoters (161, 162, 164, 166). Expression 
of VirF (during the stationary phase of the growth), IcsA and VirB (during all growth phases) are 
positively regulated by a protein called integration host factor (IHF) which binds at a 13-bp 
consensus sequence near the start of open reading frames (167). In case of VirF the positive 
regulation by IHF is confined to stationary phase of the bacterial growth, while for IcsA and 
VirB the positive regulation by IHF is observed irrespective of the bacterial growth phase (167).   
VirF activates transcription of icsA and virB genes by directly binding at their respective 
promoter regions. DNase footprinting experiments showed four VirF binding sites (each ~40 to 
60 bp in length) centered at -3, +62, +160 and +245 at icsA promoter region (165). At virB 
promoter region VirF was found to interact directly in a region spanning -17 to -105 (149). VirF 
activation of virB expression is enhanced by the presence of DNA superhelicity at the promoter 
region (168) 
VirF is required for Shigella pathogenicity. The first step in the pathogenesis of Shigella is 
invasion into colonic and rectal epithelial cells. After invasion, Shigella replicates and spreads 
from cell-to-cell within the colonic and rectal epithelium.  In addition to direct damage by 
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Shigella, host inflammatory responses also contribute to the epithelial cell damage leading to 
shigellosis (45-48, 165, 169-171).  
VirF activates the expression of icsA which encodes an outer membrane protein IcsA 
(VirG) that helps in intracellular movement of the pathogen by mediating the actin based motility 
(172). IcsA gets localized at one pole of the bacterium and interacts with the host proteins N-
WASP and vinculin. IcsA interaction with N-WASP and vinculin stimulates Arp2/3 which 
mediates actin polymerization (173-176) and thereby helps in movement.  
 VirF activates the expression of virB which encodes VirB, which in turn activates the 
expression of many virulence-associated operons, such as, mxi, spa and ipa operon (148, 177, 
178). Genes in the mxi and spa operons encode the T3SS machinery through which effectors are 
released into host cells (52).  Another AraC family protein MxiE is encoded from mxi operon 
and further activates the expression of many effectors involved in post-invasion steps of 
infection (52). 
Genes in the ipa operon encode effector proteins (IcsB, IpaA, IpaB, IpaC and IpaD) 
which translocate directly into host cells (47, 179-182). IcsB, prevents the triggering of host 
autophagy, a process that can be used by host cells to export invading bacteria to lysosomes for 
degradation (183, 184). IcsB binds to outer membrane protein IcsA and competitively inhibits its 
interaction with the host autophagy protein Atg5, and thereby prevents the uptake of Shigella by 
autophagosome (183). In addition to interaction with Atg5, IcsB interacts with cholesterol and 
this interaction interferes with the formation of autophagosome (184). Another effector IpaB has 
major roles in regulation of secretion of other effectors, formation of pores in the host cell 
membrane, lysis of phagosomes and macrophage apoptosis through interactions with other 
19 
 
effector proteins (47, 179-182). IpaB interacts with IpaD in the secretion apparatus of the 
bacterial envelope and regulates the secretion of other Ipa proteins (182). IpaB interacts with 
IpaC and forms a hydrophobic complex that penetrates into the host cell membrane to form pores 
(179). Furthermore, IpaC of this complex integrates into the host cell membrane and stimulates 
Cdc42 (GTPase) that promotes membrane ruffles to facilitate the intake of bacteria into the host 
cells (180). The IpaB-IpaC complex is involved in lysing of phagosomes in macrophages and 
epithelial cells and thereby allows bacteria to gain free access to the host cytosol (47). IpaB-IpaC 
complex lyse the double cellular membranes between two adjacent epithelial cells leading to the 
movement of bacteria from cell to cell. When secreted into epithelial cells, IpaB interacts with 
pro-apoptotic capase-1 and triggers macrophage apoptosis (181). Apoptosis of macrophages in 
turn activates pro-inflammatory cytokines that induce the inflammatory responses leading to 
bacillary dysentery (181).  
Given that VirF is required for VirB expression and that VirB activates the expression of 
multiple virulence-associated genes that are required for the earliest steps in the successful 
invasion of host cells by Shigella, VirF is considered the master regulator of Shigella virulence 
and works as an upstream regulator of all the virulence-associated genes (45-49).  Further, 
mutants of Shigella that do not express VirF are avirulent (185, 186). 
Similarities between virulence regulators Rns and VirF. Rns and VirF are virulence 
regulators in ETEC and Shigella respectively. Like many AraC family proteins both of them 
have structural domains NTD and DBD. Both Rns and VirF are fairly closely related to each 
other and share an amino acid sequence identity of 36%. Unlike the common situation in AraC 
family where relatedness is limited to DBD, Rns and VirF shares sequence similarities 
throughout their length. Both of them have substantially low G + C content (28%) compared to 
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the overall G + C content of their respective pathogens (50%). This, combined with their high 
sequence identity suggests that they may have a common ancestor outside their respective 
pathogens and were probably acquired by these pathogens by some mechanism (36, 187). 
Although Rns and VirF activate different sets of genes, it was found that Rns could activate the 
gens regulated by VirF and therefore could functionally substitute for VirF (188). In addition, 
CfaR which is ~95% identical to Rns could functionally substitute for VirF (188). Both Rns and 
VirF are sensitive to changes in temperature and activate transcription at 37
o
C from promoter 
regions that are subject to negative regulation by H-NS at low temperatures (41, 149).   
The AraC family activator RhaR 
RhaR is an AraC family protein that activates the transcription of rhaSR operon that 
encodes both RhaS and RhaR proteins (102, 189, 190). RhaS in turn activates the transcription of 
rhaBAD and rhaT operons (189, 191, 192) (Fig. 4). rhaT encodes a transporter protein that is 
involved in the uptake of L-rhamnose into the E. coli cells (193). The rhaBAD operon encodes 
proteins that are required for sugar L-rhamnose catabolic breakdown (rhaB encodes L-
rhamnulokinase that converts L-rhamnulose into L-rhamnuose 1-phospate (194); rhaA encodes 
an isomerase that converts L-rhamnose to L-rhamnulose (195); rhaD encodes an aldolase that 
breaks down L-rhamnuose 1-phospate  into dihydroxy acetone phosphate and L- lactaldehyde 
(196). Transcription activation by RhaR requires the presence of effector L-rhamnose. In the 
absence of rhamnose, RhaR can bind to the DNA but activates transcription of genes encoding 
RhaS and RhaR only to low basal levels. But when the RhaR effector L- rhamnose is available, 
RhaR can activate transcription to a 5-7 fold higher level relative to the absence of rhamnose 
(102, 189, 190, 197, 198). 
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Previously, it was found that the DNA binding domain (DBD) of RhaR, when expressed 
alone, can bind to the DNA but does not respond to sugar L-rhamnose, suggesting that L-
rhamnose binding site is in the NTD (76). It was found that DBD in the full length RhaR 
activates transcription through interactions with RNAP σ70 and C-terminal domain (CTD) of the 
RNAP α-subunit (81, 199). The separation of L-rhamnose binding and transcription activation 
activities between the two domains suggests that there must be some form of communication 
between NTD and DBD to correlate transcription activation to L-rhamnose binding. Therefore, 
we hypothesized that the signal of L-rhamnose binding in the NTD is somehow communicated to 
the DBD, and thus causing structural or conformational changes required by the DBD to activate 
transcription (presumably by binding to the DNA with higher affinity and contacting RNAP). 
Previous work from our lab (by Ana Kolin) has indicated that the linker that connects the RhaR 
NTD to DBD does not play any crucial role in the activation, suggesting that L-rhamnose 
dependent allosteric signals are not mediated through the linker region (74). To identify the 
mechanism of RhaR L-rhamnose response, she further tested the hypothesis that RhaR N-
terminal residues have a role in L-rhamnose response that is similar to N-terminal residues of 
AraC that play a role in AraC L-arabinose response (as described by light-switch mechanism 
above). She made a series of RhaR N-terminal truncations and found that the deletion of residues 
up to the first 34 amino acids did not have any role in RhaR L-rhamnose response (200). N-
terminal truncations extending after the first 34 amino acids (∆40 or more) resulted in decreased 
activation levels along with decreased protein levels, and thus restricted from drawing any 
conclusions (200). However, alignment of AraC with the RhaR showed that AraC Arm aligns 
with the RhaR residues 35-43. Further, structural prediction model I-TASSER has predicted that 
RhaR residues from 35-45 may form a loop that is positioned to contact residues in the DBD. 
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These observations led us to hypothesize that RhaR residues 35-45 may have a role as analogous 
to the role of AraC Arm residues. 
Targeting of AraC family proteins to develop novel anti-bacterial agents. Given that AraC 
family proteins are required for the expression of virulence genes in many human pathogens, 
they are considered as potential targets for novel antibacterial agents. To develop novel 
antibacterials, AraC family proteins can be targeted in two fundamentally different paths: 1) 
high-through put screening of large-libraries of molecules against AraC family proteins 2) 
designing inhibitors using a rational drug design approach (201). A successful rational drug 
design approach to target AraC family proteins would need either structure of the target or a 
better understanding of the molecular interactions involved in transcription activation by these 
proteins. Using high-throughput screening, Dr. Susan Egan lab recently identified an AraC 
family inhibitor, SE-1 (previously called OSSL_051168), which selectively inhibited two AraC 
family activators RhaS and RhaR (activators of L-rhamnose catabolic operons in E. coli), despite 
their limited sequence similarity with each other (202). We further found that SE-1 inhibited 
RhaS and the RhaS DNA-binding domain (RhaS-DBD) to the same extent, and that it blocked 
DNA binding by RhaS and RhaR (202).  Furthermore, SE-1 had little or no impact on DNA 
binding by the non-AraC family proteins LacI and CRP, indicating selectivity for at least the 
tested AraC family proteins (202). Taken together, our results support the hypothesis that SE-1 
acts on the RhaS and RhaR DBDs - the structurally conserved domain in AraC family proteins.  
These observations lead us to propose the hypothesis that this compound might selectively 












Fig. 4. E. coli L-rhamnose regulon. The relative positions of genes in the L-rhamnose operon 
are presented as arrows. DNA was shown as a black horizontal line. Proteins that bind at the 
rhaBAD and rhaSR promoters and their relative positions are shown on the DNA (Figure 






The overall goals of my research are to better understand the transcription activation 
mechanisms of Rns and RhaR, and to test a small molecule for inhibition of Rns and VirF. The 
overall goals can be divided into the following four subgoals. 
Mechanism of transcription activation in ETEC virulence activator Rns: The molecular 
mechanism of Rns activation of fimbrial genes is not clearly understood. Evidence suggests that 
Rns-DBD alone is not capable of activating transcription and requires the presence of regulatory 
domain (NTD) (156). This is supported by the deletion analysis of NTD regions and 
identification of Rns-NTD variants I14T and N16D at the N-terminus of the protein that strongly 
reduced activation at rns promoter (156). We proposed that transcription activation mechanism 
in Rns involves contacts between residues in the Rns-NTD and Rns-DBD. In the absence of 
crystal structure of Rns, we used the only available crystal structure of ToxT (79) (the only 
available structure in AraC family virulence activators) as our model. ToxT crystal structure 
solved with fatty acid effector bound in the effector binding pocket showed that β2-strand of 
NTD and several residues in the DBD are positioned to make inter-domain interactions (79). Rns 
shares ~20% identity and 46% similarity with ToxT and structural prediction model (I-TASSER) 
has predicted a structure for Rns that is very similar to ToxT (79, 157). I-TASSER predicted 
multiple contacts between a region in the Rns-NTD and several residues in the Rns-DBD. The 
region in the Rns-NTD that is analogous to the ToxT-NTD region that contacts the DBD is 
comprised of residues I12-M18 (79). We referred this region of residues in Rns-NTD as the 
regulatory site2 (RS2). The region in the Rns-DBD that is predicted to be contacted by the 
residues in the RS2 region includes several residues (Q211, S215, K216, L219, K249-G252 and 
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Y261), which we refer to as the allosteric site (AS2). Residues in both RS2 and AS2 regions also 
align with ToxT regions involved in making inter-domain interactions.  
In order to understand the roles RS2 and AS2 regions may have in transcription 
activation of Rns, we have mutagenized residues in RS2 and AS2 regions and studied their effect 
in Rns dependent LacZ expression from cfaA-lacZ
∆60 
(Wild-type Rns activates lacZ expression 
from this fusion) and nlpA
cfaA
-lacZ fusion (Wild-type Rns represses lacZ expression from this 
fusion). We identified multiple variants in specific RS2 region residues (N15, N16 and I17) and 
AS2 region residues (K216, H250, Y251 and G252) that conferred decreased Rns-dependent 
expression of cfaA-lacZ
∆60
 compared to the wild type, suggesting that specific residues in these 
regions are required for Rns-dependent cfaA-lacZ
∆60 
expression. Further analysis of variants for 
repression of Rns-dependent LacZ expression from nlpA
cfaA
-lacZ fusion resulted in 
distinguishing residues that are required for DNA binding from transcription activation (In this 
context, we refer transcription activation as an aggregate of processes such as contacts with RNA 
polymerase, alteration of promoter DNA conformation and relief of repression). Our results 
suggested that residues N15, N16, I17, K216, Y251 and G252 are likely required for 
transcription activation and residue H250 is likely required for both transcription activation and 
DNA binding. 
 Purification and properties of Rns. The second goal of this study was purification and 
biochemical characterization of Rns protein. I purified GB1 tagged Rns-DBD and MBP tagged 
full-length Rns using affinity purification and tested for their ability to bind their specific DNA 
in electrophoretic mobility shift assays (EMSAs). Behavior of MBP-Rns in vitro was further 
tested in gel filtration analysis, thermo flour analysis and dynamic light scattering analysis. The 
purified protein was used to raise antibodies against Rns for use in Western blotting. 
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Small molecule inhibitor of AraC family proteins Rns and VirF. The third goal of my 
research was to test a small molecule compound, SE-1 (previously OSSL_051168), which our 
lab had identified as an effective inhibitor of the AraC family proteins RhaS and RhaR (202), for 
its ability to inhibit virulence activators Rns and VirF. Preliminary work by Jeff Skredenske 
suggested that SE-1 inhibits Rns (unpublished) and VirF (203) activation of LacZ expression in 
E. coli cell-based reporter gene assays . I further found that SE-1 effectively inhibit Rns and VirF 
DNA binding using in vitro DNA binding assays. SE-1 was tested for its ability to inhibit VirF 
activation in Shigella using reporter gene assays. Analysis of mRNA levels for direct and 
indirect targets of VirF in the presence of SE-1was performed by real-time quantitative reverse 
transcription PCR (qRT-PCR) and showed decreased expression of all of the VirF dependent 
virulence genes tested. Invasion assays were performed (done by Ichie Osaka) to test the ability 
of SE-1 in inhibition of Shigella invasion of epithelial cells in tissue culture cells and found that 
SE-1 inhibits invasion by Shigella. 
Role of RhaR Arm in L-rhamnose response. My fourth goal of this study was to understand 
the role of Arm residues (35-45) in RhaR in transmitting L-rhamnose signal from RhaR-NTD to 
RhaR-DBD. Evidence suggests that L-rhamnose binds at the NTD of RhaR, while transcription 
activation is performed by RhaR-DBD. Therefore, one hypothesis is that signal is transmitted 
from RhaR-NTD to RhaR-DBD in response to L-rhamnose binding. Here, I have tested whether 
that signal is transmitted through Arm residues (35-45) in RhaR that align with Arm residues in 
AraC. I mutagenized residues in the RhaR Arm region by site-directed random mutagenesis and 
isolated a total of 46 unique variants. Our results suggested that residue L35 in the Arm may be 





MATERIALS AND METHODS  
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Growth conditions.  Escherichia coli strains were grown in tryptone-yeast extract (TY) broth 
(0.8% Difco tryptone, 0.5% Difco yeast extract, and 0.5% NaCl, [pH 7.0]). Difco nutrient agar 
(1.5% agar) (BD, Cockeysville, MD) was used routinely to grow E. coli strains on solid medium. 
To test for lacZ expression by Rns and RhaR on solid media, Difco nutrient agar was 
supplemented with X-gal (5-bromo-4-chloro-3-indolyl-β-D-galactoside, 40 µg/ml) and X-gal 
with L-rhamnose (0.2%), respectively. All liquid cultures were grown at 37°C with shaking, 
except for cultures carrying the temperature sensitive plasmid pAH69 pAH69, (204) which were 
grown at 30°C. β-galactosidase assays in E. coli strains that express RhaR were grown in the 
presence or absence of 0.4% L-rhamnose  in a MOPS [ 3-(N-morpholino)propanesulfonic acid]-
buffered minimal medium (40 mM MOPS, 4 mM Tricine, 10 µM FeSO4, 9.5 mM NH4Cl, 0.276 
mM K2SO4, 0.5 µM CaCl2, 0.528 mM MgCl2, 50 mM NaCl, 3 nM Na2MoO4, 0.4 µM H3BO3, 30 
nM CoCl2, 10 nM CuSO4, 80 nM MnCl2, 10 nM ZnSO4, 1.32 mM K2HPO4, 10 mM NaHCO3, 
0.002% casaminoacids, 0.002% thiamine)  with a carbon source of 0.4% glycerol. 
Cultures of Shigella strains were grown in tryptic soy broth (TSB, pH 7.0) (BD), Luria-
Bertani broth (1% tryptone, 0.5% yeast extract and 1% NaCl) or on tryptic soy agar (TSA, 1.5% 
agar) (BD) containing congo red dye (0.025%).  All Shigella strains were picked as red colonies 
from TSA plates containing Congo red.  All Shigella strains were grown at 37
o
C with shaking, 
unless otherwise specified. Appropriate antibiotics (ampicillin, 200 μg/ml; chloramphenicol, 30 
µg/ml; tetracycline, 20 µg/ml; and spectinomycin, 100 μg/ml) were used as indicated. 
General Methods. Primers used in this study were synthesized by Eurofins MWG Operon 
(Huntsville, AL). PCR was performed using Phusion High-Fidelity DNA Polymerase (Thermo 
Fisher Scientific).  Amplified DNA fragments were cleaned up using either E.Z.N.A. Cycle Pure 
(Omega Bio-tek, Norcross, GA) or IBI Gel/PCR products extraction kits (IBI Scientific, Peosta, 
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IA).  Standard methods were followed for restriction endonuclease digestion, ligation, and 
transformation. Restriction endonucleases and T4 DNA ligase were purchased from New 
England Biolabs (Beverly, MA).  Plasmid isolation from bacteria was performed using the IBI 
High-Speed Plasmid Mini kit (MIDSCI, St. Louis, MO). DNA sequencing was performed to 
obtain sequences of for both strands of the entire cloned region for all cloned and mutagenized 
DNA fragments at the NorthWestern University Genomics Core (Chicago, IL). 
Bacterial strains, plasmids and oligos. Bacterial strains, plasmids and oligos used in this study 
are shown in Tables 1, 2, 3 respectively. 
Construction of Rns and Rns-DBD plasmids for in vivo experiments. Rns and Rns-DBD 
were expressed from lac promoter in a low copy number plasmid pHG165 (Amp
r
) (205). To 
make these plasmids, rns was first subcloned from pEU2030 (a pUC18 based high copy number 
plasmid, ampicillin resistant) into pSU18 (a low copy number plasmid, chloramphenicol 
resistant) to make pSU18/rns. The subcloning method consisted of PCR amplification of the rns 
using primers 2963 and 2964. The forward primer 2963 had Shine-Dalgarno sequence (part of 
the ribosome binding site). The PCR products were then digested and ligated into pSU18 
plasmid at EcoRI and HindIII sites. The plasmid pSU18/rns was then used as template to amplify 
the regions encoding Rns and Rns-DBD (residues 157-265) including the Shine-Dalgarno 
sequence. The PCR products were digested and then ligated into pHG165 such that the lac 
promoter of the pHG165 would drive the transcription, but translation initiation site was part of 
the insert. This resulted in plasmids pHG165/rns and pHG165/rns DBD (residues 157-265).  
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Table 1.  Bacterial strains used in this study.   
Strain Genotype Source or Reference 
MC4100 F
-
 araD139 Δ (argF-lac) U169 rpsL150 relA1 



















AF51 MC4100 attBHK022::pCFAILac10 (156) 
AB97 MC4100 λMAD102 [Φ (virB-lacZ)] -259 to +308 
relative to transcription start site  
A.  Maurelli 
 
SME1362 DH5α Laboratory collection 
ECL116  F
-








SME1048 ECL116 recA::cat     Laboratory collection 
SG22166 MC4100 malP::lacI
q
 ftsH1(ts) zgj::Tn10   
SME2525 ECL116 λΦ(rhaS-lacZ)Δ128 ΔrhaSR::kan 
recA::cat 
Laboratory collection 
SME3110 ECL116 λΦ(rhaS-lacZ)Δ128 ΔrhaSR::kan Laboratory collection 
SME3160 ECL116 λΦ(rhaS-lacZ)Δ85 ΔrhaSR::kan recA::cat Laboratory collection 
SME3358 ECL116 ∆rhaS λ Φ (Phts-lacZ) recA::cat (202) 
SME3359 SME3358 + pHG165/lacI   This study 
 
SME3613(AP76) MC4100 attBHK022::pNLPALac1 (156) 
SME 3670                      AF51+ pHG165/rns This study 
SME 3676 AF51 + pSU18/rns This study 
SME 3677 SME 3110 + pSU18/rhaR This study 
SME3740 SME 2525 + pHG165/rhaR L35V This study 
SME3741 SME 2525 + pHG165/rhaR L35K   This study 
SME3742   SME 2525 + pHG165/rhaR L35Y This study 
SME3743 SME 2525 + pHG165/rhaR L35K   This study 
SME3744 SME 2525 + pHG165/rhaR L35I   This study 
SME3745 SME 2525 + pHG165/rhaR L35G This study 
SME3747 SME 2525 + pHG165/rhaR K36V This study 
SME3749 AF51 recA::cat This study 
SME3752 AF51+ pHG165/rns (117-265) This study 
SME3779 SME 3754 + pHG165/rns (157-265) This study 
SME3780 SME 3754 + pHG165 This study 
SME3781 SME2525 + pHG165/rhaR L38V This study 
SME3782 SME2525 + pHG165/rhaR L38S This study 
SME3783 SME2525 + pHG165/rhaR L38G This study 
SME3784 SME2525 + pHG165/rhaR L38R This study 
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SME3785 SME2525 + pHG165/rhaR L38W This study 
SME3786 SME2525 + pHG165/rhaR L37I This study 
SME3787 SME2525 + pHG165/rhaR L37R This study 
SME3750  BL21(DE3) DnaY cells (Km
r
) Laboratory collection 
SME3805  Rosetta2(DE3)  Novagen 
SME3817 SME3750 + pDZ1/rns This study 
SME3818 SME3750 + pDZ1/rns NTD This study 
SME3819 SME3750 + pDZ3/rns This study 
SME3820 SME3750 + pDZ3/rns NTD  This study 
SME3863 SME3750 + pDZ3/rns DBD This study 
SME3864 SME3805 + pDZ1/rns This study 
SME3865 SME3805 + pDZ1/rns NTD This study 
SME3952 SME2525 + pHG165/rhaR K36A  This study 
SME3953  SME2525 + pHG165/rhaR K36R  This study 
SME3954 SME2525 + pHG165/rhaR L37C  This study 
SME3955 SME2525 + pHG165/rhaR L37S  This study 
SME3956 SME2525 + pHG165/rhaR L37G This study 
SME3957 SME2525 + pHG165/rhaR L37M This study 
SME3958 SME2525 + pHG165/rhaR L37A  This study 
SME3961 SME2525 + pHG165/rhaR L35D  This study 
SME3963 SME3160 + pHG165/rhaR L35Y  This study 
SME3964 SME3160 + pHG165/rhaR L35V  This study 
SME3965 SME3160 + pHG165/rhaR L35K  This study 
SME3966 SME3160 + pHG165/rhaR L35I  This study 
SME3967 SME3160 + pHG165/rhaR L35G  This study 
SME3968 SME3160 + pHG165/rhaR L35D  This study 
SME3969 SME3160 + pHG165/rhaR K36R  This study 
SME3970 SME3160 + pHG165/rhaR K36A This study 
SME3971 SME3160 + pHG165/rhaR K36V This study 
SME3972 SME3160 + pHG165/rhaR L37I  This study 
SME3973 SME3160 + pHG165/rhaR L37R This study 
SME3974 SME3160 + pHG165/rhaR L37M This study 
SME3975 SME3160 + pHG165/rhaR L37S This study 
SME3976 SME3160 + pHG165/rhaR L37A This study 
SME3977 SME3160 + pHG165/rhaR L37C This study 
SME3978 SME3160 + pHG165/rhaR L37G This study 
SME3979 SME3160 + pHG165/rhaR L38V This study 
SME3980 SME3160 + pHG165/rhaR L38R This study 
SME3981 SME3160 + pHG165/rhaR L38G This study 
SME3982 SME3160 + pHG165/rhaR L38S This study 
SME3983 SME3160 + pHG165/rhaR L38W This study 
SME3985  SME3749 + pHG165/rns  This study 
SME3991 SME3160 + pHG165/rhaR K39A  This study 
SME3992 SME3160 + pHG165/rhaR K39V  This study 
SME3993 SME3160 + pHG165/rhaR K39P  This study 
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SME3994 SME3160 + pHG165/rhaR K39E  This study 
SME3995 SME3160 + pHG165/rhaR K39T  This study 
SME3996 SME3160 + pHG165/rhaR K39S  This study 
SME3997 SME3160 + pHG165/rhaR K39P  This study 
SME3998 SME3160 + pHG165/rhaR D40E  This study 
SME3999 SME3160 + pHG165/rhaR D40G This study 
SME4000 SME3160 + pHG165/rhaR D41S  This study 
SME4001 SME3160 + pHG165/rhaR D41A This study 
SME4002 SME3160 + pHG165/rhaR D41V This study 
SME4003 SME3160 + pHG165/rhaR F42M This study 
SME4004 SME3160 + pHG165/rhaR F42I  This study 
SME4005 SME3160 + pHG165/rhaR F42D This study 
SME4006 SME3160 + pHG165/rhaR F42N This study 
SME4007 SME3160 + pHG165/rhaR F42P  This study 
SME4008 SME3160 + pHG165/rhaR F43V This study 
SME4009 SME3160 + pHG165/rhaR F43C This study 
SME4010 SME3160 + pHG165/rhaR F43R This study 
SME4011 SME3160 + pHG165/rhaR F43A This study 
SME4012 SME3160 + pHG165/rhaR F43G This study 
SME4013 SME3160 + pHG165/rhaR A44G This study 
SME4014 SME3160 + pHG165/rhaR A44E  This study 
SME4015 SME3160 + pHG165/rhaR S45V  This study 
SME4016 SME3160 + pHG165/rhaR S45G  This study 
SME4017 SME3160 + pHG165/rhaR S45T  This study 
SME4019 SME1362 + pDZ1/rns This study 
SME4020 SME1362 + pSE295/rns This study 
SME4021 ECL116 λMAD102 [Φ (virB-lacZ)] -259 to +308 
relative to transcription start site   
(202) 
SME4143  KS1000 +  pMBP-Rns1 This study 
SME4147  KS1000 + pMBP-Rns1 + pRARE2 This study 
SME4149 SME1362 + pSE290/ rns
co
  This study 
SME4150 SME1362 + pSE295/rns
co
 This study 
SME4219 SME3160 + pHG165/rhaR F42L   This study 
SME4220 SME2525 + pHG165/rhaR F43S This study 
SME4240 SME4021 malP::lacI
q
 zhc-511:: Tn10 This study 
SME4259 SME4240 recA::cat This study 
SME4319 KS1000 + pMAL/virF This study 
SME4324 MC4100 attBHK022::pSE298 This study 
SME4335 SME4324 recA::cat This study 
SME4382 SME4259 + pHG165/virF This study 
SME4336 SME4335 + pHG165/rns This study 
SME4337 SME4335 + pHG165 This study 
SME4344 SME4335 + pHG165/rns I12R This study 
SME4345 SME4335 + pHG165/rns I12S This study 
SME4346 SME4335 + pHG165/rns I12G This study 
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SME4347 SME4335 + pHG165/rns I12E This study 
SME4348 SME4335 + pHG165/rns I12W This study 
SME4349 SME4335 + pHG165/rns I14W This study 
SME4350 SME4335 + pHG165/rns N15L This study 
SME4351 SME4335 + pHG165/rns N15D This study 
SME4352 SME4335 + pHG165/rns N15G This study 
SME4353 SME4335 + pHG165/rns N16C This study 
SME4354 SME4335 + pHG165/rns N16D This study 
SME4355 SME4335 + pHG165/rns N16G This study 
SME4356 SME4335 + pHG165/rns K249R This study 
SME4357 SME4335 + pHG165/rns K249Y This study 
SME4358 SME4335 + pHG165/rns K249A This study 
SME4359 SME4335 + pHG165/rns K249E This study 
SME4360 SME4335 + pHG165/rns K249N This study 
SME4361 SME4335 + pHG165/rns H250R This study 
SME4362 SME4335 + pHG165/rns H250I This study 
SME4363 SME4335 + pHG165/rns H250N This study 
SME4364 SME4335 + pHG165/rns H250T This study 
SME4365 SME4335 + pHG165/rns H250V This study 
SME4366 SME4335 + pHG165/rns H251F This study 
SME4367 SME4335 + pHG165/rns H251T This study 
SME4368 SME4335 + pHG165/rns H251L This study 
SME4369 SME4335 + pHG165/rns H251V This study 
SME4370 SME4335 + pHG165/rns G252N This study 
SME4371 SME4335 + pHG165/rns G252Q This study 
SME4372 SME4335 + pHG165/rns G252R This study 
SME4373 SME4335 + pHG165/rns G252S This study 
SME4374 SME4335 + pHG165/rns G252A This study 
SME4375 SME4335 + pHG165/rns Y261G This study 
SME4376 SME4335 + pHG165/rns Y261E This study 
SME4377 SME4335 + pHG165/rns Y261M This study 
SME4378 SME4335 + pHG165/rns Y261A This study 
SME4379 SME4335 + pHG165/rns Y261R This study 
SME4380 SME4335 + pHG165/rns Y261C This study 
SME4382 SME4259 + pHG165/virF This study 
SME4383 SME4259 + pHG165/rns This study 
SME4436  SME3989 + pSE299 This study 
SME4437 SME4335 + pHG165/rns I17V This study 
SME4438 SME4335 + pHG165/rns I17C This study 
SME4439 SME4335 + pHG165/rns I17P This study 
SME4440 SME4335 + pHG165/rns I17R This study 
SME4441 SME4335 + pHG165/rns I17N This study 
SME4442 SME4335 + pHG165/rns I17Y This study 
SME4443 SME4335 + pHG165/rns I17S This study 
SME4444 SME4335 + pHG165/rns M18R This study 
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SME4445 SME4335 + pHG165/rns M18P This study 
SME4446 SME4335 + pHG165/rns M18G This study 
SME4447 SME4335 + pHG165/rns Q211G This study 
SME4450 SME4335 + pHG165/rns Q211S This study 
SME4451 SME4335 + pHG165/rns Q211L This study 
SME4452 SME4335 + pHG165/rns Q211N This study 
SME4453 SME4335 + pHG165/rns S215V This study 
SME4455 SME4335 + pHG165/rns S215G This study 
SME4457 SME4335 + pHG165/rns S215K This study 
SME4458 SME4335 + pHG165/rns S215D This study 
SME4459 SME4335 + pHG165/rns K216P This study 
SME4460 SME4335 + pHG165/rns K216L This study 
SME4461 SME4335 + pHG165/rns L219M This study 
SME4463 SME4335 + pHG165/rns L219H This study 
SME4464 SME4335 + pHG165/rns L219P This study 
SME4465 SME4335 + pHG165/rns L219A This study 
SME4466 SME4335 + pHG165/rns L219Y This stud 
SME4467 SME4335 + pHG165/rns L219K This study 
SME4468 SME4335 + pHG165/rns L219I This study 
SME4471 SME4335 + pHG165/rns K13S This study 
SME4472 SME4335 + pHG165/rns K13G This study 
SME4473 SME4335 + pHG165/rns K13C This study 
SME4474 MC4100 attBHK022::pSE299 This study 
SME4475 SME4474 + pHG165/rns I12R This study 
SME4476 SME4474 + pHG165/rns I12S This study 
SME4477 SME4474 + pHG165/rns I12G This study 
SME4478 SME4474 + pHG165/rns I12E This study 
SME4479 SME4474 + pHG165/rns I12W This study 
SME4480 SME4474 + pHG165/rns K13S This study 
SME4481 SME4474 + pHG165/rns K13G This study 
SME4482 SME4474 + pHG165/rns K13C This study 
SME4483 SME4474 + pHG165/rns I14W This study 
SME4484 SME4474 + pHG165/rns N15L This study 
SME4485 SME4474 + pHG165/rns N15D This study 
SME4486 SME4474 + pHG165/rns N15G This study 
SME4487 SME4474 + pHG165/rns N16C This study 
SME4488 SME4474 + pHG165/rns N16D This study 
SME4489 SME4474 + pHG165/rns N16G This study 
SME4490 SME4474 + pHG165/rns I17N This study 
SME4491 SME4474 + pHG165/rns I17R This study 
SME4492 SME4474 + pHG165/rns I17S This study 
SME4493 SME4474 + pHG165/rns I17V This study 
SME4494 SME4474 + pHG165/rns I17Y This study 
SME4495 SME4474 + pHG165/rns I17C This study 
SME4496 SME4474 + pHG165/rns I17P This study 
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SME4497 SME4474 + pHG165/rns M18P This study 
SME4498 SME4474 + pHG165/rns M18R This study 
SME4499 SME4474 + pHG165/rns M18G This study 
SME4501 SME4474 + pHG165/rns Q211S This study 
SME4502 SME4474 + pHG165/rns Q211G This study 
SME4503 SME4474 + pHG165/rns Q211L This study 
SME4504 SME4474 + pHG165/rns Q211N This study 
SME4505 SME4474 + pHG165/rns S215V This study 
SME4507 SME4474 + pHG165/rns S215G This study 
SME4508 SME4474 + pHG165/rns S215D This study 
SME4509 SME4474 + pHG165/rns S215K This study 
SME4510 SME4474 + pHG165/rns K216P This study 
SME4511 SME4474 + pHG165/rns K216L This study 
SME4512 SME4474 + pHG165/rns L219M This study 
SME4513 SME4474 + pHG165/rns L219I This study 
SME4514 SME4474 + pHG165/rns L219P This study 
SME4515 SME4474 + pHG165/rns L219A This study 
SME4516 SME4474 + pHG165/rns L219Y This study 
SME4517 SME4474 + pHG165/rns L219K This study 
SME4518 SME4474 + pHG165/rns L219H This study 
SME4519 SME4474 + pHG165/rns This study 
SME4520 SME4474 + pHG165 This study 
SME4521 SME4474 + pHG165/rns K249R This study 
SME4522 SME4474 + pHG165/rns K249Y This study 
SME4523 SME4474 + pHG165/rns K249A This study 
SME4524 SME4474 + pHG165/rns K249E This study 
SME4525 SME4474 + pHG165/rns K249N This study 
SME4526 SME4474 + pHG165/rns H250R This study 
SME4527 SME4474 + pHG165/rns H250I This study 
SME4528 SME4474 + pHG165/rns H250N This study 
SME4529 SME4474 + pHG165/rns H250T This study 
SME4530 SME4474 + pHG165/rns H250V This study 
SME4531 SME4474 + pHG165/rns Y251F This study 
SME4532 SME4474 + pHG165/rns Y251T This study 
SME4533 SME4474 + pHG165/rns Y251L This study 
SME4534 SME4474 + pHG165/rns Y251V This study 
SME4535 SME4474 + pHG165/rns G252N This study 
SME4536 SME4474 + pHG165/rns G252Q This study 
SME4537 SME4474 + pHG165/rns G252R This study 
SME4538 SME4474 + pHG165/rns G252S This study 
SME4539 SME4474 + pHG165/rns G252A This study 
SME4540 SME4474 + pHG165/rns Y261G This study 
SME4541 SME4474 + pHG165/rns Y261E This study 
SME4542 SME4474 + pHG165/rns Y261M This study 
SME4543 SME4474 + pHG165/rns Y261A This study 
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SME4544 SME4474 + pHG165/rns Y261R This study 
SME4545 SME4474 + pHG165/rns Y261C This study 
SME4590 SME3989 + pSE298 This study 
S.flexneri strains   
BS536 S.flexneri virB-lacZ   
 
A.  Maurelli 




Table 2.  Plasmids used in this study.   
Plasmid Relevant characteristics Source or Reference 
pHG165 lacZα rop Amp
r
  
pHG165/virF virF expressed from pHG165 lac promoter, Amp
r
 This Study 
pHG165/lacI lacI expressed from pHG165 lac promoter, Amp
r
 (202) 
pHG165/rns rns expressed from pHG165 lac promoter, Amp
r
 This study 
pHG165/rns 
(117-265)  












pSU18 LacZα Rep(p15A), Cm
r
  
pSU18/rns rns expressed from pSU18 lac promoter, Cm
r
 This study 
pSU18/rhaR rhaR expressed from pSU18 lac promoter, Cm
r
 This study 
pAH69 Temperature sensitive helper plasmid, Amp
r
 (204) 












 This study 
pDZ1 T7 promoter, N terminal His6-GB1 tag, Amp
r
  R. DeGuzman 
pDZ3 T7 promoter, C terminal GB1-His6 tag, Amp
r
 R. DeGuzman 
pDZ1/rns  rns expressed from pDZ1 T7 promoter, Amp
r
 This study 
pDZ1/rns NTD  rns NTD expressed from pDZ1 T7 promoter, Amp
r
 This study 
pDZ3/rns rns expressed from pDZ3 T7 promoter, Amp
r
 This study 
pDZ3/rns NTD  rns NTD expressed from pDZ3 T7 promoter, Amp
r
 This study 
pDZ3/rns DBD  rns DBD expressed from pDZ3 T7 promoter, Amp
r
 This study 
pSE290 GB1
 basic
 version of pDZ1, Amp
r
  Laboratory collection 
pSE295 pDZ3 with GB1
 basic
 + linker, Amp
r





 expressed from pSE295 T7 promoter, Amp
r





 expressed from pSE290 T7 promoter, Amp
r





 New England Biolabs 
pMAL/virF virF from pMAL-c2X, Amp
r
 This study 
pMAL/rns rns from pMAL-c2X, Amp
r
 This study 
pMAL/rns NTD rns NTD from pMAL-c2X, Amp
r
 This study 
pMAL/rns DBD rns DBD from pMAL-c2X, Amp
r
 This study 












Table 3. Oligonucleotides used in this study. 
Oligo 
No. 
Oligonucleotide sequence 5’-3’ Use 
2962 GCGGAATTCCTTTTGTAGGTATAAGATGGAC Amplify rns and rns
co
 

















mutagenesis of rhaR L35 




mutagenesis of rhaR K36 




mutagenesis of rhaR L35, K36 





mutagenesis of rhaR L38 




mutagenesis of rhaR K39 




mutagenesis of rhaR D40 
(middle downstream)   
2986 GAACTCTTCTTTAACTGATGCGCCACCGTGG Site-directed random 
mutagenesis of rhaR L38, K39, 




mutagenesis of rhaR D41 
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mutagenesis of rhaR F42 




mutagenesis of rhaR F43 
(middle downstream)   
2990 GAACTCTTCTTGAGAAGTTTTAACTGATGCGC Site-directed random 
mutagenesis of rhaR D41, F42, 




mutagenesis of rhaR A44 




mutagenesis of rhaR S45 









mutagenesis of rhaR A44, S45, 














Upstream oligo to randomize 
rns N16  
3015 CAAGAATTCATTTTGTAGGTATCCAATGTCATC
TGTGAGTTTTTTTTCTG 
Upstream oligo to amplify rns 
(157-265)  
3016 ATGGACTTTAAATACACTGAAGAA Upstream rns oligo with out 
Shine-Dalgarno seq. Oligo 
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started with initiation site ATG 
3060 GCACATATGGACTTTAAATACACTGAAG Upstream oligo to amplify and 
clone rns, rns NTD in to pDZ1 
and pDZ3 
3061 ACGGGATCCTTATCCACCTTTAAAATAAGTG Downstream oligo to amplify 




Downstream oligo to amplify 
and clone rns NTD to clone  rns 
NTD in to pDZ1 
3063 GCACATATGTCATCTGTGAGTTTTTTTTCTG Upstream oligo to amplify and 




Downstream oligo to amplify 




Downstream oligo to amplify 
and clone rns NTD in to pDZ3 
3075 AGCGGATAACAATTTCACACAGGA Upstream oligo for sequencing 
pHG165 with insert 
3076 CGCCAGGGTTTTCCCAGTCACGA Downstream lacZ oligo for 
sequencing pHG165 with insert 
3119 CATGATAACTCAGCTTTTATATCTAGCTTG rns middle forward primer for 
sequencing 
3120 GCTGTTTATATTTTTTAATTCATCCAACAAGG rns middle reverse primer for 
sequencing 
3121  GGTCGTCAGACTGTCGATGAAG Upstream oligo for sequencing 
insert cloned into pMAL-c2X 
3159 TTGCATTGTCTTGTTTTTTTATCTCATTAATC IR-labeled top strand of cfaAp 
with Rns binding site (bold). 
For EMSAs. 
3160 GATTAATGAGATAAAAAAACAAGACAATGCAA IR-labeled bottom strand of 
cfaAp with Rns binding site 
(bold). For EMSAs.  
3161 CACAATTCAGCAAATTGTGAACATCATCACATT IR-labeled top strand with full 
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CATCTTTCCCTG CRP binding site for EMSA 
3162 CAGGGAAAGATGAATGTGATGATGTTCACAATT
TGCTGAATTGTG 
IR-labeled bottom strand with 









Upstream oligo to randomize 
rns I12 
3209 CAGGCTCTTCACTTGAAAATTCATACCAG Middle upstream oligo to 
randomize rns residues 216, 
217, 218, 219  
3212   CAGGCTCTTCCAAGTAGTAATAACGCAGCNNNA
CTCATTCTCAA 
Middle downstream oligo to 
randomize rns residues 216 
3215   CGAGCTCTTCCAAGTAGTAANNNCGCAGCCTTA
CTCATTCTC 
Middle downstream oligo to 
randomize rns residues 219 
3221  CGCGGATCCTTTGTTTGCATTGTCTTGTTTTTTT
ATCTCATTT 
Upstream oligo amplify cfaAp -
60 to +360 relative to TSS 
3222 CGCGAATTCCGCCTCAAAATATACTC Downstream oligo amplify 
cfaAp -60 to +360 relative to 
TSS 
3223  GCGGGATCCATAAGTGTAGTTTGCTTT Upstream oligo amplify cfaAp -
162 to +14 relative to TSS 
3224 GCGCTCTTCTTTTATTAATGATTACCTGACT Downstream oligo amplify 
cfaAp -162 to +14 relative to 
TSS 
3227  GGAATCAATGCCTGAGTG To identify single copy 
integrants pSE298/pSE299 into 
MC4100 at att HK022 site 
3228 ACTTAACGGCTGACATGG To identify single copy 
integrants pSE298/pSE299 into 
MC4100 at att HK022 site 
3229 ACGAGTATCGAGATGGCA To identify single copy 
integrants pSE298/pSE299 into 
MC4100 at att HK022 site 
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3230 GGCATCAACAGCACATTC To identify single copy 
integrants pSE298/pSE299 into 
MC4100 at att HK022 site 
3243 GCGGAATTCCTTTTGTAGGTATAAGATGGACTT
TAAATACACTGAAGAAAAAG 
Upstream rns oligo to 
randomize K249, H250, Y251, 
G252 and Y261 
3244  GCGAAGCTTTTATCCACCTTTAAAATAAGT 
GAAAAATTGCTTTGGTGTAACACCATAATG 
NNNATTAAAAATCCT 





Downstream oligo to randomize 
rns H250 
3246  GCGAAGCTTTTATCCACCTTTAAAATAAGT 
GAAAAATTGCTTTGGTGTAACACCNNNATG 
TTTATTAAAAATCC 
Downstream oligo to randomize 
rns Y251 
3247  GCGAAGCTTTTATCCACCTTTAAAATAAGT 
GAAAAATTGCTTTGGTGTAACNNNATA 
ATGTTTATTAAAAATCC 
Downstream oligo to randomize 
rns G252 
3248  GCGAAGCTTTTATCCACCTTTAAANNNAGT 
GAAAAATTGCTTTGG 
Downstream oligo to randomize 
rns Y261 
3326 TTGCATTGTCTTGTTTTTTTATCTCATTAATC  
 
Non IR-labeled top strand of 
cfaAp with Rns binding site 
(bold). For EMSAs. 
3331 GCAGAATTCATGGACTTCAAATACACGGAA 
GAAAAAG 





 NTD into 
pMAL-c2X vector 
3332  GCAGAATTCAGCAGCGTGAGCTTTTTCAGCG Upstream oligo to amplify and 
clone rns
co




Downstream oligo to amplify 
and clone rns
co
 NTD into 
pMAL-c2X vector 
3334  CGACAGAAGCTTTTAGCCGCCTTTGAAGTAGGT 
G 
 






into pMAL-c2X vector 
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3347   GGAAGGGAGATTGATGGTAG virB amplification - qRT-PCR 
(forward primer) 
3348  GAACTTCAAGATCTGCTCCTGC virB amplification - qRT-PCR 
(reverse primer) 
3349 CTCAATTCAACACTCTTTCACAG icsB amplification - qRT-PCR 
(forward primer) 








nlpA promoter +15 to +82 
relative to nlpA TSS. Replaces 
nlpA Rns binding site with cfaA 









nlpA promoter +15 to +82 
relative to nlpA TSS. Replaces 
nlpA Rns binding site with cfaA 
Rns binding site (downstream 
oligo) 
3385   CTTTCGGGTACTCAAGAAC icsA amplification - qRT-PCR 
(forward primer) 
3386  GAGAAAGTCCATCAACAGG icsA amplification - qRT-PCR 
(reverse primer) 
3387 CTGCATTTTCAAACACAGC ipaB amplification - qRT-PCR 
(forward primer) 
3388 GAGTAACACTGGCAAGTC ipaB amplification - qRT-PCR 
(reverse primer) 
3393 AACGTCAATGAGCAAAGGTATTAA rrsA amplification - qRT-PCR 
(forward primer) 












Upstream oligo to randomize 
rns M18 
3398 CAGGCTCTTCTATTACTACTTGAAAATTCATAC Middle upstream oligo to 
randomize rns residues 211, 
215   
3399 CAGGCTCTTCTAATAACGCAGCCTTNNNCATTC
TCAATTGCAT 
Middle downstream oligo to 
randomize rns residue 215   
3400  CAGGCTCTTCTAATAACGCAGCCTTACT 
CATTCTCAANNNCATTAATATCTGATT 
 
Middle downstream oligo to 
randomize rns residue 211 
3403 GCGTCGCCGCTTTCATCG Downstream oligo to sequence 
inserts cloned into pHKLac1 
vector 
3411 GCAGAAGGCCATCCTGAC  Upstream oligo to sequence 
inserts cloned into pHKLac1 
vector 
Undelined sequences are primer-template mismatches that include restriction endonuclease 










Construction of a cfaA-lacZ
∆60
 fusion with single Rns binding site. cfaA-lacZ
∆60
 fusion has 
cfaA promoter region from -60 to +360 [relative to cfaA transcription start site (TSS)] fused to a 
lacZ reporter gene. Strain SME4324 carries a single copy of this fusion integrated into the 
chromosome at att HK022 site. To construct this strain, cfaA-lacZ promoter region from -60 to 
+360 was amplified from strain SME3749 using forward primer 3221, 5’- 
CGCGGATCCTTTGTTTGCATT GTCTTGTTTTTTTATCTCATTT -3’ and reverse primer 
3222, 5’- CGCGAATTCCGCCTCAAAATATACTC -3’ (Underlined regions in the primers are 
the primer-template mismatches and includes sites for restriction endonucleases digestion ), 
digested with EcoRI and BamHI and then ligated into the same sites of pHKLac1 (39). The 
resulting plasmid pSE298 was confirmed by sequencing for the correct insertion of the cfaA-lacZ 
promoter region and then integrated into the chromosome of E. coli K-12 strain MC4100 (206) 
using a method described before (204). MC4100 was transformed with pSE298 and a 
temperature sensitive helper plasmid pAH69 (204) that helped in the integration of pSE298 into 
the chromosome of MC4100. Plasmid pSE298 had a phage attachment site attHK022 that helped in 
attachment of plasmid at bacterial attachment site (attB) in the MC4100 chromosome. Plasmid 
pAH69 was a temperature sensitive plasmid and had an int gene that encoded an integrase 
enzyme. Integrase enzyme helped in the integration of pSE298 into the chromosome of MC4100. 
The transformation mix was suspended in TY, incubated at 37°C for 60 min (for the expression 
of integrase) and 42°C for 30 min (for curing helper plasmid), spread on a spectinomycin plate 
and incubated at 37°C for 24 h. Colonies were restreaked twice on nutrient agar plates and once 
on selective spectinomycin plate at 42°C to select for the colonies that lost the helper plasmid 
and have a stable pSE298 integrant into MC4100 chromosome. Colony PCR was then performed 
to identify single copy plasmid integrants.  
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Construction of an nlpA
cfaA
-lacZ fusion. The nlpA
cfaA
-lacZ reporter fusion is a transcriptional 
fusion of the nlpA promoter region from -162 to +82 (relative to the nlpA TSS) fused to the lacZ 
reporter gene. In addition, the Rns binding site that is native to the nlpA promoter region with the 
sequence of the single Rns binding site in the cfaA-lacZ
∆60
 fusion. To construct strain SME4474, 
which carries a single copy of the nlpA
cfaA
-lacZ fusion, two sets of primers were used. One set of 
primers (forward primer 5’- GCGGGATCCATAAGTGTAGTTTGCTTT -3’ and reverse primer 
5’- GCGCTCTTCTTTTATTAATGATTACCTGACT -3’) amplified the nlpA promoter region 
between -162 to +14 from strain AP76. Another set of (forward primer 5’- 
GCGCTCTTCTAAAAGTGTTTTTTTATCAAACTGACAACACATCATCTACGGACAGG
GGCCGCATTATTGCTGGCCGGAATTCTGC -3’ and reverse primer 5’- 
GCAGAATTCCGGCCAGCAATAATGCGGCCCCTGTCCGTAGATGAT 
GTGTTGTCAGTTTGATAAAAAAACACTTTTAGAAGAGCGC -3’) were hybridized 
(without PCR amplification) to complete the remainder of the modified nlpA promoter region.  
These oligos replaced the Rns binding site sequence at nlpA (+15 to +26, indicated by bold 
letters) with the specified Rns site at cfaA, and carried the native nlpA sequence from +27 to +82.  
The DNA fragment carrying the -162 to +14 region was digested with BamHI and EarI, and the 
DNA fragment carrying the +15 to +82 region was digested with EarI and EcoRI.  The EarI 
restriction endonuclease sites allowed the two DNA fragments to be joined seamlessly (with no 
additions or deletions in the gene) (81). The two DNA fragments were ligated into plasmid 
pHKLac1 (39) digested with BamHI and EcoRI to create the transcriptional fusion with lacZ in 
plasmid pSE299.  The cloned region was sequenced to confirm the correct insertion of the 
nlpA
cfaA
 promoter region and the plasmid pSE299 was integrated into the chromosome of 
MC4100 (206) using a method identical to the integration of pSE298 into the chromosome of 
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MC4100 (described in the previous page). Single copy plasmid integrants of pSE299 into the 
chromosome of MC4100 were identified by colony PCR to make strain SME4474. 
Site-directed random mutagenesis of rns RS2 and AS2 regions. Site-directed random 
mutagenesis of the Rns RS2 and AS2 regions was performed by PCR using primers that 
incorporated NNN at one codon at a time of each of these regions. To mutagenize codons that 
were near the 5’ (encoding RS2 positions 12-18) or 3’ ends (encoding AS2 positions 249-252, 
261) of the rns gene, two primers were used to amplify the rns gene, with either the forward or 
reverse primer containing three random nucleotides (NNN) at the position to be mutagenized, 
and the other primer containing wild-type sequence. For mutagenesis of positions that were not 
near the ends of the rns gene (encoding AS2 positions 211, 215, 216 and 219), four primers were 
used, with pairs of oligos amplifying the rns gene in two fragments, and the middle downstream 
primer containing random nucleotides (NNN) at the position to be mutagenized.  The amplified 
DNA fragments were digested with EarI, EcoRI and HindIII and cloned into the EcoRI and 
HindIII sites of the moderate copy number plasmid pHG165  (205), by which rns was expressed 
from a lac promoter located in the pHG165 (205). The resulting plasmids were individually 
transformed into SME4324 and plated onto nutrient agar plates with X-gal and ampicillin. 
Variants with a range of activity levels relative to wild-type Rns were picked, restreaked to get 
pure cultures, and assayed for transcription activation of cfaA-lacZ
∆60
 by β-galactosidase assay. 
Variants were sequenced on both the strands to identify the mutation and to ensure that there 
were no additional mutations. 
β-galactosidase assays in 96-well plates. Starter cultures of strains to be assayed were grown 
overnight in tryptone-yeast extract broth (TY) supplemented with ampicillin. 10 µl of each 





C with shaking in 13 X 100 mm tubes to an OD600 of ~0.4, and placed on ice. A 10 
µl sample of each cell culture was added to each of two wells of a 96-well microtitre plate and 
diluted 10-fold by adding 90 µl of TY medium. A 50 µL aliquot of lysis/ONPG (o-nitrophenyl-
β-D-galactopyranoside) buffer [3 parts of ZOB buffer (11) to 1 part of 10 mg lysozyme (Sigma, 
St. Louis, MO) dissolved in PopCulture cell lysis reagent (EMD, Gibbstown, NJ)] was added to 
each well and incubated at room temperature. Reactions were stopped by adding 50 µL of 1M 
Na2CO3 (208). OD420 and OD550 values were measured in a PowerWave XS plate reader 
equipped with KC
4
 data analysis software (BioTek Instruments). The OD600 values for each cell 
culture were obtained from 200 µl of each culture in another 96-well plate. The OD420, OD550 and 
OD600 readings were corrected by subtracting the readings at the same wavelength obtained for 
control samples that had no bacterial cells added. β-galactosidase activities were measured by in 
Miller units using the formula below (208).  
Miller units = (OD420 – OD550)*1000/( OD600*t*V)   Eqn (1) 
where t = time of reaction (in minutes), and V = volume of cell suspension added to the reaction 
(in milliliters) 
Specific activities (Miller units) were averaged from at least three independent experiments with 
two replicates in each experiment. Activity was expressed as percentage of wild type activity. 
Error bars represent the standard deviation of the mean values.  
Western blotting. Rabbit polyclonal anti-Rns antibodies were raised commercially (Cocalico 
Biologicals, Reamstown, PA), by immunizing rabbit five times with a total of 350 µg of the 
purified MBP-Rns protein. Anti-Rns antibodies from the serum were affinity purified using 
purified MBP-Rns and used as primary antibody. Cultures expressing wild-type Rns or variants 
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were assayed by collecting 1 ml from bacterial cultures that were grown to OD600 of ~0.4 for β-
galactosidase assays. The cells were sedimented and resuspended in 100 µl of 1X SDS buffer 
(0.191M glycine, 0.0247 M tris base, 0.1% SDS), mixed with 25 µl of 5X loading dye (3.75% 
trizma base, 10% SDS, 25% (v/v) 2-mercaptoethanol, 50% (v/v) glycerol, 0.5% bromophenol 
blue), boiled for 10 min, and 20 µl was loaded onto 12% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) gel. Samples were electrophoresed, transferred onto 
nitrocellulose membranes, blocked with 5% non-fat dry milk and incubated with primary and 
secondary antibodies using standard procedures. Antibodies used in the Western blot were as 
follows; Rabbit anti-Rns primary antibody (1:500 dilution), Mouse anti-DnaK primary antibody 
(1:10,000) (Invitrogen, Grand Island, NY), IR 680-labelled anti-rabbit secondary antibody 
(1:10,000) and IR 800-labelled anti-mouse secondary antibody (1:10,000) (Abcam, Cambridge, 
MA). The blots were imaged using an Odyssey Infrared Imaging System (LI-COR, Lincoln, NE) 
and analyzed using ImageJ software (209). 
Rns structural modeling. A computational model for three-dimensional structure for Rns was 
generated using I-TASSER structural prediction program (157). The obtained structure was 
displayed in ribbon using PyMOL program (The PyMOL Molecular Graphics System, Version 
1.2r3pre, Schrödinger, LLC). 
Construction of IPTG inducible Rns plasmids for protein overexpression and purification. 
Plasmids were constructed to express Rns, Rns-NTD and Rns-DBD with GB1 tag or maltose 
binding protein (MBP) tag. To construct plasmids with GB1 at the N-terminus of the protein 
pDZ1 plasmid was used. Rns and Rns-NTD were PCR amplified (Rns: primers 3060 and 3061; 
Rns-NTD: primers 3060 and 3062) and cloned into NdeI and BamH1 sites of pDZ1 plasmid. To 
construct plasmids with GB1 at the C-terminus of the protein, pDZ3 plasmid was used. Rns, 
50 
 
Rns-NTD and Rns-DBD were PCR amplified with primers (Rns: primers 3060 and, 3064; Rns-
NTD: primers 3060 and, 3065; Rns-DBD: primers 3063 and, 3064) and cloned into NdeI and 





 at either N-terminus or C-terminus of the protein were also generated. To make N-
terminal GB1
basic




 was PCR amplified with primers 3264 and 3265 using 





 was PCR amplified with specific primers (3264, 3266) using 
pSU18/rns as template and cloned into pSE295 plasmid at NdeI and BamH1 sites. 







 were constructed by amplification of insert using primers (Rns
co
: primers 3331 and, 
3334; Rns-NTD
co
: primers 3331 and, 3333; Rns-DBD
co
: primers 3332 and, 3334) and cloning 
downstream and in-frame with malE (encoding maltose binding protein, MBP) in the vector 
pMAL-c2X (New England Biolabs, Beverly, MA) at EcoRI and HindIII restriction sites. 
Plasmids that express IPTG inducible Rns and VirF expressed from pHG165 plasmid were 
constructed by Jeff Skredenske. Rns and VirF were amplified and cloned into pHG165 at EcoRI 
and HindIII restriction sites.  
Rns-DBD-GB1-His6 purification. E. coli strain SME3863 was used for the overexpression and 
purification of Rns-DBD-GB1-His6 using Ni
2+
 affinity chromatography column at 4
o
C. In brief, 
a starter culture of 5 ml TY supplemented with ampicillin and kanamycin was inoculated with 
SME3863 and grown overnight at 37
o
C. A 1:100 dilution of bacteria was further inoculated into 
fresh medium (usually 100-200 ml), allowed to grow until OD600 of ~0.8, induced with 1 mM of 
isopropyl- β-D-1-thiogalactopyranoside (IPTG) at 15
o
C and incubated ~18 h with shaking. After 
overnight induction cells were harvested by centrifugation at 4°C and concentrated to > 40-fold 
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in ice-cold binding buffer [20 mM Tris-base, 500 mM NaCl, 1 mM Imidazole, 0.1 mM tris (2-
carboxyethyl) phosphine (TCEP), pH 7.9). Cells were added with 1 mM phenylmethylsulfonyl 
fluoride (PMSF), 0.53 mg/ml Lysozyme and kept on ice for 15 min. Cells were lysed by either 
French press for 3 times or sonication (sonicator was programmed to operate 15 sec on and 15 
sec off for a total of 4 min at 30% pressure). Cell lysates were subjected to DNase treatment (2.5 
µg/ml DNase and 30mM MgCl2) on ice for 15min and centrifuged (15,600 X g, 30 min) to 
remove cell debris. Rns-DBD-GB1-His6 was ~50% soluble and this soluble supernatant fraction 
was loaded to HiTrap immobilized Ni
2+
 affinity chromatography column (Sigma) connected to 
either BioLogic low pressure liquid chromatography system (Bio-Rad Laboratories) or AKTA 
flow pressure liquid chromatography (FPLC) system (GE Healthcare). The Ni
2+
 affinity 
chromatography column has a column volume of 5 ml and was prepared by charging the column 
with 5 column volumes (CVs) of 50 mM nickel sulphate and equilibration with 5 CVs of binding 
buffer. After running the sample, column was washed with 5 CVs of wash buffer (20 mM Tris-
base, 500 mM NaCl, 60 mM Imidazole, 0.1 mM TCEP, pH 7.9) and eluted using 5 CVs of 
elution buffer (20 mM Tris-base, 500 mM NaCl, 500 mM Imidazole, 0.1 mM TCEP, pH 7.9). 
In addition, protein was purified from pellet by using urea. This procedure was used in 
my initial purification experiments induction of cells at 37
o
C yielded no soluble protein. The 
pellet fraction of sonicated lysates were resuspended in binding buffer having either 2 or 4 or 6 
M urea and rocked overnight at 4
o
C. I found that the protein was relatively more soluble in 
binding buffer with 6 M urea. The cell supernatant (6 M urea containing fraction) was loaded 
into Ni
2+
 affinity chromatography column and eluted in 6 M urea containing elution buffer (20 
mM Tris-base, 500 mM NaCl, 500 mM Imidazole, 0.1 mM TCEP, pH 7.9). 
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Electrophoretic mobility shift assays with purified Rns-DBD-GB1-His6. Binding of purified 
Rns-DBD-GB1-His6 to a DNA fragment containing the rns binding site at cfaA promoter was 
analyzed by electrophoretic mobility shift assay (EMSA). DNA probes were generated by 
hybridizing the 5’ IR-labeled 3159 and 3160 oligonucleotides (oligos, Eurofins MWG Operon, 
Huntsville, AL). For Hybridization, oligos were mixed in 1:1 ratio (usually 10 µl of 10 µM each 
oligo) in STE buffer (50 mM NaCl, 10 mM Tris-HCl, 1 mM EDTA, pH 8.0), incubated at 94°C 
for 2 min and gradually cooled to room temperature. EMSA gels (6% acrylamide/0.1% methyl-
bis-acrylamide, 0.25x TBE) were made and pre-electrophoresed for at least 30 min (150 V) in 
0.25x TBE buffer (22 mM Tris, 22 MM boric acid and 0.5 mM disodium EDTA) before loading 
the reactions. The temperature of the gel apparatus was maintained below 10°C by keeping dry 
ice in the gel box (Bio-Rad Laboratories). Reactions containing 1 μl of 1:15 dilution of labeled 
DNA (~0.11 µM final concentration) in STE buffer, 1.2 μl of 5x EMSA buffer [50 mM Tris-HCl 
(pH 7.4), 250 mM KCl, 5 mM dithiothreitol, 32.5% (v/v) glycerol, 0.5 mg/ml bovine serum 
albumin (BSA) and 50 μg/ml salmon sperm DNA] and 2.8 μl of water were incubated at 37°C 
for 5 min. Three different dilutions of 1 μl of Rns-DBD-GB1-His6 (9 µM, 3 µM, 1 µM final 
concentrations) were then added to reaction mixture and further incubated at 37°C for 10 min 
before loading onto the gel. DNA loading dye was added only to the free DNA sample. After 
electrophoresis (~45 min at 150 V) gels were scanned using an Odyssey infrared imager (LI-
COR, Lincoln, NE). 
MBP-Rns purification. E. coli strain SME4147 (KS1000/pRARE2/pMBP-Rns1) was used for 
the overexpression a fusion of the maltose binding protein to Rns (MBP-Rns).  The fusion 
protein was purified using amylose affinity chromatography at 4
o
C.  In brief, SME4147 was 
grown aerobically at 37°C in TY medium supplemented with 200 µg/ml ampicillin, 30 µg/ml 
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chloramphenicol and 0.2% (w/v) glucose until an OD600 of ~0.4. A 1:100 dilution of bacteria was 
further inoculated into fresh medium, allowed to grow until OD600 of ~0.6, induced with 1mM of 
isopropyl- β-D-1-thiogalactopyranoside (IPTG) at 15
o
C and incubated overnight with shaking. 
Cells were harvested by centrifugation at 4°C and concentrated 40-fold in ice-cold binding buffer 
[20 mM Tris-base, 500 mM NaCl, 1 mM EDTA, 0.1 mM tris (2-carboxyethyl) phosphine 
(TCEP) or 10 mM β-mercaptoethanol, pH 7.6). 1 mM phenylmethylsulfonyl fluoride (PMSF) 
and 0.53 mg/ml lysozyme were added to the cell suspension and it was lysed by freezing 
at -80°C for 15 min and thaw on ice and then sonicating twice. Cell lysates were subjected to 
DNase I treatment (2.5 µg/ml) on ice for 15min and centrifuged (15,600 x g, 30 min) to remove 
cell debris. The soluble supernatant fraction was loaded with a BioLogic LP chromatography 
system (Bio-Rad Laboratories) onto an amylose resin column (column volume 7 ml) (New 
England Biolabs) that had been pre-equilibrated with 80 ml of binding buffer. The column was 
washed with 120 ml of wash buffer (binding buffer plus 15% (v/v) glycerol) and eluted using 
elution buffer (wash buffer plus 10 mM maltose). 
Gel filtration chromatography of purified MBP-Rns. The protein was further purified by gel 
filtration chromatography using a pre-packed analytical sephacryl 16/60 S-200 column (GE 
Healthcare). Gel filtration usually involved pre-equilibration of column with two CVs of either 
elution buffer [20 mM Tris-base, 500 mM NaCl, 1 mM EDTA, 0.1 mM TCEP, 15% Glycerol, 10 
mM Maltose pH 7.6] or tris-buffer with  KCl as salt and without maltose (15 mM Tris-base, 75 
mM KCl, 5 mM β-mercaptoethanol, 10% Glycerol, pH 7.6), loading of up to 5 ml protein sample 
and collection of 2 ml fractions of peaks using “S-200 frac peak only” program. Molecular 
weight standards ranging from 10 kDa to 200 kDa proteins were passed through the column and 
used to determine the molecular weight of the eluted MBP-Rns protein.  
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Electrophoretic mobility shift assays with purified MBP-Rns. EMSAs were performed for the 
MBP-Rns to test whether the purified protein is active and binds to its specific labeled DNA. 
EMSA reactions were prepared as similar to EMSA reactions for Rns-DBD-GB1-His6 protein 
with the following modifications. Instead of using both IR-labeled rns specific oligonucleotides 
(3159 and 3160), a non-IR labeled top oligonucleotide (3326) and IR labeled bottom 
oligonucleotide (3160) were used. DNA and protein concentrations of ~2 nM and ~0.3 µM were 
used, respectively. 
Affinity purification of Rns antibodies. Rabbit polyclonal anti-Rns sera were raised 
commercially (from Cocalico Biologicals, Reamstown, PA) by immunizing rabbit five times 
with a total of 350 µg of the purified MBP-Rns. Rns antibodies from the serum were affinity 
purified against purified MBP-Rns using the following protocol. 15-20 µg of the purified MBP-
Rns protein was run on SDS-PAGE gel and electrophoretically transferred to nitrocellulose 
membrane using the standard procedure. Protein bands corresponding to the purified MBP-Rns 
was cut from the membrane after staining with ponceau S stain. Membrane strip was cut into 
small pieces and blocked at room temperature for 2 h in 15 ml blocking buffer [5% non-fat dry 
milk in 1x PBST (137 mM NaCl, 2.7 mM KCl, 10 mM Na2HPO4, 2 mM KH2PO4;  pH of the 
mixture was adjusted to 7.4 and then added with 0.05% tween-20] using a 50 ml conical flask. 
Blocking buffer was then replaced with 20 ml of 1x PBST to which 1 ml of the rabbit serum 
sample was added. The resulting mix was rocked overnight at room temperature to facilitate the 
binding of Rns antibodies to the purified MBP-Rns on the membrane. Membrane strips were 
washed twice with 1x PBST and once with 1x PBS (15 min each) and rocked vigorously by 
adding 3 ml of 100 mM glycine at low pH (2.5) to facilitate the removal of Rns antibodies from 
the membrane. The pH of antibody solution was then adjusted to near neutral by adding 300 µl 
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of 1M Tris (pH 8.0). To ensure the correct detection of Rns by the affinity purified antibodies, 
Western blots were performed for E. coli strains SME4336 (expresses Rns from pHG165) and 
SME4337 (pHG165 control) using a standard Western blot procedure describe above. Rns 
antibodies were stored at -20
o
C for long term storage.        
Crystallization trials. The purified MBP-Rns protein was concentrated using a Millipore 
centricon (50 kDa cut off). MBP-Rns in the Tris elution buffer [20 mM Tris-base, 500 mM 
NaCl, 1 mM EDTA, 0.1 mM TCEP, 15% Glycerol, 10 mM Maltose pH 7.6] showed visible 
aggregation at higher concentrations (usually after 2 mg/ml). MBP-Rns in the Tris buffer with 
KCl as salt and without maltose (15 mM Tris-base, 75 mM KCl, 5 mM β-mercaptoethanol, 10% 
Glycerol, pH 7.6) did not show any aggregation even at concentrations as high as ~20mg/ml and 
thereby used for setting up crystal screens. Almost 400 different commercially available 
crystallization conditions (Wizard I, II, III, IV screens, Hampton I, II, PEG/Ion and salt RX 
screens) covering wide range of buffers and pH were tested. 
Effect of SE-1 on DNA binding by purified MBP-Rns protein. Binding of purified MBP-Rns 
to a DNA fragment containing the Rns binding site at cfaA promoter region was analyzed by 
electrophoretic mobility shift assay (EMSA), in the absence or presence of SE-1.  SE-1 (1-butyl-
4-nitromethyl-3-quinolin-2-yl-4H-quinoline, formerly OSSL_051168) was obtained from 
eMolecules, Inc. (Solana Beach, CA; catalog #3761-0013) or Princeton BioMolecular Research 
(Princeton, NJ; catalog # OSSL_051168) and was dissolved in 100% DMSO. DNA probes were 
generated by hybridizing the oligonucleotides 3326 (non-IR labeled top oligonucleotide) and 
3160 (IR labeled bottom oligonucleotide). Reactions containing 0.3 μl (~2 nM) of DNA, 0.6 μl 
of either 100% DMSO or various concentrations of OSSL_051168 (10.1, 20.3, 40.6, 81.25, 
162.5, 325 and 650 μM) and 1.2 μl 5x EMSA buffer [50 mM Tris-HCl (pH 7.4), 250 mM KCl, 5 
56 
 
mM Dithiothreitol, 32.5% (v/v) glycerol, 0.5 mg/ml bovine serum albumin (BSA) and 50 μg/ml 
salmon sperm DNA] and 3.9 μl water were incubated at 37°C for 5 min.  MBP-Rns (1 μl, ~0.3 
µM) was added to the reaction mixture and further incubated at 37°C for 10 min before loading 
onto the gel.  DNA loading dye was added only to the free DNA sample.  Electrophoresis was 
performed in 0.25x TBE (final concentrations: 22.25 mM Tris base, 22.25 mM boric acid, 500 
µM disodium EDTA, pH 8.3) using a non-denaturing 6% polyacrylamide gel (6% acrylamide, 
0.1% N,N-methylenebisacrylamide) that was cooled to below 10
o
C and pre-ran at ~150 V for 30 
min.  All EMSA reactions, including those without inhibitor, had a final concentration of 10% 
DMSO (the SE-1 solvent).  Gels were scanned using an Odyssey infrared imager (LI-COR, 
Lincoln, NE), and quantified using Odyssey software, version 3.0.30.  Graphs were drawn using 
Prism (GraphPad, La Jolla, CA). 
In vivo dose-response experiments in E. coli. Cultures of SME4382, SME4383 and SME3359 
grown overnight were diluted to an OD600 of ~0.1 in MOPS-buffered minimal medium with 
ampicillin. Bacterial cultures were mixed with varying concentrations of SE-1 (2.2% DMSO, 
final), induced with 6.5 mM IPTG for 3 h at 37
o
C. After 3 h of IPTG induction, cells were lysed 
with 50 μl ONPG/Lysis buffer (three parts ZOB (11) to one part 10 mg/mL lysozyme [Sigma, St.  
Louis, MO] dissolved in PopCulture cell lysis reagent [EMD Chemicals, Gibbstown, NJ]) and β-
galactosidase activity was measured at OD420 in a PowerWave XS plate reader (BioTek 
Instruments, Inc., Winooski, VT). Uninduced (no IPTG and no SE-1) and uninhibited (6.5 mM 
IPTG and no SE-1) controls were included for each strain and used as a normalizer for β-
galactosidase activity. IC50 values were calculated and graphs were drawn using Prism 
(GraphPad, La Jolla, CA). Error bars represent the standard error of the mean of three 
independent experiments with two replicates each. 
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Heterologous expression and purification of VirF. The IPTG inducible MBP-VirF
 
expression 
plasmid, pMALvirF, was constructed by cloning virF downstream and in-frame with malE 
(encoding maltose binding protein, MBP) in the vector pMAL-c2X (New England Biolabs, 
Beverly, MA).  MBP-VirF protein (referred to as VirF for simplicity) was purified using amylose 
affinity chromatography at 4
o
C. Briefly, pMALvirF was transformed into E. coli strain KS1000 
(New England Biolabs). The cells were grown to an OD600 of 0.5, transferred to 15
o
C, 0.1 mM 
IPTG was added, and then incubated overnight with shaking. Cells were harvested and 
resuspended in 10 ml of binding buffer (20 mM Tris, 500 mM NaCl, 1mM EDTA, 1mM DTT, 
pH 7.4). Cells were lysed by three freeze thaw cycles with lysozyme (0.4 mg/ml), tris (2-
carboxyethyl) phosphine (TCEP, 1 mM) and phenylmethylsulfonyl fluoride (PMSF, 1 mM), at -
80
o
C, followed by sonication and then centrifuged to remove cell debris. The supernatant was 
applied with a BioLogic LP chromatography system (Bio-Rad Laboratories) to an amylose resin 
column (New England Biolabs), pre-equilibrated with 80 ml binding buffer, the column was 
washed with 120 ml binding buffer. VirF was eluted with 40 ml of elution buffer [binding buffer 
plus 15% glycerol (w/v) and 10 mM maltose], and used directly for subsequent assays. The 
purified protein was greater than 90% pure, although some older preps showed partial 
breakdown to MBP and non-fusion VirF. EMSAs did not show any evidence of non-fusion VirF 
binding to DNA (data not shown), suggesting that the non-fusion VirF protein was inactive 
(likely due to aggregation). 
Effect of SE-1 on DNA binding by purified MBP-VirF protein. Binding of purified VirF to a 
DNA fragment containing the VirF binding site at virB was analyzed by electrophoretic mobility 
shift assay (EMSA), in the absence or presence of SE-1. DNA probes were generated by 
hybridizing the following oligonucleotides: A short IR700-labeled LUEGO oligo (5’-
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GTGCCCTGGTCTGG-3’) (210), a top oligo containing the virB binding sites (underlined) (5’-
AGAATATTATTCTTTTATCCAATAAAGATAAATTGCATCAATCCAGCTATTAAAATA
GTA-3’), and a bottom oligo that was complementary to both of the preceding oligos (5’-
TACTATTTTAATAGCTGGATTGATGCAATTTATCTTTATTGGATAAAAGAATAATATT
CT CCAGACCAGGGCAC-3’). Reactions and electrophoresis were performed as described for 
MBP-Rns EMSAs with SE-1. Gels were scanned using an Odyssey infrared imager (LI-COR, 
Lincoln, NE), and quantified using Odyssey software, version 3.0.30.  Graphs were drawn using 
Prism (GraphPad).     
Shigella virB-lacZ reporter gene assays. Colonies of S. flexneri strain BS536 that were red on 
TSA plates containing Congo red were grown overnight in Luria-Bertani broth at 30
o
C to 
maintain low basal expression from the virB promoter. The overnight grown cultures were 
diluted 1:100 into 10 ml of the same medium with either 0.3% DMSO or different concentrations 
of SE-1 dissolved in DMSO (final concentration 0.3% DMSO). Cultures were grown at 37
o
C in 
a shaking incubator to an OD600 of ~0.4, centrifuged to pellet the cells and then resuspended in Z 
buffer (61 mM Na2HPO4, 40 mM NaH2PO4-H2O, 10 mM KCl, 1 mM MgSO4.7H2O) for a two-
fold concentration of the cells (208). Control cultures were grown at 30
o
C, a temperature at 
which virF expression is not induced (37), to illustrate the basal level of expression from the virB 
promoter region.  β-Galactosidase assays were performed as described below. Each cell culture 
with two different volumes of cell suspension (usually 20 µl and 40 µl) were added to two 
nonsterile 100 x 13 mm tubes and made to a final volume of 1 ml by adding working buffer. 
Cells were permeabilized by the addition of two drops of chloroform and one drop of SDS and 
subsequent vortexing for 5 sec. Cells were incubated at room temperature for 5-10 min, added 
with 200 µl of substrate ONPG (o-nitrophenyl-β-D-galactopyranoside) (4 mg/ml), and then 
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vortexed briefly to mix ONPG with the cell suspension. Reactions were incubated at room 
temperature until yellow color was clearly visible, but still light. Reactions were stopped by 
adding 500 µl of sodium carbonate (1M). 1 ml of each sample was centrifuged for 5 min, 
supernatant (~800 µl) was transferred to a disposable cuvette and OD420 was measured. OD600 
was measured for each cell culture and β-galactosidase activity was measured in miller units.  
Miller units = (OD420*1000)/( OD600*t*V)    Eqn (2) 
t = time of reaction (in minutes), V = volume of cell suspension added to the reaction (in 
milliliters) 
Three independent assays were performed with two replicates in each assay. Activities were 
presented as a percentage of the uninhibited, DMSO-only control sample. Error bars represent 
the standard error of the mean.   
Shigella gene expression analysis. Real-time quantitative reverse transcription PCR (qRT-PCR) 
was performed to test the effects of SE-1 on the expression of the VirF regulated genes virB, 
icsA, icsB and ipaB. The gapA and rrsA transcripts were used as internal controls. These are 
constitutively expressed Shigella genes commonly used to normalize mRNA levels (211-213).  
S. flexneri strain SME4331, which carries a null mutation in ipgD (ipgD
-
), was grown at 30
o
C 
overnight in TSB with ampicillin, diluted into the same medium to an OD600 of ~0.1, and 1ml 
aliquots further grown at 30
o
C (DMSO only) or at 37
o
C (SE-1 at 20 or 40 µM, or DMSO only, 
all 0.3% DMSO). Cells were grown to an OD600 of 1.0 (~2.5 h) and RNA was isolated using an 
RNeasy MiniElute Cleanup Kit (Qiagen, Germantown, MD), with DNA contamination 
eliminated using a Turbo DNase Kit (Ambion, Austin, TX). Complementary DNA (cDNA) was 
synthesized by random priming using a cDNA Reverse Transcription Kit (Applied Biosystems, 
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Foster City, CA). Primers (Table 2) were tested for PCR specificity using genomic DNA 
template to ensure a single amplicon of the expected size for each primer pair, and validated 
using 5-fold dilutions of cDNA (2000 to 0.0256 ng) to ensure a linear plot of cycle threshold (Ct) 
versus cDNA concentration. Validated primer sets were used to test mRNA profiles in reactions 
that contained 10 ng of cDNA, 10 µl of SYBR green master mix (Applied Biosystems), specific 
primers (0.5 µM each) and water to a final volume of 20 µl, using a Step One Plus Real-Time 
PCR System (Applied Biosystems). The data was analyzed using the 2
-∆∆Ct
 method and by 
Applied Biosystems real-time analysis software. The data analyzed by the 2
-∆∆Ct
 method is 
reported; however, both analyses produced comparable results. In brief, ∆∆Ct values (see 
equation below) were separately obtained for each sample relative to two internal controls, gapA 
and rrsA.  
[∆∆Ct = (Ct,Target - Ct,Internal Control) SE-1 - (Ct,Target - Ct, Internal Control) no SE-1]  Eqn (3) 
The ∆∆Ct values relative to the two internal controls for each sample were averaged and 
then used to calculate the relative expression levels (2
-∆∆Ct
). As a control, we normalized each 
internal control to the other internal control. Control reactions used templates generated without 
reverse transcriptase to ensure low genomic DNA contamination. To ensure that products were 
not likely to be due to primer dimer artifacts, additional control samples were performed in 
which reaction mixtures contained primers alone (no template). 
Testing the effect of SE-1 on growth of E. coli strains used for in vivo assays. To test the 
impact of SE-1 on growth of the bacterial strains used for in vivo assays (SME4382, SME4383 
and SME3359), we compared growth rates in the presence and absence of SE-1. Briefly, the cells 
were grown at 37
o
C with shaking for 8 h in MOPS-buffered minimal medium with glycerol and 
plus 6.5 mM IPTG, in 24-well plates, with or without: SE-1 (44 µM SE-1, 0.3% DMSO), or 
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DMSO (0.3%) in a PowerWave XS plate reader equipped with KC
4 
data analysis software 
(BioTek Instruments). Readings were taken at 15 min intervals. Error bars represent the standard 
error of the mean.   
  Testing the effect of SE-1 on growth of Shigella. The S. flexneri ipgD
-
 strain (SME4331) was 
grown overnight at 30°C and then diluted to an OD600 of ~0.1 in TSB supplemented with 
ampicillin. SE-1 was diluted in DMSO and added to the SME4331 cultures at final 
concentrations of 0, 20, or 40 μM SE-1 and 0.3% DMSO. These cultures were grown at 37°C in 
24-well plates containing 1.2 ml of each sample in the temperature-controlled chamber of a 
PowerWave XS plate reader equipped with KC
4 
data analysis software (BioTek Instruments).  
Bacterial growth was continued at 37°C for 8 h with shaking and OD600 was monitored every 5 
min for growth curves (20 min time intervals were plotted). 
Site-directed mutagenesis of RhaR Arm (residues 35-45) region. Wild-type rhaR and all 
mutants were cloned into and expressed from the plasmid pHG165 where expression was 
expressed from lac promoter on the vector. First, wild-type rhaR was cloned into pSU18 vector 
at EcoRI and HindIII restriction sites to make pSU18/rhaR, which was used as template for 
amplification of rhaR during mutagenesis. Site-specific random mutagenesis of rhaR was 
performed using PCR to make oligonucleotide-directed random mutations at each position in the 
proposed Arm region. Two sets of oligos were used to generate site-directed mutations at the 
desired position. One set of two oligos amplified a small fragment of rhaR and encoded random 
mutations (NNN) at the desired position. Another set of two oligos amplified the rest of the rhaR 
gene. Oligonucleotides that hybridized in the middle of the gene had EarI restriction 
endonuclease recognition site and allowed seamless ligation of both the pieces of rhaR into 
pHG165. The ligation mix was transformed into the strain SME2525 [λ (rhaS-lacZ)∆128 
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∆(rhaSR)::Km recA::cat] and plated onto nutrient agar plates supplemented with X-gal, 
ampicillin and L-rhamnose. Variants with varied levels of activity relative to the wild type were 
picked, and restreaked to obtain pure colonies. Plasmid DNA was isolated from the variants, 
transformed into SME3160 strain [λ (rhaS-lacZ)∆85 ∆(rhaSR)::Km recA::cat] and assayed for 
activation levels by β-galactosidase assay. Variants were sequenced on both strands to identify 
the mutation and to ensure that there were no additional mutations apart from the mutation at 
desired position. 
β-galactosidase assays to measure activation levels of RhaR Arm variants. Starter cultures 
for β-galactosidase assays were grown by inoculating a single well isolated bacterial colony in 2 
ml TY + ampicillin and incubating in a rotator for 7 h at 37
o
C. 40 µl of this culture was further 
inoculated in 2.5 ml of pre-warmed overnight medium [MOPS buffered minimal medium with 
limiting glycerol (0.04%)] and grown overnight (15 h) in rotator at 37
o
C. 100 µl of the overnight 
grown bacterial cultures were inoculated in 10 ml of pre-warmed growth medium (0.4% glycerol 
in MOPS buffered medium, with and without 0.4% sugar rhamnose) in 125 ml baffled flasks. 
Cultures were grown with vigorous shaking (~250rpm) until an OD600 of ~0.4 and stopped by 
keeping on ice. Cells were pelleted down by centrifugation, resuspended in working buffer (61 
mM NaHPO4, 40 mM NaH2PO4, 10 mM KCl, 1 mM MgSO4, 250 mM dithiothreitol), and 
assayed for β-galactosidase activity using the protocol outlined already (see above).  
Specific activities were averaged for three independent experiments with two replicates 
in each experiment. Standard deviation of the mean was calculated for all the variants and used 
to determine the level of significance. β-galactosidase activities were expressed as percentage of 
wild type activity, with or without L-rhamnose. 
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Western blotting to quantify RhaR protein levels of variants. All the steps of Western 
blotting were carried as described above for Western blotting of Rns variants, except using RhaR 
antibodies in place of Rns antibodies. Antibodies used in the Western blotting were as follows; 
rabbit anti-RhaR primary antibody (1:500 dilution), mouse anti-DnaK primary antibody 
(1:10000) (Invitrogen, Grand Island, NY), IR 680-labelled anti-rabbit secondary antibody 
(1:10000) and IR 800-labelled anti-mouse secondary antibody (1:10000) (Abcam, Cambridge, 
MA). The blots were imaged using an Odyssey Infrared Imaging System (LI-COR, Lincoln, 
NE), quantified using ImageJ software and presented as percentage of wild-type RhaR protein 




Mechanism of transcription activation in Rns: Role of residues in RS2 and 
AS2 regions in transcription activation  
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Variants in the Rns NTD RS2 region affect Rns-dependent cfaA-lacZ
∆60
 expression.  
Previous studies by Basturea et al showed that NTD of Rns is required for DNA binding and 
transcription activation (156). In addition, they also found that substitutions near the amino-
terminus of Rns, I14T and N16D, alter the Rns DNA sequence specificity (156) suggesting that 
residues at the amino terminus of the Rns may be required for Rns activity. In order to 
characterize the function of the NTD in Rns, we first defined the two domains of Rns.  
Earlier it was predicted that the Rns NTD is from residues 1-100 and DBD is from 
residues 131-265 with a possible linker between the residues 101-130 (156). However, after 
comparison of DBDs of other AraC family members including AraC, MarA and ToxT (which 
are ~100 amino acids long, rather than the ~30 amino acid domain previously predicted), we 
hypothesized that DBD may extend from residue 157 to 265. We first made an Rns DBD 
construct that included residues 157-265 and assayed the activation levels of Rns(157-265) in 
comparison to the wild type and found that DBD does not activate transcription (Fig. 5). Our 
electrophoretic mobility shift assays using purified Rns-DBD showed that the DBD (from 
residues 157-265) is functional and is capable of binding DNA, suggesting that the construct 
157-265 can serve as DBD.  
Then using ClustalW method (157) we aligned a group of Rns homologs (done by Dr. 
Susan Egan) and found a substantially higher sequence identity of 74% among residues around 
I14 and N16 (I12-M18) compared to the overall sequence identity of 26% among NTDs of these 
proteins (Fig. 6). We called this highly conserved region of the Rns NTD (residues I12-M18) 
RS2, for its predicted role as a regulatory site that contacts subdomain 2 of the DBD, at least in 
AraC family proteins that responds to effector molecules  (79, 100, 101). Then, by using I-
TASSER predicted structure of Rns (157) (Fig. 7) and the sequence alignment of Rns with ToxT 
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(Fig. 8) we found that Rns RS2 region residues aligns with ToxT 2 sheet residues (Y20-Y26) 
that are positioned to make inter-domain interactions with the ToxT DBD (79). With this 
information, we hypothesized that the Rns RS2 region may play a role in maintaining Rns in its 
activating state, and therefore, we mutagenized residues in the Rns RS2 region by site-directed 
random mutagenesis to understand the role RS2 region plays in overall Rns function. 
 
 
Fig. 5. N-terminal domain (NTD) of Rns is required for the Rns activation. Wild-type Rns 
and deletion constructs were expressed from a low copy number plasmid pHG165 and analyzed 
for their ability to activate transcription at cfaA-lacZ promoter region that has three Rns binding 
sites. Results shown were the average of three independent experiments with two replicates each. 




















Fig. 6. Alignment of Rns RS2 region with the most closely related proteins. ClustalW 
method was used to align sequences. The over lined residues indicate RS region. Identical 
positions are red and marked “*”; strongly similar positions are green and marked “:”; 
weakly similar positions are blue and marked “.”; different positions are black and 
unmarked.  Gaps in the alignment are marked “-”. Rns from ETEC, CfaD from ETEC 
10407, AggR [Escherichia coli O104:H4], HdaR [Escherichia coli], CsvR [Escherichia 






Fig. 7. Predicted Rns three-dimensional structure with RS2 region mapped. I-TASSER 
(157) was used to predict the 3D structure of the Rns. NTD was shown in green and DBD was 

















Rns             --------MDFKYTEEKETIKINNIMIHKYTVLYTSNCIMDIYSEEEKITCFSNRLVFLE 52 
ToxT            MIGKKSFQTNVYRMSKFDTYIFNNLYINDYKMFWIDSGIAKLIDKNCLVSYEINSSSIIL 60 
                         :.   .: :*  :**: *:.*.::: .. * .: .::  ::   *   ::  
 
Rns             RGVNISVRMQKQILSEK--PYVAFRLNGDMLRHLKDALMIIYGMSKIDTNACRSMSRKIM 110 
ToxT            LKKNSIQRFSLTSLSDENINVSVITISDSFIRSLKSYILGDLMIRNLYSENKDLLLWNCE 120 
                   *   *:.   **::     .: :...::* **. ::    : :: ::    :  :   
 
Rns             TTEVNKTLLDELKNINSHDNSAFISSLIYLISKLENNEKIIESIYISSVSFFSDKVRNLI 170 
ToxT            HNDI--AVLSEVVNGFREINYSDEFLKVFFSGFFSKVEKKYNSIFITDDLDAMEKISCLV 178 
                 .::  ::*.*: *   . * :     ::: . :.: **  :**:*:.     :*:  *: 
 
Rns             EKDLSRKWTLGIIADAFNASEITIRKRLESENTNFNQILMQLRMSKAALLLLENSYQISQ 230 
ToxT            KSDITRNWRWADICGELRTNRMILKKELESRGVKFRELINSIRISYSISLMKTGEFKIKQ 238 
                :.*::*:*  . *.. :.:..: ::*.***...:*.::: .:*:* :  *:  ..::*.* 
 
Rns             ISNMIGISSASYFIRIFNKHYGVTPKQFFTYFKGG--- 265 
ToxT            IAYQSGFASVSNFSTVFKSTMNVAPSEYLFMLTGVAEK 276 
                *:   *::*.* *  :*:.  .*:*.:::  :.*     
 
Fig. 8. Alignment of Rns withToxT. ClustalW method (157) was used to align sequences. 
Residues in the RS2 region of Rns and the corresponding residues in ToxT were marked red.  
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  We mutagenized the Rns RS2 region by randomizing one codon at a time (using 
oligonucleotides with NNN at the codon to be mutagenized) and generated an assortment of 
variants. Wild type and different variants of Rns (cloned into pHG165 vector) were tested for 
Rns-dependent cfaA-lacZ
∆60
 expression levels at CFA/I promoter. The cfaA-lacZ
∆60
 fusion strain 
has a single Rns binding site that overlaps the -35 promoter element at which Rns is in a position 
to contact RNAP. The level of Rns dependent LacZ expression in this strain is consistently 90 
fold higher for wild type compared to the strain transformed with vector only control (Table 4).  
We isolated 25 unique variants at 7 positions in the Rns RS2 region. Out of the total 25 
variants, 13 (52%) variants had significantly decreased Rns dependent LacZ expression. None of 
the variants increased Rns-dependent cfaA-lacZ
∆60
 expression relative to wild type (Table 5). 
Variants that were defective for Rns-dependent cfaA-lacZ
∆60
 expression were identified at every 
position in the RS2 region except K13 (Table 5). In principle, the decreases in the Rns-dependent 
cfaA-lacZ
∆60
 expression could be due to decreased Rns activity or reduced Rns protein levels 
(resulting from poor protein expression or protein instability). To test this possibility, we 
performed Western blots for all the mutant strains, using antibodies raised against purified MBP-
Rns protein. Figures 9 and 10 show the protein levels of different variants isolated from the RS2 
region. Defective variants from I14, N15, N16 and I17 showed Rns protein levels similar to wild 
type (Table 5), suggesting that the defects observed in these variants were due to the protein 
activity and cannot be attributed to lower protein levels. However, all the defective variants 
isolated from I12 (I12R, I12G, I12E and I12W) (Fig. 9) and M18 (M18P and M18R) (Fig. 10) 
had significant decrease in protein levels (Table 5). The remainder of the substitutions at I12 
(I12S) and M18 (M18G) had no significant defects in either LacZ expression or protein levels. 
Given that many of the variants had decreased protein levels at I12 and M18, these residues may 
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be required to stabilize Rns. However, the direct involvement of I12 and M18 in Rns dependent 
LacZ expression could not be concluded as all the defective variants had defects in protein levels 
(Table 5).  
Despite having substitutions with various physico-chemical properties, none of the K13 
variants showed any Rns-dependent cfaA-lacZ
∆60
 expression defects, indicating that this residue 
was not important for Rns-dependent cfaA-lacZ
∆60
 expression (Table 5). We could not make any 
definitive conclusions regarding the importance of I14 residue as we were able to isolate only 
one variant at this position, although the only variant isolated (I14W) was defective for Rns-
dependent cfaA-lacZ
∆60
 expression (Table 5).  
Overall, we isolated multiple defective variants at positions N15, N16 and I17, 
suggesting that these residues are important for Rns-dependent cfaA-lacZ
∆60
 expression (Table 
5). Altogether, this data demonstrates that specific residues in the RS2 region of NTD are 
required for the transcription activation by Rns. 
Distinguishing DNA binding defects from transcription activation defects in RS2 region.  
In principle, Rns-dependent cfaA-lacZ
∆60
 expression defects observed in Rns RS2 region could 
be the result of either defects in DNA binding or direct defects in transcription activation (In this 
context, we refer to transcription activation as processes such as contacts with RNA polymerase, 
alteration of promoter DNA conformation and relief of repression). In order to further 
characterize the variants and identify the nature of these defects (DNA binding vs direct 
activation), assays were performed to test their ability to repress the transcription in a repression 
strain that carried nlpA
cfaA
-lacZ fusion (Table 4). Repression of LacZ expression in nlpA
cfaA
-lacZ 





 which requires both DNA binding and direct transcription activation to 
activate transcription. Therefore, comparison of results from both the fusion strains can 
differentiate variants that impact DNA binding versus direct transcription activation. Rns 
variants that are defective for both repression of LacZ expression at nlpA
cfaA
-lacZ and activation 
of LacZ expression from cfaA-lacZ
∆60
 likely indicate defects in DNA binding. Rns variants with 
defects only in Rns dependent LacZ expression from cfaA-lacZ
∆60
 (wild-type repression levels 
nlpA
cfaA
-lacZ) likely indicate direct defects in transcription activation. To eliminate the sequence-
specific differences in Rns binding to the nlpA and cfaA promoter regions (due to differences in 
the Rns binding site sequences), we replaced the Rns binding site at nlpA promoter with one that 
is identical to the one found in cfaA promoter region in nlpA
cfaA
-lacZ fusion. In nlpA
cfaA
-lacZ 
fusion strain, wild-type Rns represses LacZ expression by ~2 fold compared to the strain 
transformed with vector only control (unrepressed state). 
Our analysis of RS2 region variants for repression at nlpA
cfaA
-lacZ and Rns-dependent 
cfaA-lacZ
∆60
 expression levels and protein levels for the same variants have led to the following 
findings. All of the variants with wild type expression from the cfaA-lacZ
∆60
 showed wild-type 
protein levels and repression levels at nlpA
cfaA
-lacZ, indicating no significant defects in those 
variants (Table 5). With the exception of I14W, all of the variants in the RS2 region that had 
defects in cfaA-lacZ
∆60
 expression showed protein levels and repression levels similar to the wild 
type. This suggests that these variants primarily impact activation function and the wild type 
residues at these positions (N15, N16 and I17) are required for full transcription activation by 
Rns (Table 5). The only substitution isolated at residue I14 (I14W) was defective for both cfaA-
lacZ
∆60
 expression and nlpA
cfaA
-lacZ repression indicating defects in DNA binding. However, the 
defects in cfaA-lacZ
∆60





-lacZ repression (~2 fold). These results suggest that I14 may impact both 
DNA binding and transcription activation, although with only one variant, we cannot draw a 
strong conclusion (Table 5). 




-lacZ strains suggested 




Table 4. Rns dependent activation of cfaA-lacZ and repression of nlpA
cfaA
-lacZ.  











 -60 to +360 40 ± 5 3650 ± 150 
nlpA
cfaA
-lacZ -160 to +82 60 ± 1 30 ± 2 
 a
Represents promoter sequence relative to the transcription start site 
b
β-galactosidase activity (Miller units) from fusion strains transformed with vector only control 
(pHG165)  
b
β-galactosidase activity (Miller units) from fusion strains transformed with pHG165 plasmid 
cloned with rns.  






























I12G 41±11 65±7 49±13 Less protein 
I12E 47±12 70±7 50±0 Less protein 
I12W 73±23 47±3 30±11 Less protein 
I12R 60±6 63±4 58±3 Less protein 
I12S 72±9 77±4 103±32 ~WT 
K13C 81±10 100±4 153±21 ~WT 
K13S 83±12 86±4 106±5 ~WT 
K13G 84±16 78±4 136±25 ~WT 
I14W 6±2 58±3 104±0 Activate/Bind 
N15G 17±3 76±4 64±9 Activate 
N15L 23±9 66±2 179±1 Activate 
N15D 75±1 88±4 109±15 ~WT 
N16C 5±2 66±3 72±8 Activate 
N16D 25±3 76±3 106±15 Activate 
N16G 64±8 83±4 146±20 ~WT 
I17P 0±0 69±4 93±0 Activate 
I17N 2±1 78±3 96±1 Activate 
I17R 2±3 87±4 79±20 Activate 
I17S 3±4 65±4 92±0 Activate 
I17Y 50± 83±3 81±6 Activate 
I17V 60±3 77±3 98±1 ~WT 
I17C 79±4 102±4 91±13 ~WT 
M18P 14±2 45±5 32±13 Less protein 
M18G 68±17 97±4 86±2 ~WT 
M18R 80±16 67±4 50±8 Less protein 
 
a





-lacZ fusion strains and assayed by β-galactosidase 
reporter gene assay. Expression of cfaA-lacZ
∆60
 and repression of nlpA
cfaA
-lacZ by wild-type Rns 
was set to 100%. Results are the average of three independent experiments. Percentage cfaA-
lacZ
∆60
 expression less than 60% of wild type and non-overlapping standard deviation were used 
as a significant change in cfaA-lacZ
∆60
 expression. Non-overlapping standard deviation and three 





levels were estimated for different variants by Western blotting and presented as a relative 
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percentage of wild type. Non-overlapping SD and protein levels less than 60% of wild type were 
used to determine level of significance 
c
Different categories of mutants isolated: Less protein, variants with decreased Rns protein 
levels; ~WT, variants with wild type activation, repression and protein levels; Activate, variants 
with significant defects in transcription activation; Bind, variants with significant defects in 






















Fig. 9. Western blot analysis of variants  in the RS2 region. Western blot was performed to 
quantify the level of wild-type Rns and different variants of Rns from RS2 region. DnaK served 
as loading control (Top arrow). The bottom arrow represents the Rns band. Numbers 1 to 12  
represent different variants isolated from residues I12, K13, I14 and N15 in the RS2 region. V, 
vector control; W, wild-type Rns; 1, I12S; 2, I12W; 3, I12R; 4, I12G; 5, I12E; 6, K13S; 7, K13C; 



































Fig. 10. Western blot analysis of variants  in the RS2 region. Western blot is performed to 
quantify the level of wild-type Rns and different variants of Rns from RS2 region. DnaK served 
as loading control (Top arrow). The bottom arrow represents the Rns band. Numbers 13 to 20 on 
the top gel and 21 to 25 on the bottom gel to 25  represents different variants isolated from 
residues N16, I17 and M18. W, wild-type Rns; 13, N16C; 14, N16D; 15, N16G; 16, I17R; 17, 
I17P; 18, I17N; 19, I17S; 20, I17Y; 21, I17C; 22, I17V; 23, M18P; 24, M18R; 25, M18G;  
































Variants in the Rns DBD AS2 region affect Rns-dependent cfaA-lacZ
∆60
 expression. Site-
directed random mutagenesis was also performed for 9 residues in the Rns-DBD that are 
predicted to be contacted by the residues in the RS2 region of NTD (based on I-TASSER 
prediction). We refer this region as AS2 region (allosteric site in the sub domain 2 of DBD). 
According to the predicted I-TASSER structural model, the residues in Rns AS2 region were in a 
similar position to residues in the ToxT structure that were positioned to make inter-domain 
interactions with the ToxT-NTD (79, 157).  The AS2 region constituted residues Q211, S215, 
K216, L219, K249-G252 and Y261. In the predicted Rns structure, residues Q211, S215, K216 
and L219 were in the α7 helix (helix between two helix-turn-helix motifs) and K249-G252 and 
Y261 were in the 9 – loop - 10 region (Fig. 11). These residues were structurally analogous to 
residues in the ToxT-DBD (α7 helix and 9 – loop - 10 region) that were positioned to contact 
the residues in the ToxT-NTD (ToxT Y20 to Y26) (Fig. 12).  
Mutagenesis of Rns residues in the α7 helix (Q211, S215, K216, L219) resulted in 
isolation of 17 variants, among which 13 (77%) had wild type cfaA-lacZ
∆60
 expression (Table 6) 
and four were defective for cfaA-lacZ
∆60
 expression. Among the four variants that were 
defective, two of them (Q211P, S215V) were defective for protein levels and thereby not 
considered as true defects of cfaA-lacZ
∆60
 expression. The other two defective variants at residue 
K216 (K216P, K216L) were the only two variants isolated at this position. Both of these variants 
had near wild-type protein levels, suggesting that Rns K216 is important for Rns-dependent 
cfaA-lacZ
∆60
 expression.  
We also mutagenized 5 positions in the predicted 9 – loop - 10 region of Rns AS2, and 
isolated a total of 24 unique variants. Unlike the residues in the α7 region of the AS2 region, the 





 expression (75% of variants, 18 out of 24) (Table 6). Our Western blots showed no 
detectable changes in protein levels for these variants (Table 6). Strikingly, all 14 variants 
isolated at residues H250, Y251 and G252 had reduced Rns-dependent cfaA-lacZ
∆60
 expression, 
suggesting the importance of these consecutive residues in Rns function (Table 6). Two of the 
five variants isolated at K249 and two of the six variants isolated at Y261 were defective for 
Rns-dependent cfaA-lacZ
∆60
 expression (Table 6). Given that the majority of variants at K249 
and Y261 had cfaA-lacZ
∆60
 expression similar to wild type, the defective variants may be gain of 
function mutants. This suggests that residues K249 and Y261 may not be required for cfaA-
lacZ
∆60
 expression or that specific substitutions can influence other residues that play a direct 
role in cfaA-lacZ
∆60
 expression. Altogether, our results suggest that residues H250, Y251 and 
G252 in the 9 – loop - 10 region are important for Rns-dependent cfaA-lacZ
∆60
 expression. 
Distinguishing DNA binding defects from transcription activation defects in AS2 region. 
Similar to the previous analysis of RS2 region variants in the repression strain (nlpA
cfaA
-





 expression, and protein levels were used to identify the variants that 
impacted DNA binding or transcription activation. Our western blot analysis showed that none of 
the variants had defects in the protein levels. Among the two variants isolated at position K216, 
one variant K216P was defective exclusively for cfaA-lacZ
∆60
 expression, suggesting that this 
variant is defective for transcription activation. The other variant K216L was defective for both 
cfaA-lacZ
∆60
 expression and nlpA
cfaA
-lacZ repression (defects in both DNA binding and 





-lacZ repression, suggesting that the variant is mainly defective for 
transcription activation function of Rns. 
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A total of five variants were isolated from the residue H250. Among the five variants, 
two were defective only for cfaA-lacZ
∆60
 expression (H250R, H250V), suggesting that these 
variants show defects in transcription activation. Three variants were defective for both cfaA-
lacZ
∆60
 expression and nlpA
cfaA
-lacZ repression (H250I, H250N and H250T), suggesting that 
these variants show defects in DNA binding and transcription activation. Among these three 
variants, one variant (H250I) had ~6 fold higher defects in cfaA-lacZ
∆60
 expression than nlpA
cfaA
-
lacZ repression. Overall, the residue H250 seems to be required for both DNA binding and 
transcription activation (Table 6). All the four variants isolated from AS2 region residue Y251 
were defective for cfaA-lacZ
∆60
 expression activation but not for repression, indicating that this 
residue is important for transcription activation function of Rns (Table 6). For residue G252, 
three variants (G252Q, G252S and G252A) were defective for cfaA-lacZ
∆60
 expression and two 
variants (G252N and G252R) were defective for both cfaA-lacZ
∆60
 expression and nlpA
cfaA
-lacZ 
repression. G252R showed ~7 fold higher defects in cfaA-lacZ
∆60
 expression than nlpA
cfaA
-lacZ 
repression. Overall, this residue seems to be required for both DNA binding and transcription 
activation.  
For residue K249, one variant (K249Y) showed defects in cfaA-lacZ
∆60
 expression and 
another one (K249A) showed defects in both cfaA-lacZ
∆60
 expression and nlpA
cfaA
-lacZ 
repression. For residue Y261, two variants showed only cfaA-lacZ
∆60
 expression defects (Y261G 
and Y261E) (Table 6). However, majority of the variants at K249 and Y261 were found to have 
no cfaA-lacZ
∆60
 expression and nlpA
cfaA
-lacZ repression defects, likely suggesting that the 
defective variants at these positions may be gain of function variants (Table 6).  




-lacZ strains suggested 
that two residues in AS2 region (K216 and Y251 ) were required for transcription activation 
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function of Rns and two residues H250 and G252 were required for both DNA binding and 
transcription activation function of Rns. 





strains.Previous reports by Basturea et al showed that Rns I14T and N16D variants (expressed 
from a high copy number plasmid pUC18) alter the Rns DNA sequence specificity at rns 
promoter region, and thereby decrease the expression from rns-lacZ fusion (156). Their results 
also showed that I14T did not affect cfaA-lacZ and nlpA-lacZ expression (156) and thus 
suggesting that I14T substitution may not impact the DNA binding by Rns at cfaA and nlpA 
promoter regions, and transcription activation from cfaA promoter region. Results of N16D 
substitution showed greater defects in cfaA-lacZ expression than nlpA-lacZ expression (156), and 
thus indicated us that N16D may impact the transcription activation function by Rns from cfaA 
promoter region. Our mutagenesis of I14 residue did not result in isolation of I14T substitution. 
However, we isolated N16D substitution that was defective for transcription activation function 




-lacZ fusions differ 
from cfaA-lacZ (differs in number of Rns binding sites) and nlpA-lacZ (differs in both number 
and sequence of binding sites) fusions used by Basturea et al, we tested the effect of Rns I14T 










lacZ expression, and thus indicating that I14T may not interfere with DNA binding and 
transcription activation function by Rns, at least at the Rns binding site from cfaA (Fig. 13). Our 





showed that N16D was defective only for  cfaA-lacZ
∆60
 expression (Fig. 13), and thus indicating 
defects in transcription activation function from cfaA promoter region. The impairment of 
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transcription activation function by N16D further supports our observation that the residue N16 







Fig. 11. Predicted Rns three dimensional structure with AS2 region mapped. I-TASSER 
(157) was used to predict the 3D structure of the Rns. NTD was shown in green and DBD was 







Fig. 12. ToxT structure with residues corresponding to RS2 and AS2 regions mapped (79). 
Ribbon diagram of the ToxT with the effector palmitoleic acid (grey, shown in stick form) bound 
in the NTD. The ToxT structure is colored with rainbow effect with the violet at the N-terminus 
and red at the C-terminus. Residues shown as purple spheres indicate the ToxT residues that 
correspond to Rns RS2 region residues. Residues shown as blue spheres indicate the ToxT 





























Q211P 15±6 40±4 35±12 Less protein 
Q211N 67±16 83±3 140±1 ~WT 
Q211L 69±10 95±4 104±0 ~WT 
Q211S 77±15 87±3 ND
d
 ~WT 
Q211G 96±11 97±4 106±16 ~WT 
S215V 46±17 55±10 39±17 Less protein 
S215D 74±8 98±4 93±10 ~WT 
S215G 84±3 106±5 ND
d
 ~WT 
S215K 113±7 102±4 93±11 ~WT 
K216L 1±0 57±4 83±25 Activate/Bind 
K216P 9±1 86±4 78±4 Activate 
L219H 95±9 78±4 89±0 ~WT 
L219I 97±8 65±2 105±6 ~WT 
L219A 107±18 72±5 79±12 ~WT 
L219K 122±11 74±1 113±19 ~WT 
L219M 121±9 78±4 92±1 ~WT 
L219Y 124±22 80±3 96±0 ~WT 
K249Y 31±8 81±4 93±11 Activate 
K249A 45±8 52±8 79±10 Bind 
K249N 65±12 79±4 95±7 ~WT 
K249E 79±3 75±4 131±27 ~WT 
K249R 107±21 91±4 91±13 ~WT 
H250I 9±3 49±6 128±6 Activate/Bind 
H250V 18±11 81±9 122±28 Activate 
H250R 42±8 81±5 104±1 Activate 
H250N 44±13 64±6 100±29 Bind 
H250T 48±12 62±6 92±28 Bind 
Y251L 1±0 68±6 140±43 Activate 
Y251V 1±0 78±5 68±7 Activate 
Y251T 2±1 71±4 94±9 Activate 
Y251F 19±6 71±5 71±2 Activate 
G252R 9±8 62±3 113±25 Activate/Bind 
G252Q 11±10 79±4 94±33 Activate 
G252A 17±12 70±4 119±47 Activate 
G252S 19±14 82±5 78±3 Activate 
G252N 43±12 58±4 86±12 Bind 
Y261E 9±7 78±4 92±11 Activate 
Y261G 20±14 68±4 111±28 Activate 
Y261C 64±10 76±3 85±31 ~WT 
Y261M 64±6 83±3 140±13 ~WT 
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Y261A 68±9 64±3 118±23 ~WT 
Y261R 68±11 76±3 74±2 ~WT 
     
 
a





-lacZ fusion strains and assayed by β-galactosidase 
reporter gene assay. Expression of cfaA-lacZ
∆60
 and repression of nlpA
cfaA
-lacZ by wild-type Rns 
was set to 100%. Results are the average of three independent experiments. Percentage cfaA-
lacZ
∆60
 expression less than 60% of wild type and non-overlapping standard deviation were used 
as a significant change in cfaA-lacZ
∆60
 expression. Non-overlapping standard deviation and three 





levels were estimated for different variants by Western blotting and presented as a relative 
percentage of wild type. Non-overlapping SD and protein levels less than 60% of wild type were 
used to determine level of significance 
c
Different categories of mutants isolated: Less protein, variants with decreased Rns protein 
levels; ~WT, variants with wild type activation, repression and protein levels; Activate, variants 
with significant defects in transcription activation; Bind, variants with significant defects in 
DNA binding; Activate/Bind, variants with defects in both transcription activation and DNA 
binding. 
d












-lacZ. Rns variants I14T and N16D expressed from a high copy number plasmid 




-lacZ fusion strains using β-
galactosidase assays. Results from both these strains were compared to identify the defects in 





lacZ by wild type Rns were adjusted to 100%. Results are the average of three independent 






Purification and properties of Rns 
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In order to perform in vitro assays and to generate antibodies for Western blotting we wanted to 
have purified Rns protein. In addition, we wanted to test oligomerization state of Rns (monomer 
or dimer), as previous reports on oligomerization state of Rns were quite contradictory (155, 
156). Progress in biochemical analysis of AraC family proteins has traditionally been hampered 
by poor solubility and stability of these proteins in vitro. Therefore, in order to increase the 
solubility of Rns, I made fusion constructs that links Rns with proven solubility enhancement 
proteins GB1 (~8 kDa) and MBP (~42.5 kDa). Studies by Basturea et al had shown that Rns can 
be successfully purified using MBP tag (156). Rns has many rare codons whose expression is 
limited in E. coli strains (most of the rare codons were present in the NTD). In order to overcome 
the limitations of the rare codons, codon-optimized rns (purchased from GenScript, Piscataway, 
NJ) was linked to the GB1 tag. Table 7 shows the list of Rns constructs made for overexpression. 
Despite my efforts in overexpression of Rns and Rns-NTD with GB1 attached at both the 
N-terminus and C-terminus of the protein (expressed from lacI controlled T7 promoter), I was 
not able to detect any overexpression from these constructs. However, one construct Rns-DBD-
GB1-His6 overexpressed in all the conditions. In addition, full-length Rns and Rns-NTD 
overexpressed when linked with MBP tag and expressed from Ptac promoter (lacIq controlled).  
Purification of Rns-DBD-GB1-His6. Rns-DBD-GB1-His6 was overexpressed at 37
o
C from 
pDZ3 plasmid from the strain BL21 (DE3)DnaY (100 ml initial culture). Cells were lysed by 
sonication and run on SDS-PAGE which showed that the protein was insoluble. The pellet 
fraction was resuspended in buffer containing either 2 or 4 or 6 M urea and incubated overnight. 
Protein was found to be soluble by ~50% in 6M urea. The soluble fraction of the protein was 
purified using Ni
2+ 
affinity purification under denaturing conditions (6 M urea containing elution 
buffer). Urea was subsequently removed from the sample using a HiPrep 26/10 desalting column 
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into 10ml of elution buffer (20 mM Tris-base, 500 mM NaCl, 500 mM Imidazole, 0.1 mM 
TCEP, pH 7.9) (Fig. 14A). The protein was stable at 0.3 mg/ml. 
Alternatively, Rns-DBD-GB1-His6 was soluble (~50%) when overexpressed overnight at 
15
o
C. The soluble fraction of the protein was purified using Ni
2+ 
affinity purification into 10 ml 
elution buffer (Fig. 14B). The protein was stable at 1.1 mg/ml. Protein fractions showing only 
the Rns-DBD-GB1-His6 were pooled and tested for binding using electrophoretic mobility shift 
assays (EMSAs). The result in the figure 15 demonstrates that Rns-DBD-GB1-His6 could bind 
to the DNA and the amount of binding decreases with decrease in protein concentrations. For 
long-term storage of active Rns-DBD-GB1-His6, glycerol was added to a final concentration of 
25% and stored at -80
o
C. 
Previously, DNaseI footprinting experiments by Basturea et al (156) using a longer 
MBP-Rns construct (Rns residues 128-265) that included the DBD has shown that this construct 
did not bind to the cfaA promoter region even at high protein concentrations of 2.5 µM. 
Surprisingly, our EMSA experiments with the purified Rns-DBD-GB1-His6 showed that this 
protein can bind to cfaA promoter region even at concentrations of 1 µM. However, even at 
highest protein concentration tested (9 µM), only 7% of the DNA was bound by the protein. We 
expect that the differences in the sensitivities of the techniques may have contributed to 
observation of these varied results. DNase foot printing is more sensitive than EMSA in terms of 
using P
32 
labeled DNA as opposed to IR labeled DNA in our EMSAs. However, it is harder to 
detect 7% DNA binding in DNase foot printing as we look for decrease in intensity of the DNA 





Table 7. Rns constructs for overexpression and purification. 
Construct Cloning Overexpression 
GB1-Rns Yes None 
Rns-GB1 Yes None 
GB1-RnsNTD Yes None 
RnsNTD-GB1 Yes None 
RnsDBD-GB1 Yes Yes 
GB1-Rns
co
 Yes None 
Rns
co
-GB1 Yes None 
MBP-Rns Yes Yes 
MBP-RnsNTD Yes Yes 
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                            B. 
 
 
Fig. 14. Purification of Rns-DBD-GB1-His6. A) Fusion protein was solubilized from the pellet 
using urea and purified using Ni
2+ 
affinity chromatography into elution buffer (20 mM Tris-base, 
500 mM NaCl, 500 mM Imidazole, 0.1 mM TCEP, pH 7.9) containing 6M urea. B) Purification 
of fusion protein from soluble fraction by using Ni
2+ 
affinity chromatography into elution buffer. 
S, supernatant fraction; P, pellet fraction; E1-E7, elution fractions. In addition to Rns-DBD-GB1-
His6 (22 kDa), an additional prominent lower band of ~14 kDa was found in few fractions 
consistently, although further experiments were not carried out to identify the protein 




























Fig. 15. Electrophoretic mobility shift assay of DNA binding by Rns-DBD-GB1-His6. 
Binding of purified Rns-DBD-GB1-His6 to a DNA fragment containing the Rns binding site 
from the cfaA promoter was assayed using electrophoretic mobility shift assays (EMSAs). Black 
triangle represents decreasing concentrations of Rns-DBD-GB1-His6, 9 μM to 1μM, with serial 






 Overexpression and Purification of MBP-Rns protein. MBP-Rns fusion protein was 
expressed from pMBP-Rns1 plasmid in the E. coli strain KS1000. The strain was also 
transformed with pRARE2 (Novagen) plasmid that has seven tRNAs genes that encode rare 
codons required by Rns. After overnight induction, cells were sonicated and centrifuged to 
remove the cell debris. The soluble supernatant was then loaded on a BioLogic LP 
chromatography system to an amylose resin column and eluted in 25 ml of elution buffer 
containing 10 mM maltose [20 mM Tris-base, 500 mM NaCl, 1 mM EDTA, 0.1 mM TCEP, 
15% Glycerol, 10 mM Maltose pH 7.6] (Fig. 16). Although the final protein had some 
impurities, we obtained a total of ~5 mg of soluble protein from 1 L initial culture. To further 
purify the protein and to determine whether Rns act as monomer or dimer, eluted fractions were 
concentrated to not more than 2 mg/ml (above which it aggregated) and passed through a size 
exclusion Sephacryl 16/60 S-200 chromatography column. The majority of the protein eluted at a 
mass of very large aggregates, although some fraction of the protein was found at the size of 
monomer (~73 kDa) (Fig. 17). In addition, some fraction of the protein was eluted at a size of 
MBP (~40 kDa) indicating the partial cleavage of the MBP from the Rns protein. Protein 
markers of sizes 150 kDa and 75 kDa corresponding to dimer and monomer of Rns, respectively 
were run through column and used to determine the oligomerization status of Rns fractions. 
In order to find the suitable buffer in which Rns is less prone to aggregation, I exchanged 
the subsequent protein preps in to a simple Tris-buffer with less salt and no maltose (15 mM 
Tris-base, 75 mM KCl, 5 mM β-mercaptoethanol, 10% Glycerol, pH 7.6) using a Hiprep 26/10 
desalting column. The protein was concentrated to ~2 mg/ml and then passed through a size 
exclusion chromatography column. Unlike elution buffer, protein did not visibly aggregate in 
this buffer. Majority of the protein was eluted at ~53 ml which corresponds to a molecular 
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weight of ~75 kDa in this buffer (Fig. 18) (Running of a protein marker of 75 kDa showed that 
53 ml corresponds to ~75 kDa in this buffer). This suggests the MBP-Rns behaves as a monomer 
in solution in vitro. Similar to the previous observation, some fraction of the protein was eluted 
at a size of MBP (~40 kDa) indicating the partial cleavage of the MBP from the Rns protein. 
EMSAs were performed using purified MBP-Rns protein to test whether the protein is active in 
vitro. DNA fragments (one IR labeled and one non-IR labeled oligo) containing the Rns binding 
site from cfaA promoter region was used to test in vitro DNA binding ability of Rns. EMSA 
results indicated that MBP-Rns is active in vitro and can bind to DNA (Fig. 19). In addition, 
presence of large MBP tag did not inhibit the binding of protein to the DNA, suggesting that 
MBP tag may not interfere with Rns. This observation further supports the previous observations 
that MBP tag does not interfere with Rns activity in vivo and in vitro (147, 154). Purified active 
MBP-Rns was stored at -80
o
C for long-term storage.  
The purified MBP-Rns was injected into rabbit five times (at 15 days interval) to make 
polyclonal Rns antibodies for the use in Western blotting (Cocalico Biologicals, Reamstown, 
PA). The sera obtained were affinity purified against purified MBP-Rns protein to isolate Rns 
antibodies and tested for their ability to detect Rns expressed from pHG165 in the E. coli strain 
SME4336. Figure 20 demonstrates that the affinity purified Rns antibodies detect Rns from 
SME4336, with very little background. 
Rns was found to be very prone to aggregation when cleaved from MBP tag. Cleavage 
reaction were performed at room temperatures (for 1-4 h) using a protease factor XA (1:100 ratio 
of XA to MBP-Rns) that cleaves in the linker region between MBP and Rns. When the cleavage 
reaction components were run on SDS-PAGE, only a high intense band that corresponds to MBP 
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protein was visible (Fig. 21). It might be possible that majority of Rns aggregated in the tube 
after cleavage. Alternatively, protease factor XA may have cleaved Rns at multiple places. 
Given that Rns aggregated when cleaved from MBP protein, crystallization trial were 
conducted using MBP-Rns fusion protein. MBP-Rns protein was concentrated using a Millipore 
centricon (50 kDa cut off) and concentrated to ~20 mg/ml (in buffer with 15 mM Tris-base, 75 
mM KCl, 5 mM β-mercaptoethanol, 10% Glycerol, pH 7.6) without any visible aggregation. 
Aggregation at 20 mg/ml concentration was tested using dynamic light scattering (DLS). DLS 
measures the fluctuations in scattered light intensity due to diffusing particles, and thereby 
calculates the mean effective diameter of the particles in the population. If the protein is 
monodisperse, a single mean effective diameter of the protein was possible. Depending on the 
size of the protein the mean effective diameter of the protein may vary   However, if the protein 
is aggregated we can see measurements of multiple diameters. Our results showed that the 
majority of the protein scattered belongs to a single diameter and thus indicates no aggregation 
(Fig. 22). Crystallization trials were conducted using 20 mg/ml concentrated protein. Almost 400 
different commercially available crystallization conditions were tested, but none resulted in 
crystals. In the fusion protein, MBP and Rns were connected by a flexible 25 amino acid linker 
region (S3N10LGIEGRISEFGS) that may have resulted in heterogeneity leading to non-formation 
of crystals. In addition, the predicted secondary structure of Rns showed an unstructured region 
near the N-terminus of the protein which may have further increased the flexibility between 
proteins. Future crystallization trials by removing these flexible regions will be needed to test 











Fig. 16. Purification of MBP-Rns. The fusion protein was purified using amylose
 
affinity 
chromatography into elution buffer [20 mM Tris-base, 500 mM NaCl, 1 mM EDTA, 0.1 mM 
TCEP, 15% Glycerol, 10 mM Maltose pH 7.6]. Purified elution fractions were electrophoresed 






















Fig. 17. Size exclusion chromatography of MBP-Rns in elution buffer. Sephacryl 16/60 S-
200 chromatography column was used. Y-axis shows UV absorbance at 280 nm and X-axis 
shows elution volume. The peak at 40.46 ml retention represents aggregation. The next small 
peak at 49.22 ml retention eluted at the size of ~85 kDa (Probably Monomer). The next peak at 






Fig. 18. Size exclusion chromatography of MBP-Rns in elution buffer. Sephacryl 16/60 S-
200 chromatography column was used. Y-axis shows UV absorbance at 280 nm and X-axis 
shows elution volume. The highest peak at 53.01 ml retention eluted at the size of monomer (~75 















Fig. 19. Electrophoretic mobility shift assay of DNA binding by MBP-Rns. Binding of 
purified MBP-Rns to a DNA fragment containing the Rns binding site from the cfaA promoter 
was assayed using electrophoretic mobility shift assays (EMSAs). DNA and protein were added 



















Fig.20. Western blot analysis of affinity purified MBP-Rns antibodies. Affinity purified 
antibodies were tested in Western blot for their ability to properly recognize Rns expressed from 
pHG165 in the strain SME4336 (labeled “+”). The strain SME4337 (pHG165 vector control) 
was used as negative control (labeled “-”). DnaK served as loading control (Top arrow). The 
bottom arrow represents the Rns band. M, marker.  





























Fig.21. Cleavage of MBP-Rns with protease factor XA. MBP-Rns was incubated with 
protease factor XA (1:100 dilution) at room temperature for 1-4 h, ran on SDS-PAGE gel, and 
stained with Coomassie Blue. M, Marker; N, negative control (MBP-Rns without factor XA 
added).  
MBP Rns + XA 
MBP  
(42.5 kDa) 


























   
 
Fig.22. Dynamic light scattering analysis of MBP-Rns protein. A 200 µl of 20 mg/ml 
concentrated protein was analyzed to test the aggregation levels of the protein. Each of the three 
panels represents an average of 60 different readings taken in a span of 60 sec. D, mean radius of 




















Mean effective diameter 
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Chapter 5 
Small molecule inhibitor of AraC family proteins Rns and VirF  
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Rns and VirF are the virulence regulators in Enterotoxigenic E. coli (ETEC) and Shigella 
respectively and are required by their respective pathogens to cause disease (41, 42, 45-49). Rns 
and its orthologs are required for expression of majority of the colonization factor antigens (CFs) 
that are required for the successful adherence of ETEC to its host intestinal epithelial cells (41, 
42). ETEC causes diarrhea and is responsible for a high rate of mortality in infants and children 
under the age of five (300,000 – 500,000 deaths annually), especially in developing countries 
(117, 214). In the United States, ETEC is most often acquired during travel to nations where it is 
endemic or through sporadic food borne outbreaks (119, 120). VirF is required for the expression 
of genes responsible for intracellular invasion and cell-to-cell spread, and is thereby central to 
Shigella virulence (45-49). Shigella is responsible for 165 million illnesses and over 1.1 million 
deaths worldwide each year (158, 159). 
Given the enormous number of infections caused by both these bacteria, it is important to 
find effective treatment strategies to successfully treat these infections. Despite many efforts 
there was no vaccine released for public use (although some vaccines are under trials) (215-218). 
A major obstacle in vaccine development is the substantial heterogeneity of surface antigens 
among different strains of these pathogens (215-218). Both Shigella and ETEC are becoming 
increasingly resistant to the currently available antibiotics (3, 219). A study carried out by 
National Antimicrobial Resistance Monitoring System (NARMS, USA) in 2001 showed that out 
of 344 Shigella isolates available, ~71% of the isolates were found to have developed resistance 
against 2 or more antibiotics (3). Our central hypothesis is that inhibition of transcription 
activation of Rns and VirF will prevent the expression of virulence factors in ETEC and Shigella, 
thereby reducing the ability of these pathogens to cause human diseases. Although VirF and Rns 
have different gene targets, Rns is functionally inter-changeable with VirF and activates the 
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expression of VirF regulated virulence genes (220), suggesting that inhibitors identified against 
one protein may inhibit the other. Moreover, sequences of Rns and VirF are very well conserved 
among different strains of ETEC and Shigella respectively. Therefore, identification of inhibitors 
against Rns and VirF can reduce infections by different other ETEC and Shigella strains. 
Recently using high-throughput screening the Egan lab identified a compound SE-1 (Fig. 
23A) that successfully inhibited AraC family activators RhaS and RhaR. SE-1 specifically 
inhibited RhaS and RhaR activation in vivo in E. coli LacZ based reporter gene assays, and 
blocked DNA binding by both purified full-length RhaS and RhaR proteins (202). In addition, 
we found that SE-1 inhibited RhaS and the RhaS DNA-binding domain (RhaS-DBD) to the same 
extent (202). Given that AraC family proteins have a (relatively) conserved DNA binding 
domain, we hypothesized that SE-1 might exhibit fairly broad inhibition of DNA binding by 
other AraC family proteins in addition to RhaS and RhaR. Here, I have tested whether this 
hypothesis applies to ETEC and Shigella major virulence activators Rns and VirF. 
SE-1 inhibited Rns and VirF activation of a virB-lacZ fusion in E. coli. SE-1 inhibition of 
transcription activation by Rns and VirF was first tested using cell-based assays in E. coli.  These 
assays were performed by a former graduate student Jeff Skredenske from my lab. To test the 
SE-1 inhibition of VirF and Rns, β-galactosidase assays were performed for bacteria grown in 
the absence or presence of inhibitor. Non-pathogenic strains of E. coli that carried a single copy 
of the lacZ reporter gene under the control of the virB promoter, virB-lacZ, in the chromosome 
(Fig. 23B, Top) and plasmids with IPTG-inducible expression of either Rns or VirF were used. 
Rns and VirF activation levels were tested from the same virB promoter region as both Rns and 
VirF are functionally interchangeable (220). A control strain carried plasmid-encoded LacI and 




                      A) 
 
                   B) 
 
Fig. 23.  Reporter fusions used for in vivo assays and structure of SE-1.  (A). Chemical 
structure of SE-1, 1-butyl-4-nitromethyl-3-quinolin-2-yl-4H-quinoline. (B). VirF-activated virB-
lacZ fusion (Top) and LacI-repressed hts-lacZ control fusion (Bottom), each shown in their 
uninduced (-) IPTG state (left) and their induced (+) IPTG state (right). Gray rectangles: VirF 
and LacI (lacO) binding sites. Gray arrows: lacZ gene expressed from virB or synthetic hts 
promoter. Thick black/gray lines: Promoter region DNA.  Right angle black arrows: 
Transcription start sites. Rounded gray shapes: RNAP, VirF or LacI proteins. Wavy lines: active 
transcription in the presence of IPTG. (Fig 23B; Courtesy: Dr. Susan Egan)  
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(202) (Fig. 23B, Bottom). This control strain does not require Rns or VirF for LacZ expression 
and therefore served to distinguish inhibition of overall transcription or β-galactosidase activity 
from selective inhibition of transcription activation by Rns and VirF. IPTG was added to the 
cells (to induce Rns/VirF expression or release LacI from repressing hts-lacZ) at the same time 
as inhibitor. Thus, β-galactosidase was maintained at an uninduced level until inhibitor was 
added, and it was not necessary to wait for decay of preformed β-galactosidase to detect 
inhibition. Expression of lacZ from uninduced and induced controls was set to 0% and 100%, 
respectively, thus normalizing the effect of inhibitor on the all the fusions. SE-1 inhibition of 
transcription activation by either of these virulence activators (Rns and VirF) was predicted to 
decrease lacZ expression from their respective strains carrying virB-lacZ fusions with little or no 
effect on hts-lacZ expression. In contrast, a decrease in lacZ expression from both virB-lacZ and 
hts-lacZ would indicate that the inhibition was not specific for Rns and VirF. 
We found that SE-1 showed a substantially greater dose-dependent inhibition of the VirF-
activated lacZ fusion than the LacI-repressed fusion (Fig. 24A). Inhibition of the expression from 
the VirF-activated fusion had an IC50 value of 8 μM. This is a typical potency for a hit from a 
high throughput screen (low μM to high nM potency range) that has not yet been chemically 
optimized (221) and more potent than the IC50 value of 30 μM found in similar assays with RhaS 
(202). Similar to the previous report in which we used hts-lacZ as a control (202), there was 
some non-specific inhibition of the LacZ expression from the LacI-repressed fusion at higher 
doses of SE-1. 
Similar to dose-dependent inhibition of the VirF-activated virB-lacZ fusion, we found 
dose-dependent inhibition of the LacZ expression from Rns-activated virB-lacZ fusion. The 
inhibition had an IC50 value of 9 μM, suggesting that SE-1 inhibits Rns and VirF to the same 
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extent in vivo in E. coli (Fig. 24B). Overall, our cell-based assays suggested that SE-1 inhibits 
transcription activation by Rns and VirF, at least in E. coli, with reasonable selectivity. 
SE-1 did not impact E. coli growth. Bacterial growth assays were performed to ensure that the 
observed inhibition of Rns and VirF activation could not be attributed to toxicity toward the 
strains of E. coli used in the cell-based reporter assays. Strains carrying the Rns-activated, VirF-
activated and LacI-repressed fusions were grown for 8 h at 37
o
C in the same minimal medium 
used for the in vivo dose-response assays. We found no detectable effect of SE-1 on growth of 
any of the strains, indicating that the inhibition observed in the whole cell assays could not be 
attributed to effects on cell growth (Fig. 25 and Fig. 26). As a control, we tested whether 0.3% 
DMSO (the solvent for SE-1) had any impact on the growth rate of these strains of E. coli, and 
found that it did not have any impact on the growth rate (Fig. 25 and Fig. 26). The finding that 
the tested concentrations of SE-1 had no detectable effects on the bacterial growth rates further 
supports the conclusion that SE-1 exhibits selectivity for Rns and VirF inhibition.   
SE-1 inhibited in vitro DNA binding by VirF. Electrophoretic mobility shift assays (EMSAs) 
were performed to investigate whether, similar to RhaS and RhaR (202), SE-1 inhibits DNA 
binding by purified VirF protein (MBP-VirF).  The VirF protein was purified using amylose 
affinity chromatography (done by Bria Kettle) (Fig. 27), and the DNA tested included the VirF 
binding site sequence from the virB promoter region. Our results indicate that SE-1 was able to 
fully inhibit DNA binding by VirF in a dose-dependent manner (Fig. 28). The concentration of 
SE-1 required for half-maximal inhibition of DNA binding was higher than the IC50 for the cell-
based assays. However, it was not possible to calculate an accurate IC50 value from the DNA 
binding assays due to limitations of the detection method sensitivity, solubility of SE-1, and 





Fig. 24. SE-1 inhibition of in vivo Rns and VirF activation in E. coli. (A) β-galactosidase 
(LacZ) activity was assayed at the indicated concentrations of inhibitor SE-1 from two reporter 
fusions in E. coli: VirF-activated virB-lacZ (SME4382, circles) and LacI-repressed hts-lacZ 
(SME3359, triangles).  (B) β-galactosidase (LacZ) activity was assayed at the indicated 
concentrations of inhibitor SE-1 from two reporter fusions in E. coli: Rns-activated virB-lacZ 
(SME4382, circles) and LacI-repressed hts-lacZ (SME3359, triangles). Rns, VirF and LacI were 
expressed from plasmid pHG165. Activity in the absence of SE-1 was set to 100% in each case, 
and corresponded to approximately 950 Miller Units for VirF-activated virB-lacZ, 1000 Miller 
Units for Rns-activated virB-lacZ and 350 Miller Units for hts-lacZ. Results are the average of 





Fig. 25.  Growth curves of E. coli strains carrying virB-lacZ and VirF expressed from pHG165 
(SME4382, squares) or hts-lacZ and LacI expressed from pHG165 (SME3359, circles) grown in 
the absence (-) or presence (+) of SE-1 (44 μM), or the absence or presence of DMSO (0.3%). 




Fig. 26.  Growth curves of E. coli strains carrying virB-lacZ and Rns expressed from pHG165 
(SME4383, squares) or hts-lacZ and LacI expressed from pHG165 (SME3359, circles) grown in 
the absence (-) or presence (+) of SE-1 (44 μM), or the absence or presence of DMSO (0.3%). 






Fig. 27.  MBP-VirF protein (right lane) after purification using amylose affinity chromatography 
column. Pre-stained protein ladder (left lane, Thermo Fisher Scientific) with molecular weights 
of 170, 130, 100, 70, 55, 40, 35, 25, 15 and 10 kDa (from top). MBP-VirF protein has a predicted 





Fig. 28. SE-1 inhibition of in vitro DNA binding by VirF. (A) A representative EMSA gel 
picture. Black triangle represents decreasing concentrations of SE-1, from 1.3 mM to 10 μM, 
with serial two-fold dilutions. (B) Binding of purified VirF to a DNA fragment containing the 
VirF binding site from the virB promoter was assayed using electrophoretic mobility shift assays 
(EMSAs) with inhibitor SE-1 concentrations from 10 to 650 µM (serial 2-fold dilutions). DNA 
and protein were at final concentrations of 2 and 300 nM, respectively. The DNA shifted (bound 
by VirF) was quantified, and the value at the lowest concentration of SE-1 was set to 100%.  
Results are the average of three independent replicates.  
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DNA binding by the LacI or CRP proteins (202). LacI and CRP are not members of the AraC 
family, and each are founding members of their own protein families (222-224). Overall, our 
EMSA results indicate that SE-1 can block the ability of VirF to bind to its specific DNA site. 
SE-1 inhibited in vitro DNA binding by Rns.  Electrophoretic mobility shift assays (EMSAs) 
were performed to investigate whether SE-1 inhibits DNA binding by purified MBP-Rns protein. 
MBP-Rns was purified using amylose affinity column as described above. Specific labeled DNA 
template (one IR labeled and one non-IR labeled oligo) containing Rns binding site from cfaA 
promoter region was used. This promoter is a native target for Rns activation (unlike the virB 
promoter tested in the in vivo assays) where Rns binds and activates the transcription of genes 
encoding CFA/I fimbriae that mediate the host cell attachment to intestinal epithelium (225, 
226). EMSA results indicated that SE-1 inhibits DNA binding by Rns in a dose-dependent 
manner (Fig. 29). The IC50 value of inhibition was found to be similar to half maximal inhibition 
of DNA binding by VirF in EMSAs.  
Molecular docking prediction of SE-1 binding site. We used BSP-SLIM (227) to predict 
where SE-1 may bind in the I-TASSER predicted structures of Rns and VirF. Given that, SE-1 
inhibits the activity of the DBD to a similar extent as full-length protein (based on experiments 
on RhaS) (202), we focused only on the Rns-DBD and VirF-DBD in our docking simulations. 
SE-1 identified was from pub chem library and ZINC library (ZINC library from University of 
California, SanFransisco, CA) with codes STK330322 and 4046855, respectively. The top 
models generated by BSP-SLIM predicted SE-1 to bind in a pocket between the two helix-turn-
helix motifs (HTH). Figure 30 and 31 shows the binding of SE-1 in the predicted structures of 
Rns and VirF, respectively. Binding of SE-1 between two HTH motifs could sterically prohibit 
the binding of Rns-DBD and VirF-DBD to their respective promoter DNA. In the past, docking 
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predictions of SE-1 carried out by Jeff Skredenske using SwissDock program 
(www.swissdock.ch, Molecular Modeling Group, Swiss Institute of Bioinformatics, Lausanne, 
Switzerland) on other AraC family proteins including I-TASSER predicted full-length RhaS and 
RhaS-DBD structures, AraC-DBD NMR structure (PDB 2K9S) and MarA co-crystal structure 
with DNA (PDB 1BL0) placed SE-1 between two HTH motif. All these results suggest that SE-1 









Fig. 29. SE-1 inhibition of in vitro DNA binding by Rns. (A) A representative EMSA gel 
figure. Decreasing concentrations of SE-1, from 1.3 mM to 10 μM, with serial two-fold dilutions 
were represented by black triangles. (B) Binding of purified Rns to a labeled DNA fragment 
containing the Rns binding site from the cfaAp was assayed using EMSAs with 10 to 650 µM 
(serial 2-fold dilutions) inhibitor concentrations. DNA and protein were at final concentrations of 
2 and 300 nM, respectively. The Rns bound DNA (Shifted band) was quantified. The %DNA 
binding at the lowest concentration of SE-1 was set to 100%. Results are the average of three 






Fig. 30. Prediction of SE-1 binding site on Rns-DBD. A computational docking program BSP-
SLIM was used to predict the binding site of SE-1 on I-TASSER (157) predicted structure of 













Fig. 31. Prediction of SE-1 binding site on VirF-DBD. A computational docking program 
BSP-SLIM was used to predict binding site of SE-1 on I-TASSER (157) predicted structure of 






SE-1 inhibited VirF activation of a virB-lacZ fusion in Shigella. Our cell-based assays in E. 
coli indicated that SE-1 was able to effectively inhibit activation by VirF at the virB promoter 
region. To test whether a similar inhibition occurred in Shigella, we assayed the effect of SE-1 
on VirF activity in a S. flexneri strain carrying a virB-lacZ fusion. β-galactosidase assays were 
performed on bacterial cultures grown at 37
o
C in the absence or presence of varying 
concentrations of inhibitor. Our results show a dose-dependent inhibition of virB-lacZ 
expression, with a maximum inhibition of greater than two fold at 40 μM SE-1 (Fig 32). This 
inhibition was most likely due to inhibition of VirF activity. We calculated an IC50 value of 
approximately 30 μM, which is somewhat higher than the 8 μM IC50 achieved in E. coli. S. 
flexneri samples grown in 80 μM SE-1 were not analyzed as they exhibited growth defects. 
Cultures of Shigella grown at 30
o
C in the absence of SE-1 were used to identify the basal level of 
virB-lacZ expression (161, 162, 166). These assays, similar to the cell-based assays in E. coli, 
indicate that SE-1 inhibits transcription activation by VirF at the virB-lacZ promoter region, and 
further provide evidence that SE-1 is effective in Shigella.   
SE-1 reduced VirF-regulated virulence gene expression in Shigella. Our next goal was to test 
the impact of SE-1 on expression of other VirF-regulated genes in Shigella. Previous reports 
have shown that icsA and virB genes are direct targets of VirF activation at 37
o
C (161). VirB, in 
turn, activates the expression of many operons that play a crucial role in Shigella pathogenesis 
(148). Thus, any compound that inhibits transcription activation by VirF should also affect the 
expression levels of genes that either directly or indirectly require VirF for their expression. To 
test this hypothesis, we used qRT-PCR to quantify mRNA levels of two direct VirF target genes, 
icsA and virB, and two indirect VirF target genes, icsB and ipaB (both directly activated by VirB) 
(148).   
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Before testing the effect of SE-1 on the expression of VirF regulated genes, we first 





C. In addition, we wanted to identify the growth stage at which the relative expression of 
VirF regulated genes reaches to maximal levels. Therefore, we performed real-time PCR analysis 





C. Quantification of mRNA levels showed that virB and icsB genes were 
expressed at higher levels at 37
o
C compared to 30
o
C (Table 8). In addition, expression of virB 
and icsB was also higher in samples grown until late log phase (OD600 ~1.0) (Table 8).  
To test the effect of SE-1 on VirF regulated genes, S. flexneri samples were grown to an 
OD600 of ~1.0 in the absence or presence of two different concentrations of SE-1 (20 μM, 40 
μM) and the mRNA levels from each of these genes were quantified. S. flexneri samples grown 
at 30
o
C in the absence of SE-1 were included to illustrate the basal expression levels of 
expression of these genes. Results were normalized to the gapA (encodes glyceraldehyde-3-
phosphate dehydrogenase) and rrsA (encodes 16S rRNA) genes, which are two constitutively 
expressed genes that are commonly used as qRT-PCR controls in Shigella (211-213). Example 




Fig. 32. SE-1 inhibition of in vivo VirF activation in Shigella. β-galactosidase (LacZ) activity 
was assayed at the indicated concentrations of inhibitor SE-1 from a virB-lacZ transcriptional 
fusion in Shigella, with native VirF expression. Activity in the absence of SE-1 was set to 100% 
and corresponded to approximately 3,000 Miller Units. Shigella grown at 30
o
C illustrates basal 





Table 8. Real-time PCR analysis of expression of virB and icsB genes at 37
o




 Expression at 37
o
C relative to 30
o
C at different OD600 
Gene OD600 =0.55 OD600= 0.75 OD600=1 
virB 0.84 6.92 9 
icsB 4 26.2 33 
 
S. flexneri samples grown until OD600 of approximately 0.55, 0.75 and 1 were compared for the 
expression of virB and icsB genes at 37
o
C relative to 30
o
C. Data was normalized to gapA internal 
control. Level of expression at 30
o





Table 9.  Analysis of example real-time PCR gene expression data.      
 








gapA 0 26.70  0 0 1 
gapA 20 27.33  1 1 0.5 
gapA 40 26.76  -0.69 -0.69 0.62 
rrsA 0 18.91 0  0 1 
rrsA 20 18.55 -1.0  -1.0 2 
rrsA 40 18.29 0.69  0.69 1.62 
virB 0 22.00 0 0 0 1 
virB 20 23.26 0.63 1.63 1.13 0.46 
virB 40 23.18 1.12 1.81 1.47 0.36 
icsA 0 27.70 0 0 0 1 
icsA 20 27.88 -0.46 0.54 0.04 0.97 
icsA 40 28.59 0.82 1.52 1.17 0.44 
icsB 0 26.17 0 0 0 1 
icsB 20 26.25 -0.56 0.44 -0.06 1.04 
icsB 40 27.04 0.80 1.49 1.14 0.45 
ipaB 0 24.32 0 0 0 1 
ipaB 20 25.57 0.62 1.61 1.11 0.46 
ipaB 40 26.23 1.85 2.54 2.20 0.22 
 
1
∆∆Ct values after normalizing data to gapA         
2
 ∆∆Ct values after normalizing data to rrsA 
∆∆Ct  = (Ct,Target - Ct,Internal Control) SE-1 - (Ct,Target - Ct, Internal Control) no SE-1.  
The values in the table are for a single replicate. The RQ values from three such replicates were 
averaged to get the average gene expression levels and to calculate the standard error.  
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Our qRT-PCR results showed that the icsA expression level remained essentially 
unchanged at 20 μM inhibitor, but was significantly reduced (P < 0.05) at 40 μM inhibitor (Fig. 
33A). Expression of virB, another direct target of VirF exhibited a significant decrease in 
expression with increasing concentrations of inhibitor, and a maximal inhibition of more than 
two fold at 40 μM SE-1 (P < 0.05) (Fig. 33B). Expression of icsB, an indirect target of VirF 
(183, 184), showed a significant two-fold reduction at 40 μM SE-1 (P < 0.05) (Fig. 34A). The 
greatest inhibition was detected for expression of ipaB, another indirect target of VirF, which 
was reduced by up to 4-fold at 40 μM inhibitor (P < 0.05) (Fig. 34B). As a control, we 
normalized each of the internal control genes relative to the other internal control gene. We 
found that there was no decrease in the expression of either control gene with 40 µM SE-1 (Fig. 
35), arguing that SE-1 did not result in a global decrease in gene expression. Together, our data 
demonstrate that SE-1 is capable of reducing the expression of at least four VirF-regulated 
virulence-associated genes in Shigella, presumably through its inhibition of transcription 
activation by VirF.     
SE-1 inhibited host cell invasion by Shigella. Our qRT-PCR experiments with SE-1 
showed a decrease in expression of virulence genes in Shigella. In order to test the impact of this 
decrease in virulence gene expression on the ability of Shigella to invade host cells, invasion 
assays (228) were performed using the mouse fibroblast cell line L-929. These experiments were 
performed in collaboration with Dr. Scott Hefty’s lab and a graduate student Ichie Osaka 
performed these experiments. L-929 cells were used to study the invasion of Shigella into the 
host cells (229-232). The S. flexneri strain used in the assays was an ipgD
-
 strain, which has 
hemolysis and invasion properties that are similar to wild type, but is safer to work with due to 





and then diluted and grown at 37
o
C (to induce expression of VirF-regulated genes) in the 
presence or absence of various concentrations of SE-1. In addition, S. flexneri strain SB116 
(mxiH
-
) was used as a negative control for invasion since it does not form a T3SS needle and 
thereby is unable to invade host cells (46). S. flexneri grown at 30
o
C was used as a second 
negative control for invasion, as these bacteria have reduced expression of VirF and VirB and 
thereby are defective for invasion of host cells (148). Our results showed a dose-dependent 
decrease in invasion of Shigella into L-929 cells upon addition of SE-1 (Fig. 36). SE-1 resulted 
in invasion decreases of 1.7-fold at 20 μM and 3-fold at 40 μM relative to no inhibitor.  As 
expected, both of the negative controls (wild type S. flexneri grown at 30
o
C and the mxiH
-
 strain) 
showed substantially decreased invasion relative to the wild type strain grown at 37
o
C. Similar to 
our growth assays in E. coli, we found that 0.3% DMSO did not detectably slow the growth of 
Shigella (data not shown), and SE-1 resulted in no detectable decrease in the Shigella growth rate 
at concentrations up to 40 µM (Fig. 37).   
Overall, our results support the hypothesis that SE-1 inhibits Shigella invasion by 
decreasing the expression of the genes in the VirF regulon, including the genes that encode the 
T3SS. Thus, Shigella grown under inducing conditions (37
o
C) without SE-1 would not be 
inhibited by addition of SE-1 unless growth with SE-1 was continued until the loss of preformed 
T3SS. To test this hypothesis, Shigella were grown at 37
o
C in the absence of inhibitor, and then 
Shigella and SE-1 were added at the same time to L-929 cells. This control also tested whether 
SE-1 had any impact on the L-929 cells that affected invasion by Shigella. Our result suggest 
that the inhibition of invasion by SE-1 was likely not due to post-transcriptional effects on 
Shigella or effects on the eukaryotic cells, as this control sample invaded to the same extent as 
Shigella grown in the absence of inhibitor (Fig. 36). Overall, our results support the hypothesis 
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that SE-1 decreases the expression of VirF-regulated virulence genes, and that this decrease in 
turn resulted in a reduction in the ability of Shigella to invade host cells.   
In principle, the decrease in L-929 cell invasion by Shigella might be the result of SE-1 
compromising host cellular processes, and thereby decreasing the viability of the host cells.  To 
test this possibility, the effect of SE-1 on the viability of L-929 cells was assayed using an 
AlamarBlue
®
 cell viability assay (Invitrogen, Grand Island, NY). The AlamarBlue
®
 assay is a 
fluorescence-based assay of the viability of host cells based on their metabolic activity (236). 
During invasion assays, the L-929 cells were only exposed to SE-1 concentrations of 0.2 and 0.4 
μM, due to dilution of the SE-1-containing Shigella culture into the invasion assays. 
AlamarBlue
®
 assays indicated that these concentrations of SE-1 did not detectably decrease the 
viability of L-929 cells (Fig. 38). In fact, a concentration 100-fold higher than this (40 μM) had 
no effect on the host cell viability. These results support the hypothesis that the effect of SE-1 on 
invasion by Shigella was not an indirect effect on L-929 cell viability. Further, the results 
provide evidence that SE-1 did not have detectable toxicity toward the L-929 cells at 




 Fig. 33. SE-1 inhibition of VirF regulated virulence gene expression in Shigella. qRT-PCR 
was used to determine the relative quantity (RQ) of expression of icsA (A), virB (B), in Shigella 
grown at 30
o
C (without SE-1) and at 37
o
C (without or with 20 and 40 μM SE-1). RNA levels 
were normalized to two constitutively expressed genes, gapA and rrsA. RNA levels were set to 1 
in the absence of SE-1. Shigella grown at 30
o
C illustrates basal expression of each gene. Error 
bars represent the standard error of the mean calculated from three independent replicates. 
Significance of inhibitor-treated values was calculated using a non-parametric Mann-Whitney 
test, with P-values less than 0.05 considered significant (*). Results are the average of three 




Fig. 34. SE-1 inhibition of VirF regulated virulence gene expression in Shigella. qRT-PCR 
was used to determine the relative quantity (RQ) of expression of icsB (A), ipaB (B), in Shigella 
grown at 30
o
C (without SE-1) and at 37
o
C (without or with 20 and 40 μM SE-1). RNA levels 
were normalized to two constitutively expressed genes, gapA and rrsA. RNA levels were set to 1 
in the absence of SE-1. Shigella grown at 30
o
C illustrates basal expression of each gene. Error 
bars represent the standard error of the mean calculated from three independent replicates. 
Significance of inhibitor-treated values was calculated using a non-parametric Mann-Whitney 
test, with P-values less than 0.05 considered significant (*). Results are the average of three 




Fig. 35.  Relative quantification of mRNA levels of the constitutively expressed genes gapA and 
rrsA of Shigella, with gapA normalized to the rrsA values, and vice versa. Cultures were grown 
at 30
o
C (Black bars) or at 37
o
C with 40 μM SE-1 (Grey bars). Values are relative to the mRNA 
levels of gapA (for gapA) or rrsA (for rrsA ) for Shigella grown at 37
o
C with no SE-1, which 
were set to one. Error bars represent the standard error of the mean calculated from three 





Fig. 36. SE-1 inhibition of Shigella host cell invasion. The invasion index of Shigella into L-
929 (mouse fibroblast) cells was determined by gentamycin protection assay. Cultures were 
grown in the absence or presence of SE-1 (20 μM and 40 μM). A mxiH
-
 Shigella strain (SH116) 
and an ipgD
-
 strain (SME4331) grown at 30
o
C were used as negative controls of invasion. As an 
additional control, 40 μM SE-1 and Shigella grown at 37
o
C without inhibitor were added at the 
same time to L-929 cells to test the effect of inhibitor on invasion by Shigella with a preformed 
T3SS and on host cells. Assays in were performed in triplicate and error bars represent the 






Fig. 37. Growth curves of Shigella strain carrying ipgD
-
 (SME4331) in the absence (filled 
square) or presence of SE-1 (20 μM, open squares; 40 μM, filled circles). Results are the average 






Fig. 38. SE-1 does not inhibit host cell metabolism. AlamarBlue
®
 assays to test the effect of 
SE-1 (at the indicated concentrations) on the metabolic activity (viability) of L-929 cells. The 
absorbance level in the absence of inhibitor and the presence of DMSO was set to 100%. Assays 
in were performed in triplicate and error bars represent the standard error of the mean. (Figure 





Functional analysis of RhaR N-terminal domain Arm region  
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RhaR activates the transcription of rhaSR operon in response to its effector L-rhamnose. 
Evidence suggests that L-rhamnose binds at the NTD and transcription activation is carried by 
DBD in the full length RhaR. The separation of L-rhamnose binding and transcription activation 
activities between the two domains led us to hypothesize that the signal of L-rhamnose binding 
in the NTD is somehow communicated to the DBD (allosteric signal), and thus causing structural 
or conformational changes required by the DBD to activate transcription. We earlier discovered 
that deletion of RhaR extension (first 34 amino acids) does not play any role in transmitting this 
signal. However, we could not identify the role of RhaR residues that align with the AraC Arm 
because of defects in protein levels in RhaR variants with deletions in the aligned region (200). 
Site-directed random mutagenesis of RhaR Arm region. To investigate the potential role of 
the proposed RhaR Arm residues (residues 35-45) (Fig. 39) in inter-domain interactions, I 
performed site-directed random mutagenesis of residues in this region. I randomized one codon 
at a time in the RhaR Arm and generated multiple variants at each position to understand the role 
each residue plays in potentially transmitting the allosteric signal. Variants were first isolated in 
the strain SME2525 [λ (rhaS-lacZ)∆128 ∆(rhaSR)::Km recA::cat]. This strain included a CRP 
binding site upstream of RhaR binding site and has higher activation levels as CRP activates the 
expression of rhaSR operon both in the absence (-) and presence (+) of rhamnose. The higher 
activation levels helped in identification of variants with different levels of activation on 
indicator X-gal plates. After identification of variants in SME2525, variants were ultimately 
assayed for activation levels by β-galactosidase reporter gene assays in strain SME3160 [λ 
(rhaS-lacZ)∆85 ∆(rhaSR)::Km recA::cat] which does not have a CRP binding site. A comparison 










Amino acid sequence of N-terminal residues of RhaR and AraC (aligned by I-TASSER program) 
(157). Arm residues in both RhaR and AraC were labeled in green. Residues before the Arm 
region in RhaR represents the proposed extension region.   
 
Table. 10. Comparison of RhaR activation of lacZ expression rhaS promoter regions with 






(rhaS-lacZ)∆128 166±9 875±90 
(rhaS-lacZ)∆85 1.5±0.4 8.5±0.5 
 
a
β-galactosidase activity (miller units) levels in the absence and presence of rhamnose for 
samples expressing RhaR from a low copy number plasmid pHG165 at different rhaS-lacZ 
fusions. Miller unit values were presented as mean ± standard error of three independent 
experiments with two replicates each.  
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The increase in the RhaR activation levels in the presence of rhamnose could be because 
of stimulatory inter-domain interactions, likely involving Arm residues, (+) rhamnose or 
inhibitory inter-domain interactions, likely involving the Arm, (-) rhamnose. Variants at an Arm 
residue involved in stimulatory inter-domain interactions (+) rhamnose are expected to have wild 
type activation levels (-) rhamnose and decreased activation levels (+) rhamnose. Variants at an 
Arm residue involved in inhibitory inter-domain interactions (-) rhamnose are expected to have 
increased activation levels (-) rhamnose and wild type activation levels (+) rhamnose. Two other 
possible outcomes from the site-directed random mutagenesis are variants with no defects in 
activation [wild type activation levels both (-) and (+) rhamnose] and variants with similar 
defects in activation [decreased activation levels both (-) and (+) rhamnose]. Variants with 
decreased activation levels both (-) and (+) rhamnose probably have stability defects or 
decreased protein levels or decreased DNA binding and thereby are not considered important in 
inter-domain allosteric signaling. 
I mutagenized all 11 residues in the proposed RhaR Arm and identified a total of 46 
unique variants. Variants with changes in activation levels of 1.5 fold and a non-over lapping 
standard deviation intervals relative to the wild type were considered to differ significantly. Out 
of the total 46 variants, only two variants F43C and A44G had significantly decreased activation 
levels both (-) and (+) rhamnose, suggesting that the Arm region may not be involved in the 
stability of the RhaR (Table 11). In addition, our results showed that none of the Arm variants 
had defects in activation only (+) rhamnose, suggesting that the residues in the Arm likely are 
not involved in making stimulatory inter-domain interactions in the (+) rhamnose state (Table 
11). 
In 5 out of 11 residues mutagenized, we found a total of nine variants with increased 
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activation levels (-) rhamnose and wild type activation levels (+) rhamnose [Table 11, Up (-)]. 
These include four variants at residue L35 and one variant each at residues L37, K39, D41, F42 
and F43. At L35, in addition to the four variants with increased activation levels, the other two 
variants isolated at L35 had small increases in activation levels (-) rhamnose (although the 
increases were not significant). This indicates that the side chain at position L35 may be involved 
in making inter-domain interactions (-) rhamnose that lead to inhibition of RhaR activation, and 
contribute to the low basal activity of RhaR (-) rhamnose. All the other variants with increased 
activation levels (one each at positions L37, K39, D41, F42 and F43) in RhaR Arm are likely to 
be gain-of-residue-function variants (Table 11).  
An unexpected phenotype was observed in 15 out of the 46 variants in the RhaR Arm 
region. In these variants, RhaR activation was significantly decreased (-) rhamnose while 
maintaining wild type activation levels (+) rhamnose [Table 11, Down (-)].The greater defects in 
activation by RhaR variants in the (-) rhamnose state relative to the (+) rhamnose state could be 
explained by the differences in the binding affinity of RhaR to its DNA in those two states. In the 
(-) rhamnose state RhaR binds to DNA with less affinity relative to the (+) rhamnose state. Given 
that the variants of this class have reduced protein levels there may be a bigger effect activation 
in (-) rhamnose state relative to the (+) rhamnose state. 
Another class of variants that had wild type activation levels both (+) and (-) rhamnose 
were also found. 20 out of the total 46 unique variants were identified to be in this class and 
these were spread across many residues in the Arm region. Interestingly, all the variants isolated 
from position L38 (5 out of 5) belongs to this class and suggests that this residue is not involved 
in making any inter-domain interactions. 
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Western blots to quantify the protein levels of variants. In order to understand whether 
changes in the activation levels (-) and (+) rhamnose had anything to do with the RhaR protein 
levels, I performed Western blots to quantify the levels of RhaR protein. I picked variants that 
represented all the different types of variants isolated during mutagenesis and tested for protein 
levels under both (-) and (+) rhamnose conditions. Protein levels are presented as a percentage 
relative to the amount of wild-type RhaR. Among the class of variants with wild type activation 
levels, two variants were tested for RhaR levels and found that these variants had no defects in 
protein levels both (-) and (+) rhamnose (Table 12). A total of five variants with increased 
activation (-) rhamnose and wild type activation (+) rhamnose were tested (L35D, L35K, L37R, 
D41S and F42I) and found that none of them had increased protein levels (-) rhamnose, 
suggesting that increased protein levels were not the cause of the increased activation (-) 
rhamnose (Table 12). This further supports our conclusion about the involvement of residue L35 
in inhibitory inter-domain interactions. A total of four variants (K36R, K39T, D40G and F43R) 
were tested in the class of variants with decreased activation (-) rhamnose and wild type 
activation (+) rhamnose. Consistent with our previous hypothesis that these variants may have 
defects in protein stability, we found all variants had decreased protein levels (-) rhamnose, 
although one variant had reduced protein levels (+) rhamnose (Table 12).  
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(-)  Rha (+) Rha (-) Rha (+) Rha 
L35I 122±5 98±11 ~WT K39T 54±6 102±4 Down (-) 
L35Y 131±10 94±4 ~WT K39S 94±6 82±16 ~WT 
L35D 143±12 93±9 Up (-) K39V 110±25 128±17 ~WT 
L35G 143±7 94±5 Up (-) K39A 162±16 122±2 Up (-) 
L35V 171±13 96±3 Up (-) D40G 13±22 79±1 Down (-) 
L35K 180±8 99±6 Up (-) D40E 85±9 134±15 ~WT 
K36A 52±23 87±14 Down (-) D41V 108±3 124±3 ~WT 
K36R 64±15 88±23 Down (-) D41A 168±9 148±28 Up 
K36V 71±17 91±18 ~WT D41S 178±10 99±9 Up (-) 
L37G 34±5 76±15 Down (-) F42D 15±9 107±40 Down (-) 
L37C 36±2 97±9 Down (-) F42P 37±23 110±35 Down (-) 
L37A 79±5 108±16 ~WT F42N 135±9 89±40 ~WT 
L37I 81±10 96±9 ~WT F42I 215±29 88±19 Up (-) 
L37S 90±7 83±15 ~WT F43C 12±19 38±30 Down 
L37M 125±14 98±11 ~WT F43R 13±6 85±4 Down (-) 
L37R 192±14 75±20 Up (-) F43A 15±7 96±13 Down (-) 
L38G 63±17 101±7 ~WT F43G 15±18 101±5 Down (-) 
L38R 69±8 10±6 ~WT F43V 148±1 75±4 Up (-) 
L38W 83±7 105±4 ~WT A44G   18±3 43±6   Down 
L38S 105±12 105±2 ~WT A44E 105±4 90±4 ~WT 
L38V 112±17 88±1 ~WT S45V 13±9 61±1 Down (-) 
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K39E 39±38 102±7 Down (-) S45E 85±6 80±6 ~WT 
K39P 53±9 89±18 Down (-) S45T 14±5 72±17 ~WT 
 
a
β-Galactosidase activity was assayed from a single-copy Φ(rhaS-lacZ)Δ85 fusion in a strain 
with Δ(rhaSR)::kan recA::cat and wild type or RhaR variants expressed from a plasmid pHG165.  
Cultures were grown with or without L–rhamnose. Variants were assayed in groups with a wild-
type RhaR activity range of 1.5-1.9 Miller Units (-) Rha and 8.5-9.0 Miller Units (+) Rha. Error 
is shown as the standard deviation converted to percent of the Miller Unit values. 
b
Variants were categorized as follows: Down, reduced activity (-) and (+) Rha; Down (-), 
reduced activity (-) Rha, near wild type (+) Rha; ~WT, near wild type activity (-) and (+) Rha; 












(-) rhamnose (+) rhamnose 
L35K Up (-) 79±19 68±3 
L35D Up (-) 112±18 114±3 
K36R Down (-) 36±3 83±1 
L37R Up (-) 37±4 86±2 
L37M ~WT 138±1 139±1 
L38S ~WT 116±6 94±2 
K39T Down (-) 31±8 25±0 
D40G Down (-) 14±2 2±0 
D41S Up (-) 31±1 40±3 
F42I Up (-) 85±1 95±0 
F43R Down (-) 23±3 19±1 
b
RhaR levels were estimated for different classes of variants by Western blotting and presented 
as a relative percentage of wild type. 
a
Category of variants: Down (-), reduced activity (-) Rha, near wild type (+) Rha; ~WT, near 









AraC family proteins are transcriptional regulators in many bacteria and are found to be essential 
for the expression of virulence factors required to cause diseases (24-28). With the ultimate goal 
of discovery of novel antibacterial agents that inhibit the AraC family proteins, here I have 
investigated the molecular mechanism of transcription activation by two AraC family activators 
Rns (virulence activators in Enterotoxigenic Escherichia coli) and RhaR (activator of L-
rhamnose catabolic operons in E. coli). We expect that a better understanding of the molecular 
interactions involved in transcription activation could lead us to the rational design of the 
compounds that could target these AraC family proteins.  In addition, we also tested a small 
molecule compound that was previously identified as an inhibitor of AraC family proteins RhaS 
and RhaR (activators of L-rhamnose catabolic operons in E. coli), for its ability to inhibit 
virulence regulators Rns and VirF. 
Role of RS2 and AS2 regions in transcription activation by Rns. Rns is a key regulator in 
ETEC pathogenesis, because it activates the expression of major virulence factors called 
colonization factors (CFs) (41, 42). Although it was known that Rns activates expression of CFs 
required for successful ETEC colonization of the human gut, limited information has been 
gained on how Rns activates transcription of these genes. Mutational analysis by earlier 
researchers has found two mutations (I14T and N16D) in the Rns NTD that affected the 
transcription activity of Rns at its own promoter region, although these mutations have disparate 
effects on activation of other promoters (156). In addition, it was found that mutations in the 
HTH motifs of the Rns DBD inhibit Rns from binding to DNA and thereby affected transcription 
activation  (93). Here, we have further expanded this analysis by assessing the role of a region of 
residues (RS2 region) in the NTD that are conserved among closely related Rns homologs and 
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their predicted contacting residues in the DBD (AS2 region) at both cfaA and modified nlpA 
promoter regions.  
Our site-directed random mutagenesis has revealed the importance of RS2 residues in 
transcription activation. Despite the fact that the DBD of Rns is directly responsible for DNA 
binding and transcription activation, our analysis of variants for cfaA-lacZ
∆60
 expression and 
nlpA
cfaA
-lacZ repression indicated that RS2 region residues N15, N16 and I17 in the NTD were 
required for the transcription activation function of Rns. Previous reports by Basturea et al 
showed that N16 residue is required for DNA binding function of Rns at rns promoter region 
(156). However, their analysis of N16D variant at nlpA-lacZ and cfaA-lacZ strains and my 




-lacZ suggested that N16D 
affects the transcription activation function by Rns. The impairment of transcription activation 
function by N16D supported our observation that the residue N16 is required for transcription 
activation function by Rns. Our site-directed mutagenesis of residues I12 and M18 resulted in 
inconclusive results, as protein levels were defective for most variants at these positions. Given 
the defects in protein levels for majority of variants at I12 and M18, these residues may be 
required for maintaining the stability of Rns. Residues K13 does not seem to be required for 
DNA binding and transcription activation function of Rns.  
Our working model is that Rns residues N15, N16, I17 and possibly I14 in the RS2 
region interact with the residues in the AS2 region and that the interactions between these two 
regions may hold the DBD in a conformation that enables it to activate transcription (most likely 
by direct interaction with RNAP). These kind of inter-domain interactions have previously been 
identified for the AraC family proteins AraC and ToxT (79, 101). For ToxT, interactions 
between the NTD and DBD have been identified in the presence of effector palmitoleic acid and 
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these interactions hold ToxT in a closed conformation such that ToxT does not activate 
transcription (79). The crystal structure of ToxT showed that in the effector-bound state, residues 
in each of the first two -strands (1, residues 7-14; 2, residues 19-26) are positioned to contact 
the ToxT-DBD residues (79). Most importantly, the residues N15, N16 and I17 of Rns align with 
[based on ClustalW analysis (Fig. 8) and I-TASSER predicted structures (157)] ToxT residues 
N23, N24 and L25 that are part of a ToxT 2 strand that contacts the ToxT DBD. Given the high 
sequence similarity of ToxT and Rns at these positions, I- TASSER structural prediction of N15, 
N16 and I17 of Rns in making inter domain interactions, and the involvement of N15, N16 and 
I17 in transcription activation function of Rns, we hypothesize that Rns N15, N16 and I17 
residues may interact with the Rns AS2 region residues to activate transcription.  In contrast to 
ToxT, no effector ligand has been identified for Rns. Therefore in the absence of effector, it is 
possible that the Rns NTD and DBD interact to form a constitutive open conformation to activate 
transcription and the mutations isolated in N15, N16 and I17 might have affected those 
interactions.      
In order to test the possibility of the inter-domain interactions hypothesis, we 
mutagenized residues in the Rns AS2 region. Rns AS2 region residues are located in the middle 
of 7 helix and in a region from the end of 9 helix through the loop between 9 and 10 helix, 
and into 10 helix (7, 9 – loop - 10). According to Rns I-TASSER structural model (157), 
these AS2 region residues are in an analogous position to residues in ToxT-DBD that are 
positioned to contact 2 sheet of ToxT NTD. Among the four residues mutagenized in the 7 
helix of the Rns-DBD, variants at three residues, Q211, S215 and L219, suggested that these 
positions are not involved in either DNA binding or transcription activation function of Rns. 
Nonetheless, residue K216 was found to be required for transcription activation function of Rns. 
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In AraC, a number of AraC residues in 7 have been predicted to contact the AraC Arm in the 
absence of arabinose (101). In ToxT, the residue that aligns with Rns K216 (ToxT Y224), is 
adjacent to residue S223 (within 7 helix), that is positioned to make inter-domain interaction in 
the presence of effector (79). Although majority of the mutagenized residues in the 7 helix of 
Rns-DBD were not required for Rns activity, we found at least one residue K216 involved in the 
transcription activation function of Rns. 
Variants isolated from Y251 were defective for cfaA-lacZ
∆60
 expression activation but not 
for repression, indicating that this residue is important for transcription activation function of 
Rns (Table 6). From residue G252, variants defective for cfaA-lacZ
∆60
 expression and variants 
defective for both cfaA-lacZ
∆60
 expression and nlpA
cfaA
-lacZ repression were isolated, suggesting 
that G252 is required for both DNA binding and transcription activation function by Rns. I-
TASSER prediction (157) of Rns structure showed that Rns residues Y251 and G252 are in the 
loop that follows the 9 helix that is located near the RS2 region residues. In the predicted 
structure, these two residues (Y251 and G252) are on the surface of the DBD that faces NTD, 
suggesting that they may play a role in imparting the structural conformation adopted by the 
DBD through interactions with NTD. Our results suggested that both Y251 and G252 are 
required for the transcription activation function of Rns.  Residues Y251 and G252 are highly 
conserved in many AraC family proteins (Fig. 40) (35, 177, 237) and found to be important for 
transcription activity. For example, in PerA, the equivalent of Y251 residue, PerA Y255, is 
required for expression of fimbrial genes (92). In ToxT, the equivalent of Y251 (ToxT M259) 
and G252 (ToxT N260) are required for expression of cholerae toxin and toxin co-regulated pilus 
genes (238). In addition, in ToxT, the equivalent residue of Rns Y251 (ToxT M259) is 
positioned to enclose the effector binding pocket and predicted to contact residues in the NTD 
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and maintain the tertiary structure of ToxT (79, 238). The equivalent of Rns G252 in ToxT 
(ToxT N260), was a surface-exposed residue and predicted to be required for inter domain  
interactions within ToxT and interactions with RNA polymerase. Given the above evidence, we 
propose that Y251 and G252 are involved in inter-domain interactions with RS2 region residues, 
and these interactions are required for the transcription activation function of Rns (likely 
involving interaction with RNAP).       
Mutagenesis of Rns residue H250 revealed a role for this residue in influencing both 
DNA binding and transcription activation. I-TASSER structural prediction of Rns showed that 
this residue is at the C-terminal end of the 9 helix (second helix of HTH2 motif or DNA 
recognition helix) and close to the RS2 region residues. Co-crystal structure of MarA with DNA 
showed that the residue corresponding to Rns H250 in MarA (MarA Y101) is at the C-terminal 
end of the DNA recognition helix of HTH2.  (91). Although MarA Y101 was not found to be 
involved in making direct DNA interactions, positively charged residues before Y101 were 
involved in making direct contacts with DNA back bone. Given this, it is possible that H250 may 
contact the DNA directly. In addition, an equivalent residue of Rns H250 in ToxT (ToxT T258) 
was found to be involved in inter domain interactions (238). Therefore, we hypothesize that Rns 
H250 may participate in inter domain interactions and these interactions may keep the H250 in a 
conformation to either directly contact the DNA or make interactions required for transcription 
activation function of Rns.  
In summary, our study expanded the knowledge with respect to the requirement of inter-
domain interactions in Rns dependent expression from cfaA promoter region. We specifically 
identified residues in the Rns RS2 (N15, N16 and I17) and AS2 regions (K216, H250, Y251 and 
G252) that are required for Rns activity (Fig. 41). Our results indicate that Rns residues N15, 
150 
 
N16 and I17 are required for transcription activation function. Residues K216 and Y251 are 
required for transcription activation and residues H250 and G252 are required for both DNA 
binding and transcription activation function by Rns. The NTD residues (N15, N16 and I17) and 
the DBD residues (K216, H250, Y251 and G252) are located close to each other in the predicted 
Rns structure and a computational program ResMap (239) that predicts the inter-domain 
interactions predicted contacts between these residues in the structure model. ResMap predicted 
inter-domain interactions of N15 with H250; N16 with H250; and I17 with K216, H250 and 
Y251 (Table 13). In addition, we also found a very high sequence identity of these residues 
among the closely related homologs of Rns. Rns residues N15, N16, I17, H250, G252 showed 
100% identity, while K216 and Y251 showed 100% similarity among the closely related 
homologs of Rns. This further suggested that these residues may have a conserved functional 
role in Rns activity.  Among these seven residues that are predicted to be involved in making 
inter-domain interactions, a contact propensity matrix (240) showed high probability of 
interactions between side chains of Aspargine (N) with side chains of Histidine (H), Glycine (G) 
and Tyrosine (Y).  This suggests a possibility of direct interactions between N15, N16 of RS2 
region and H250, Y251 and G252 of AS2 region.  
Although we could not conclude the role of I14 residue in Rns activity (because of 
isolation of a single variant I14W at this position), ResMap also predicted contacts between I14 
and H250, Y251 and G252. In addition, previous reports by Basturea et al showed that I14T is 
required for making base specific DNA contacts by Rns at rns promoter region (156). However, 
I14T did not show any effect on Rns dependent expression from cfaA and nlpA promoter regions. 
Given the predicted interactions of I14 with AS2 residues, isolation of I14W that was defective 
for both DNA binding and transcription activation function, and previous observation of 
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involvement of I14T in DNA binding function of Rns at rns promoter region, we hypothesize 
that I14 residue may also be required for Rns both DNA binding and transcription activation 
function of Rns.  
Overall, we propose that at least one mechanism of transcription activation in Rns 
involves inter-domain interactions between N15, N16, I17 and possibly I14 of NTD and K216, 
H250, Y251, G252 of DBD, and these interactions may impart the structure needed by Rns to 
activate transcription. In future, we would like to identify any specific interactions between these 






Fig. 40. Sequence similarity comparison of residues in the conserved DBD of AraC family 
proteins. Residues with a similarity score of above 0.5 (dotted line) represent the conserved 
residues among AraC family proteins. Residue corresponding to the Rns G252 had a similarity 
score of above 0.5 and was shown using red arrow. Residue corresponding to the Rns Y251 had 







Table 13. ResMap prediction of inter domain interactions. 
Rns residues found important Predicted contacts in other Rns domain 
I14 H250, Y251*, G252 
N15 K249*, H250* 
N16 E207*, Q211*, K249*, H250* 
I17 Q211, S215, K216, H250, Y251* 
K216 N15*, N16*, I17, H20 
H250 I14, N15*, N16*, I17 
Y251 I12*, K13*, I14*, N15*, I17* 
G252 K13, I14, N15*, N16* 
 
Computational prediction program ResMap (239) was used to predict the inter domain 
interactions from the I-TASSER predicted structure of Rns (done by Dr. Susan Egan).  The 
predicted contacted residues marked with an asterisk (*) have contact propensities equal to or 
greater than 1.0 for the residue they are predicted contact, suggesting a relatively high probability 









Fig. 41. RS2 and AS2 regions residues that are required for transcription activation by 
Rns. I-TASSER (157) was used to predict the 3D structure of Rns. NTD was shown in green 
color and DBD was shown in red color. Residues that were found to be essential for transcription 
in both RS2 and AS2 regions were shown as spheres and labeled in different colors as pointed 
with black arrows in the figure.  
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Purification and properties of Rns. Among AraC family proteins, only a fraction of the 
proteins have been characterized biochemically as the solubility of the proteins in this family 
tends to be very limited. To circumvent the problem of insolubility, I used GB1 and MBP 
solubility enhancement tags and purified Rns-DBD (residues 157-265) with GB1-His6 tag and 
full-length Rns with MBP tag. Overexpression of the Rns-DBD-GB1-His6 fusion at 15
o
C has 
solubilized ~50% of the overexpressed protein. When the protein was purified using a Ni
+
 
affinity chromatography column, we obtained a fairly high amount of soluble protein (~11mg for 
100 ml initial culture). Later we performed EMSAs to test whether Rns-DBD can bind to DNA 
in vitro. Previously, DNaseI foot printing experiments by Basturea et al (156) using an MBP-Rns 
(128-265) construct that included DBD has shown that this construct did not bind to the cfaA 
promoter region even at high concentrations of 2.5 µM. Surprisingly, our EMSA experiments 
with the purified Rns-DBD-GB1-His6 showed that this protein can bind to cfaA promoter region 
even at concentrations of 1 µM. However, even at highest protein concentration tested (9 µM), 
only 7% of the DNA was bound by the protein. We expect that the differences in the sensitivities 
of the techniques may have led to observation of these varied results. DNase foot printing is 
more sensitive than EMSA in terms of using P
32 
labeled DNA as opposed to IR labeled DNA in 
our EMSAs. However, it is harder to notice a 7% DNA binding in DNase foot printing as we 
look for decrease in intensity of the DNA band by 7% in foot printing (100% to 93%) compared 
to gaining a new band in EMSA (0% to 7%). 
Overexpression and purification of full-length Rns with MBP tag (attached at the N-
terminus of Rns) showed that, as previously reported (156), the fusion protein is soluble, active 
and functional in vitro. Aggregation is a major problem of Rns and Rns aggregates readily when 
cleaved from MBP tag, and in elution buffer at concentrations above 2 mg/ml even without 
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cleavage. Aggregation was minimized by buffer exchange of protein into Tris buffer with 
reduced salt and no maltose (15 mM Tris-base, 75 mM KCl, 5 mM β-mercaptoethanol, 10% 
Glycerol, pH 7.6), and protein was successfully concentrated in this buffer to 20 mg/ml with 
minimal aggregation. Gel filtration analysis showed that the fusion protein elutes at the size of 
~75 kDa indicating that Rns behaves as a monomer in vitro.       
SE-1 as a small molecule inhibitor of AraC family activators. Many bacterial pathogens that 
pose severe health threats require AraC family transcriptional regulators to cause disease (24-28, 
36). Given that AraC family proteins are required for the expression of virulence genes in 
multiple bacteria, they were thought to be excellent targets for the development of novel anti-
bacterial agents (19-28, 36). AraC family virulence activators are non-essential for the growth of 
the bacteria and therefore targeting these proteins may not put pressure on the bacteria to develop 
resistance (9, 16-18). Dr. Susan Egan’s lab recently identified an inhibitor, SE-1, which inhibited 
transcription activation by the AraC family proteins RhaS and RhaR (involved in activation of 
sugar rhamnose catabolic operons) by blocking their ability to bind to DNA (202). SE-1 
inhibited RhaS and the RhaS DNA-binding domain (RhaS-DBD) to the same extent, suggesting 
that SE-1 acts on the structurally conserved DNA binding domain of the AraC family proteins 
(202). The goal of this study was to further test SE-1 potential to inhibit AraC family virulence 
activators VirF and Rns from Shigella and ETEC, respectively. 
Using a cell-based reporter gene assay to test the ability of SE-1 to inhibit transcription 
activation by the VirF and Rns protein, we found that SE-1 decreased virB-lacZ reporter fusion 
expression in an E. coli strain with plasmid-expressed VirF (203) and Rns (done by Jeff 
Skredenske).  The inhibition was dose-dependent and had an IC50 value of approximately 8 μM, 
suggesting that SE-1 inhibited transcription activation by VirF. An initial indication that this 
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inhibition was selective for Rns and VirF activity was the finding that SE-1 was substantially 
less inhibitory toward lacZ expression from a control fusion (hts-lacZ) than VirF and Rns 
dependent lacZ expression. The strains carrying the VirF-dependent and control lacZ fusions 
showed no detectable growth defects in the presence of SE-1, indicating that SE-1 did not have 
general toxicity toward these E. coli strains at the concentrations tested. 
Given that SE-1 inhibition of the AraC family activators RhaS and RhaR involved 
blocking binding to DNA (202), we tested SE-1 for inhibition of DNA binding of purified VirF 
and Rns proteins to DNA carrying their respective binding sites, and found that SE-1 was able to 
fully inhibit DNA binding by Rns and VirF. We previously showed that SE-1 did not inhibit 
DNA binding by two proteins that are not related to the AraC family, LacI and CRP (202), 
suggesting that SE-1 is selective for AraC family proteins. Overall, our results support the 
hypothesis that the mechanism of action of SE-1 inhibition involves selectively blocking DNA 
binding by VirF and Rns by binding to the protein.  
We next tested inhibition by SE-1 in Shigella, initially of endogenously expressed VirF in 
a Shigella strain carrying a virB-lacZ reporter construct. Similar to our findings in E. coli, we 
observed dose-dependent inhibition of VirF activation of virB-lacZ in Shigella. In addition, 
Shigella grown in the presence of SE-1 showed a decrease in transcription (assayed by qRT-
PCR) of genes that are directly activated by VirF (virB, icsA) as well as genes that are directly 
activated by VirB (indirect VirF targets, icsB, ipaB). In these experiments, we observed up to 
two- to four-fold decreases in expression of these VirF-dependent genes, with values consistent 
with the virB-lacZ assays in Shigella. However, the same concentration of SE-1 resulted in lower 
levels of inhibition in Shigella than in E. coli, suggesting differences in uptake, efflux and/or 
stability of SE-1 in these two bacteria. Alternatively, similar to many commonly used antibiotics 
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(241) , there may be differences in the sensitivity to SE-1 in minimal media (used for E. coli 
growth) versus rich media (used for Shigella growth).   
Several findings argue that the decreases in virB-lacZ, virB, icsA, icsB, and ipaB 
expression in Shigella were due to inhibition of VirF activity and not a global decrease in gene 
expression in the presence of SE-1. First, there was no detectable decrease in the growth rate of 
Shigella in the presence of up to 40 µM SE-1, whereas global decreases in gene expression of a 
comparable magnitude would be expected to affect the growth rate. Second, the qRT-PCR 
results were normalized to two different internal control genes (which would be expected to 
exhibit decreased expression if there was a global decrease in gene expression). Normalization of 
each of the internal control genes relative to the other showed that there was no significant 
change in the expression of the control genes in the presence of 40 μM SE-1. Finally, the 
magnitude of the inhibition of virB expression by SE-1 detected in the virB-lacZ assays and the 
qRT-PCR assays were essentially the same, indicating that the normalization of the qRT-PCR 
results to the internal controls did not alter the extent of the inhibition (as would have been 
expected if expression of the internal control genes was also inhibited).   
Finally, we investigated the effect of SE-1 on the ability of Shigella to invade mouse 
fibroblast (L-929) cells in tissue culture. A dose-dependent decrease in invasion was observed 
with a maximum inhibition of 70% at 40 μM inhibitor. This inhibition required pre-incubation of 
Shigella with SE-1, consistent with the hypothesis that SE-1 did not destabilize preassembled 
T3SS or other Shigella virulence components, inhibit post-transcriptional processes in Shigella, 
or cause cytotoxicity to the L-929 cells at the concentrations tested. The latter is further 
supported by the finding that SE-1 did not result in a detectable decrease in metabolism of L-929 
cells in AlamarBlue
®
assays at these same concentrations. Overall, our results suggest a model in 
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which SE-1 inhibits VirF-dependent transcription activation of Shigella virulence genes, 
including at least icsA, virB, icsB and ipaB. The decrease in invasion we detected is consistent 
with and can be attributed to the effect of decreased expression of these virulence genes in the 
VirF regulon. The two- to four-fold decreases in expression of these genes appear to be sufficient 
to decrease invasion of Shigella by 70%, compared to the uninhibited invasion level. The ipaB 
gene exhibited the largest decrease in expression, four-fold, suggesting that reduction in IpaB 
expression may have limited invasion in the presence of SE-1. This is a reasonable hypothesis 
given the central role IpaB plays in Shigella invasion.  IpaB is a component of the translocon 
pores in the host cell membrane (179) that enable translocation of Shigella effectors into host 
cells (182), ultimately modulating host cell cytoskeletal dynamics and leading to bacterial 
invasion (180). In addition, only a subset of the VirF-regulated virulence genes that are required 
for invasion were assayed (177, 178), thus, decreased expression of other genes likely also 
contributed to the invasion defects. Overall, SE-1 is non-cytotoxic toward the eukaryotic cells 
tested (at concentrations up to 40 µM) and non-bactericidal toward E. coli and Shigella (at 
concentrations up to 40 µM) and has potential to be developed into a novel anti-bacterial agent. 
However, SE-1 does show evidence of non-specific inhibition at higher concentrations (partial 
inhibition of hts-lacZ at higher concentrations and inhibition of Shigella growth at 80 µM SE-1), 
and its current potency is not sufficient for therapeutic applications. Thus, chemical optimization 
of SE-1 will be needed to improve both its potency and its specificity before it can be considered 
a lead compound for further development.  
We have now shown that SE-1 selectively inhibits DNA binding by four different AraC 
family proteins RhaS, RhaR (202), Rns and VirF. The VirF protein shares only about 15% amino 
acid sequence identity and 40% similarity with RhaS and RhaR (the pairwise RhaS-VirF and 
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RhaR-VirF comparisons are nearly the same) (Fig. 42). Rns shares only very limited sequence 
identity with RhaS (8%) and RhaR (12%), and relatively high identity with VirF (35%). Given 
our prior finding that SE-1 blocks transcription activation by the RhaS DBD to at least the same 
extent as the full-length RhaS protein (202), we hypothesize that the DNA binding domain is the 
likely site of action of SE-1. The sequence comparisons in the conserved DNA binding domain 
are somewhat higher than the full-length proteins, but are still relatively low, with the VirF DBD 
sharing about 22% identity and 52% similarity with the RhaS and RhaR DBDs (the pairwise 
comparison of Rns DBD with the RhaS and RhaR DBDs are nearly the same). Despite having 
these sequences differences, the DNA binding of all these proteins were inhibited by SE-1. This 
finding supports the hypothesis that SE-1 may bind to a relatively conserved region of AraC 
family DNA binding domains. In addition, our computational docking with BSP-SLIM (227) and 
Swiss-Dock (www.swissdock.ch, Molecular Modeling Group, Swiss Institute of Bioinformatics, 
Lausanne, Switzerland) predicted that SE-1 can bind between the two HTH motifs of the 
predicted DBD structures of RhaS, RhaR, Rns and VirF, and thus could sterically inhibit the 
binding of these proteins to their respective promoter DNA.  
We predict that SE-1 can inhibit other AraC family virulence activators in addition to 
RhaS, RhaR, VirF and Rns. Recently, our lab also showed that SE-1 can inhibit DNA binding by 
AraC family transcription activator ToxT from Vibrio cholerae. The ability of SE-1 to inhibit 
several AraC family activators led us to hypothesize that SE-1 can bind to a region that shares 
high structural and likely sequence similarity among AraC family proteins. Our docking results 
of SE-1 with the DBD of RhaS predicted 10 residues in the DBD (V188, W190, D191, L220, 
N221, R224, F248, S249, H253 and L257) (performed by Jeff Skredenske and Dr. Susan Egan) 
that could potentially interact with SE-1. In addition, docking of SE-1 on to the predicted 
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structures of Rns DBD and VirF DBD also showed interactions of SE-1 at positions that align 
with RhaS DBD. Sequence comparison of RhaS, RhaR, Rns, VirF and ToxT showed sequence 
similarities (ClustalW) in a range of 60-80% (60% for ToxT and 80% for Rns and VirF) at these 
10 positions relative to the most common residue found at each position (Table 14). Among 
these 10 positions, 8 of the positions share sequence similarity among this set of proteins, and 
align with RhaS V188, L190, L220, R224, F248, S249, H253 and L257.  The high sequence 
similarities in RhaS, RhaR, Rns, VirF and ToxT proteins among these 8 residues suggests that 
the mechanism of inhibition of these proteins by SE-1 may involve contacts with these residues.  
In order to find whether SE-1 has potential to inhibit many other AraC family proteins, I 
searched for the sequence similarities in the predicted SE-1 interaction residues among 197 AraC 
family proteins that were previously aligned by Dr. Susan Egan. Our results indicated a 
substantially higher sequence similarity in five out of the total eight predicted SE-1 interaction 
residues. These include residues that align with RhaS V188, L190, L220, R224 and F248. The 
residue at the position of RhaS V188 shared 72% similarity (24% identity), L190 shared 93% 
similarity (46% identity), L220 shared 90% similarity (62% identity), R224 shared 99% 
similarity (88% identity) and F248 shared 100% similarity (69% identity) among these 197 AraC 
family proteins (Table 15). In addition, the residue that aligns with RhaS H253 also shared 43% 
sequence identity, but had less similarity relatively to other positions. The high level of sequence 
similarity among the residues predicted to make interactions with SE-1 suggests that the 
compound can inhibit many other AraC family proteins in addition to RhaS, RhaR, Rns, VirF 
and ToxT, and could be developed into a broad spectrum antibiotic. We also compared 
sequences of 197 proteins to find the proteins that have least sequence similarities in the 
predicted SE-1 binding sites. We expect that identification of these proteins would give us an 
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idea of the percentage of proteins that are not inhibited by SE-1.  Our results only showed one 
protein, YeaM, which had completely different sequences at three of the five positions that are 
highly conserved (RhaS V188, R224 and F248) among the predicted eight SE-1 interaction 
















Fig. 42.  Alignment of Rns, VirF, ToxT, RhaS and RhaR .  Sequences were aligned using 
ClustalW method (157). Residues that are predicted to be contacted by SE-1 are shown in black 
boxes.   Gaps in the alignment are marked “-”.   
Rns             --------MDFKYTEEKETIKINNIMIHKYTVLYTSNCIMDIYSEEEKITCFSNRLVFLE 52 
VirF            ----MVYSVEFMMDMGHKNKIDIKVRLHNYIILYAKRCSMTVSSGNETLTIDEGQIAFIE 56 
RhaS            --MTVLHSVDFFPSGNASVAIEPRLPQADFPEHHHDFHEIVIVEHGTGIHVFNGQPYTIT 58 
RhaR            --MLKLLKDDFFASDQQAVAVADRYPQDVFAEHTHDFCELVIVWRGNGLHVLNDRPYRIT 58 
ToxT            MIGKKSFQTNVYRMSKFDTYIFNNLYINDYKMFWIDSGIAKLIDKNCLVSYEINSSSIIL 60 
                         :.            .     :     .     :      :    .    :  
 
Rns             RGVNISVRMQKQILSEK-----PYVAFRLNGDMLRHLKDALMIIYGMSKIDTNACRSMSR 107 
VirF            RNIQINVSIKKSDSIN------PFEIISLDRNLLLSIIRIMEPIYSFQHSYSEEKRGLNK 110 
RhaS            GGTVCFVRDHDRHLYEHTDNLCLTNVLYRSPDRFQFLAGLNQLLPQELDGQYPSHWRVNH 118 
RhaR            RGDLFYIHADDKHSYASVNDLVLQNIIY-CPERLKLNLDWQGAIPGFNASAGQPHWRLGS 117 
ToxT            LKKNSIQRFSLTSLSDEN---INVSVITISDSFIRSLKSYILGDLMIRNLYSENK----D 113 
                                          :    . :                           
 
Rns             KIMTTEVNKTLLDELKNINSHDN-SAFISSLIYLISKLENNEKIIES-IYISSVSFFSDK 165 
VirF            KIFLLSEEEVSIDLFKSIKEMPFGKRKIYSLACLLSAVSDEEALYTS-ISIASSLSFSDQ 169 
RhaS            SVLQQVRQLVAQMEQQEGENDLPSTASREILFMQLLLLLRKSSLQEN---LENSASRLNL 175 
RhaR            MGMAQARQVIGQLEHESSQHVPFANEMAELLFGQLVMLLNRHRYTSDSLPPTSSETLLDK 177 
ToxT            LLLWNCEHNDIAVLSEVVNGFREINYSDEFLKVFFSGFFSKVEKKYNSIFITDDLDAMEK 173 
                  :    .       :  :     .     *   :  .  .     .     .     :  
 
Rns             VRNLIEKDLSRKWTLGIIADAFNASEITIRKRLESEN-TNFNQILMQLRMSKAALLLLEN 224 
VirF            IRKIVEKNIEKRWRLSDISNNLNLSEIAVRKRLESEK-LTFQQILLDIRMHHAAKLLLNS 228 
RhaS            LLAWLEDHFADEVNWDAVADQFSLSLRTLHRQLKQQTGLTPQRYLNRLRLMKARHLLRHS 235 
RhaR            LITRLAASLKSPFALDKFCDEASCSERVLRQQFRQQTGMTINQYLRQVRVCHAQYLLQHS 237 
ToxT            ISCLVKSDITRNWRWADICGELRTNRMILKKELESRG-VKFRELINSIRISYSISLMKTG 232 
                :   :   :        ...    .   :::.:...   . .. :  :*:  :  *:  . 
 
Rns             SYQISQISNMIGISSASYFIRIFNKHYGVTPKQFFTYFKGG--- 265 
VirF            QSYINDVSRLIGISSPSYFIRKFNEYYGITPKKFYLYHKKF--- 269 
RhaS            EASVTDIAYRCGFSDSNHFSTLFRREFNWSPRDIRQGRDGFLQ- 278 
RhaR            RLLISDISTECGFEDSNYFSVVFTRETGMTPSQWRHLNSQKD-- 279 
ToxT            EFKIKQIAYQSGFASVSNFSTVFKSTMNVAPSEYLFMLTGVAEK 276 
                   :.:::   *: . . *   *    . :* .            
   


































RhaS V W D L N R F S H L 4 3 3 
RhaR F L D L R R F E Y V 5 2 3 
Rns W L G L M R I S Y I 6 2 2 
VirF W L S L L R I S Y K 6 1 3 
ToxT W W A I N R F A N V 3 3 4 
 
a
Position of SE-1 interaction residues in RhaS 
b
 Number of residues identical to the most common residue 
c
Number of residues similar to the most common residue 
d
Number of residues different from the most common residue  









Table 15. Sequence similarity comparison among the predicted SE-1 interaction residues in 


















V 47 27 9     61 
L 40 91 122    2  
W 42 33       
F 34 2 1  136    
I 19 23 45  8   7 
M 
 
7 1  1   1 
E         
Q      2   
H    3     
K    20     
Y     52  84  
T      2   
N      7   
A   2    6 25 
M      68 11  
S         
R    173     
Percent 
Similarity 
72 93 90 99 100 40 52 54 
Percent 
Identity 




Position of the predicted SE-1 interaction residues in RhaS 
Total number of proteins with residues identical to the most common residue at each position are 
labeled red.  
Total number of proteins with residues similar to the most common residue at each position are 






Table 16. Sequence alignment of the predicted SE-1 interaction residues in 197 AraC 
family proteins. 
Protein 188 190 220 224 248 249 253 257 
AARP_PROST/22-120 L L I R F D S R 
ADA_ECOLI/85-183 V L Q R F P S K 
ADA_MYCTU/87-185 D V A R F S Q T 
ADAA_BACSU/102-200 L L I R I A Y L 
ADIY_ECOLI/149-246 W L I R Y N Y V 
AGGR_ECOLX/164-261 W L L R F S Y L 
APPY_ECOLI/139-236 W L L R Y N Y A 
ARAC_CITFR/180-279 F I R R F D Y V 
ARAC_ECO57/180-279 F I R R F D Y V 
ARAC_ECOLI/180-279 F I R R F D Y V 
ARAC_ERWCH/186-284 L I R R Y D Y V 
ARAC_SALTY/180-279 F I R R F D Y V 
ARACL_STRAT/202-300 W V L R Y G A A 
ARACL_STRLI/202-300 W V L R Y G A A 
CAF1R_YERPE/8-107 I I I R Y D T E 
CFAD_ECOLX/164-261 W L L R I S Y V 
CHBR_ECOLI/168-274 S L I R Y S L T 
CSVR_ECOLX/166-263 W L L R I S Y I 
ENVY_ECOLI/149-246 W L V R Y S Y V 
EUTR_ECOLI/243-344 V V L R F W Q D 
EUTR_SALTY/243-344 L V L R F W Q D 
EXSA_PSEAE/171-269 W L I R F S Y S 
FAPR_ECOLX/154-251 W L I R Y T Y T 
FEAR_ECOLI/199-299 L P I R F S H V 
GADW_ECO57/139-236 W L L R Y S Y T 
GADW_ECOL6/139-236 W L L R Y S Y T 
GADW_ECOLI/139-236 W L L R Y S Y T 
GADW_SHIFL/139-236 W L L R Y S Y T 
GADX_ECO27/145-242 W L L R Y H Y V 
GADX_ECO57/145-242 W L L R Y H Y V 
GADX_ECOL6/145-242 W L L R Y H Y V 
GADX_ECOLI/145-242 W L L R Y H Y V 
GADX_SHIFL/145-242 W L L R Y H Y V 
GLXA_RHIME/223-321 L R Y R F S H A 
HILD_SALTY/209-306 W L Y R Y D Y C 
HRPB_RALSO/375-477 L T I R I R A G 
INVF_SALTI/112-210 N M L R Y S H E 
INVF_SALTY/112-210 N M L R Y S H E 
LACR_STAXY/174-272 I V L R Y K L N 
LCRF_YERPE/167-265 W L I R F S Y S 
LUMQ_PHOLE/148-246 I V V R F S S A 
MARA_ECO57/12-110 L L I K F E T T 
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MARA_ECOLI/12-110 L L I K F E T T 
MARA_SALEN/12-110 L L I K F E T T 
MARA_SALTI/12-110 L L I K F E T T 
MARA_SALTY/12-110 L L I K F E T T 
MARA_SHIFL/12-110 L L I K F E T T 
MELR_ECOL6/194-292 L I I R F R R T 
MELR_ECOLI/194-292 L I I R F R R T 
MMSR_PSEAE/201-299 L L F K Y D Y L 
MSMR_STRMU/176-274 L V I R F S A A 
MXIE_SHIFL/99-199 V I L R Y A H E 
MXIE_SHISO/99-199 V I L R Y A H E 
ORUR_PSEAE/241-338 P L L R F N N A 
PCHR_PSEAE/201-296 P L L R Y S H A 
PERA_ECO27/168-265 W L M K F N Y V 
POCR_SALTY/195-293 L L V R F S Y V 
PQRA_PROVU/7-107 I I V R F S T I 
RAFR_PEDPE/176-274 C I L R Y K T A 
RAMA_ENTCL/9-107 L I I K F E T I 
RAMA_KLEPN/9-107 L I I K F D T V 
RHAR_ECO24/179-277 F L L R F E Y V 
RHAR_ECO57/179-277 F L L R F E Y V 
RHAR_ECOHS/179-277 F L L R F E Y V 
RHAR_ECOK1/179-277 F L L R F E Y V 
RHAR_ECOL5/179-277 F L L R F E Y V 
RHAR_ECOL6/179-277 F L L R F E Y V 
RHAR_ECOLI/179-277 F L L R F E Y V 
RHAR_ECOUT/179-277 F L L R F E Y V 
RHAR_ENT38/179-277 F L L R F E Y V 
RHAR_ENTS8/179-277 F L L R F E Y V 
RHAR_ERWCT/181-279 F F L R F E Y V 
RHAR_KLEP7/178-276 F L L R F E Y V 
RHAR_MANSM/174-272 F L L R Y S Y V 
RHAR_SALAR/179-277 F L L R F E Y V 
RHAR_SALCH/179-277 F L L R F E Y V 
RHAR_SALPA/179-277 F L L R F E Y V 
RHAR_SALPB/179-277 F L L R F E Y V 
RHAR_SALTI/179-277 F L L R F E Y V 
RHAR_SALTY/179-277 F L L R F E Y V 
RHAR_SHIBS/179-277 F L L R F E Y V 
RHAR_SHIDS/179-277 F L L R F E Y V 
RHAR_SHIF8/179-277 F L L R F E Y V 
RHAR_SHIFL/179-277 F L L R F E Y V 
RHAR_YERP3/179-277 F M L R F E Y V 
RHAR_YERPA/179-277 F M L R F E Y V 
RHAR_YERPE/179-277 F M L R F E Y V 
RHAR_YERPN/179-277 F M L R F E Y V 
RHAR_YERPP/179-277 F M L R F E Y V 
RHAR_YERPS/179-277 F M L R F E Y V 
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RHAS_CITK8/174-272 V W L R F G H L 
RHAS_ECO24/174-272 V W L R F S H L 
RHAS_ECO57/174-272 V W L R F S H L 
RHAS_ECOHS/174-272 V W L R F S H L 
RHAS_ECOK1/174-272 V W L R F S H L 
RHAS_ECOL5/174-272 V W L R F S H L 
RHAS_ECOL6/174-272 V W L R F S H L 
RHAS_ECOLC/174-272 V W L R F S H L 
RHAS_ECOLI/174-272 V W L R F S H L 
RHAS_ECOUT/174-272 V W L R F S H L 
RHAS_ENT38/174-272 V W L R F G H L 
RHAS_ERWCT/175-273 V W L R F S H Q 
RHAS_KLEP7/174-272 I W L R F G H L 
RHAS_MANSM/171-268 I W V R F N Y C 
RHAS_SALAR/174-272 V W L R F G H L 
RHAS_SALCH/174-272 V W L R F G H L 
RHAS_SALPA/174-272 V W L R F G H L 
RHAS_SALPB/174-272 V W L R F G H L 
RHAS_SALTI/174-272 V W L R F G H L 
RHAS_SALTY/174-272 V W L R F G H L 
RHAS_SHIBS/174-272 V W L R F S H L 
RHAS_SHIDS/174-272 V W L R F S H L 
RHAS_SHIF8/174-272 V W L R F S H L 
RHAS_SHIFL/174-272 V W L R F S H L 
RHAS_SHISS/174-272 V W L R F S H L 
RHAS_YERP3/174-272 V W L R F G H L 
RHAS_YERPA/174-272 V W L H F G H L 
RHAS_YERPE/174-272 V W L H F G H L 
RHAS_YERPN/174-272 V W L H F G H L 
RHAS_YERPP/174-272 V W L R F G H L 
RHAS_YERPS/174-272 V W L R F G H L 
RHRA_RHIME/210-310 F I V R F N Y T 
RIPA_CORDI/119-216 T L R R F S S A 
RIPA_COREF/112-209 T L R R F S S A 
RIPA_CORGL/112-209 T L R R F A S A 
RNS_ECOLX/164-261 W L L R I S Y I 
ROB_ECO57/8-106 L L I R F D T A 
ROB_ECOLI/8-106 L L I R F D T A 
ROB_SHIFL/8-106 L L I R F D T A 
SIRC_SALTI/195-292 W Q Y R Y D Y I 
SIRC_SALTY/195-292 W Q Y R Y D Y I 
SOXS_ECO57/8-106 L I I R Y V T V 
SOXS_ECOL6/8-106 L I I R Y V T V 
SOXS_ECOLI/8-106 L I I R Y V T V 
SOXS_SALTY/8-106 L I I R Y V T V 
TCPN_VIBC3/172-269 W W I R F A Y V 
TCPN_VIBCH/172-269 W W I R F A Y V 
TETD_ECOLX/31-129 L L I R F D S R 
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THCR_RHOER/227-328 L V L R F L R E 
URER_ECOLX/171-268 W L L R F G Y V 
URER_PROMI/171-268 W L L R F G Y A 
VIRF_SHIDY/161-258 W L L R I S Y K 
VIRF_SHIFL/161-258 W L L R I S Y K 
VIRF_SHISO/161-258 W L L R I S Y K 
VIRF_YERE8/167-265 W L I R F S Y S 
VIRF_YEREN/167-265 W L I R F S Y S 
VIRS_MYCTU/236-334 C A I R Y S A S 
VQSM_PSEAE/226-323 P L V R Y S S A 
XYLR_ECO57/288-386 I V I K Y P Y V 
XYLR_ECOL6/288-386 I V I K Y P Y V 
XYLR_ECOLI/288-386 I V I K Y P Y V 
XYLR_HAEIN/288-386 I V I K Y P Y V 
XYLS_PSEPU/214-315 I L I K F L R N 
XYLS1_PSEPU/214-315 I L I K F L R N 
XYLS2_PSEPU/39-140 I L I K F L R K 
XYLS3_PSEPU/214-315 I L I K F F R N 
XYLS4_PSEPU/214-315 I L I K F F R N 
Y077_STAAW/158-256 L L L R F S S T 
Y078_STAAS/158-256 L L L R F S S T 
Y084_STAAC/158-256 L L L R F S S T 
Y097_STAAN/158-256 L L L R F S S T 
Y101_STAAM/158-256 L L L R F S S T 
Y1052_HAEIN/194-295 W I L R Y Q H V 
Y107_STAAR/158-256 L L L R F S S T 
Y1395_MYCTU/242-343 P F L R Y T T A 
Y1430_MYCBO/242-343 P F L R Y T T A 
Y161_STAAB/153-250 V V L R F S M H 
Y165_STAES/152-249 V V L R F S M H 
Y184_STAA8/153-250 V V L R F S M H 
Y198_STAAS/153-250 V V L R F S M H 
Y198_STAAW/153-250 V V L R F S M H 
Y201_STAAC/153-250 V V L R F S M H 
Y214_STAAR/153-250 V V L R F S M H 
Y215_STAAN/153-250 V V L R F S M H 
Y217_STAA3/153-250 V V L R F S M H 
Y223_STAAM/153-250 V V L R F S M H 
Y2406_STAEQ/152-249 V V L R F S M H 
Y4FK_RHISN/318-417 V I L R F S R L 
YBBB_BACSU/166-264 I L I R Y Q Y I 
YBCM_ECOLI/165-262 W A L R Y K R R 
YCGK_ALTCA/67-163 I I I R F N Y V 
YDEO_ECO57/137-233 W L L R Y A Y A 
YDEO_ECOL6/137-233 W L L R Y A Y A 
YDEO_ECOLI/137-233 W L L R Y A Y A 
YDEO_SHIFL/137-233 W L L R Y A Y A 
YDIP_ECOLI/183-281 I L V R Y E H L 
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YEAM_ECOLI/158-258 G L R Q Y D A M 
YFIF_BACSU/192-289 L L V K F S Y V 
YHTH1_STAAU/158-256 L L L R F S S T 
YIDL_ECOLI/197-295 W V Y R F F H A 
YIJO_ECOLI/172-270 L R L R F V Y L 
YISR_BACSU/183-281 T I T R M E Y L 
YKGA_ECOLI/19-117 I I I R F D S E 
YKGD_ECOLI/177-278 W V L R Y A S A 
YMCR_STRLA/184-281 R V A R F A H D 
YPDC_ECOLI/184-282 L R V R F P Y V 
YQHC_ECOLI/213-311 L V L R Y E Q E 
Residues similar to the most common residue at each position are shown in colored boxes. 
(Original alignment of these proteins was provided by Dr. Susan Egan).  
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Role of RhaR Arm in L-rhamnose response. Given that RhaR DBD activates transcription in 
response to binding of L-rhamnose at the N-terminal domain, we sought to identify how the L-
rhamnose signal is transmitted from NTD to the DBD. We earlier discovered that deletion of 
RhaR extension (first 34 amino acids) does not play any role in transmitting this signal. 
However, we could not identify the role of RhaR residues that align with the AraC Arm because 
of defects in protein levels in the RhaR variants with deletions in the aligned region (200). 
In the present study, I mutagenized residues in the RhaR Arm region (residues 35-45) by 
site-directed random mutagenesis and isolated a total of 46 unique variants. Unlike the instability 
of protein truncations, we expected that single mutations may be less likely to cause defects in 
protein stability, and thus enable functional analysis of the Arm region. Our results showed that 
none of the variants had decreased activity in the presence of rhamnose, suggesting that this 
region may not be involved in making stimulatory inter-domain contacts (+) rhamnose. We 
found several variants that had increased activity (-) rhamnose. Most of the variants in position 
L35 had this phenotype [increased activation (-) rhamnose without increased protein levels] 
suggesting that this residue may be involved in making inhibitory inter-domain contacts in the (-) 
rhamnose state of wild-type RhaR. In AraC, the equivalent residue of RhaR L35 (AraC D7) is 
the first residue in the AraC Arm that makes inhibitory inter-domain interactions with AraC-
DBD in the (-) arabinose state (100). Our results identified one residue, L35, in the RhaR Arm 
that is involved in keeping the protein in a non-activation state in the absence of rhamnose 
through making inhibitory inter-domain interactions.  
Our mutagenesis also resulted in identification of variants with increased  activation in (-) 
rhamnose state for residues L37, K39, F42 and F43. However, variants with this phenotype were 
unique at their respective residues, suggesting that those variants are probably gain-of-residue-
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function variants (They may not be a loss-of-residue-function variants because for a loss-of-
residue-function we expect the majority of variants to have increased activation (-) rhamnose at 
these positions). Although these residues may not make direct inhibitory interactions with the 
DBD in (-) rhamnose state, they may be close enough to the DBD, such that some variants could 
make inhibitory contacts with the DBD or alter the conformation of other residues in the NTD to 
contact the DBD.  
Overall, our site-directed random mutagenesis of the RhaR Arm region suggested that 
residue L35 makes inhibitory contacts until the availability of L-rhamnose to the cells. We 
hypothesize that RhaR Arm might make inter-domain interaction with the residues in the DBD in 
(-) rhamnose state and those interactions might inhibit RhaR activation. In order to find the 
residues in the DBD that may contact the Arm residues, another graduate student Bria Kettle 
mutagenized residues in a region (allosteric site 2, AS2) that were predicted to be near the RhaR 
Arm region. Mutagenesis of residues in the AS2 region resulted in identification of variants at 
H269 with increased activation in (-) rhamnose state, suggesting the involvement of H269 in 
inhibitory inter-domain contacts in (-) rhamnose state. Further, she found the potential 
interactions between L35 and H269 by screening for second-site-suppressors that restore the 
RhaR activation levels to wild type in the absence of rhamnose. The structural model of RhaR 
(Fig. 43) also predicted inter-domain interactions between H269 and L35.  These results 
suggested to us that interactions between residues L35 and H269 in the absence of rhamnose 
may keep the protein in a non-activating state. Previously, Ana Kolin from our lab found several 
variants in a RhaR residue T279 with increased activation in (-) rhamnose state (200). This 
residue T279 is on the surface of the RhaR DNA binding domain and in a region (between D276 
and D285), which was shown to be involved in making contacts with σ70 of RNAP (81, 200). 
173 
 
These results led us to hypothesize that the residue T279 may interfere with RNAP contacts in 
the (-) rhamnose state and thus keep the RhaR activity to basal levels. Given the current and 
previous reports, we propose that in the absence of rhamnose, inhibitory inter-domain 
interactions between L35 and H269 may alter the conformation of RhaR DBD such that T279 
interferes with the RNAP contacts made by RhaR. However, availability of rhamnose may lead 
to loss of inhibitory inter-domain interactions between L35 and H269, and thus allow the 






Fig. 43. I-TASSER prediction of RhaR structure. I-TASSER (157) was used to predict the 3D 
structure of RhaR. NTD was shown in green and DBD was shown in red. Residue T279 was 
shown as sphere in cyan. Residues L35 and H269 that were found to make inhibitory inter 
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